

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 491/04, A61K 31/415 // (C07D 491/04, 311:00, 209:00) (C07D 491/04, 311:00, 221:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/24791 (43) International Publication Date: 11 June 1998 (11.06.98)</p>
<p>(21) International Application Number: PCT/US97/22279 (22) International Filing Date: 4 December 1997 (04.12.97) (30) Priority Data: 08/761,423 6 December 1996 (06.12.96) US 08/980,130 26 November 1997 (26.11.97) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: MEYER, Michael, D.; 25151 Amanda Court, Lake Villa, IL 60046 (US). ALTENBACH, Robert, J.; 7405 N. Oketo, Chicago, IL 60031 (US). BASHA, Fatima; 41 East Heron Drive, Lake Forest, IL 60045 (US). CARROLL, William, A.; 2514 Prairie #3B, #3 Bevanston, IL 60201 (US). DRIZIN, Irene; 16764 W. Cherrywood Lane, Wadsworth, IL 60083 (US). KERWIN, James, F.; 301 West Willowby Court, Grayslake, IL 60030 (US). WENDT, Michael, D.; 3506 Green Bay Road #304A, North Chicago, IL 60064 (US). HAIGHT, Anthony, R.; 40381 Reed Court, Wadsworth, IL 60083 (US). ZHANG, Weijiang; 389 Ashford, Grayslake, IL 60030 (US).</p>	<p>(74) Agents: WARD, Michael, J. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS

(57) Abstract

The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are α -1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are α -1 antagonist compositions and a method for antagonizing α -1 adrenoreceptors and treating BPH.



(1)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Benzopyranopyrrole and Benzopyranopyridine Alpha-1 Adrenergic Compounds

This application is a continuation-in-part application of U.S. Patent Application Serial No. 08/761,423 which was filed on December 6, 1996.

1. Technical Field

The present invention relates to novel organic compounds and compositions which are alpha-1 (α -1) adrenoreceptor antagonists, processes for making such compounds, synthetic intermediates employed in these processes, and a method for inhibiting alpha-1 adrenoreceptors and treating benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy, or other urological diseases such as bladder outlet obstruction and neurogenic bladder, or gynecological syndromes such as dysmenorrhea.

2. Background of the Invention

Adrenergic neurons play a major role in the innervation of heart, blood vessel and smooth muscle tissue. Compounds capable of interacting with adrenoreceptor sites within adrenergic nerves can initiate a variety of physiological responses, including vasoconstriction, vasodilation, and increased or decreased heart rate (chronotropic), contractility (inotropic) and metabolic activity. In the past, various adrenergic compounds have been employed to affect these and other physiological responses. However, many adrenergic compounds do not possess significant selectivity to enable desirable interactions with adrenergic adrenoreceptor sites. That is, these adrenergic compounds do not demonstrate a high degree of specificity for differing adrenoreceptor types within adrenergic neurons in order to obtain a desired physiological response separate from other possible, and perhaps less desirable, responses of the system.

Benign prostatic hyperplasia (BPH) is a condition which develops in middle-aged and elderly males and refers to the benign overgrowth of the stromal and epithelial elements of the prostate associated with aging. Symptoms of BPH include increased frequency of urination, nocturia, a weak urine stream and hesitancy or delay in starting the urine flow. Chronic consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder and an increased incidence of urinary tract infection.

Typically, BPH begins at an age in the mid-fifties and is the most common cause of urinary tract problems of men of this age. BPH is apparently rare in men prior to age 40, but at age 60, approximately 50% of men have histological evidence of BPH. The prevalence of BPH continues to increase with age until, at age 80, approximately 80% of men have pathological evidence of BPH.

Although prostatic hyperplasia is a common finding in older men, the presence of urinary symptoms is the essential feature that distinguishes simple anatomic enlargement of the prostate from prostatism, which is the clinical syndrome whereby the patient experiences significant obstruction of urinary flow. It is not uncommon in older men to have a palpably enlarged prostate without showing the symptoms of prostatism. From the patient's perspective, however, the incidence and progression of urinary symptoms are more important than the mere presence of an enlarged prostate.

The discovery in the 1970's (M. Caine, *et al.*, *Brit. J. Urol.*, 47: 193-202 (1975)) of large numbers of alpha-adrenergic adrenoreceptors in the smooth muscle of the prostatic capsule and bladder neck led to the conclusion that there is both a static and a dynamic component to bladder outlet obstruction associated with BPH. The static component derives from the progressive hyperplasia of the prostate with aging, leading to urethral narrowing which causes symptoms of urinary obstruction. Superimposed on this essentially mechanical problem is the variable degree of smooth muscle contraction controlled by the sympathetic nervous system and which is affected by factors such as stress, cold and sympathomimetic drugs. It is this dynamic component which explains the often rapid fluctuations in symptoms observed in patients with prostatism.

The currently most effective treatment for BPH is the surgical procedure of transurethral resection of the prostate (TURP). Since it removes the obstructing tissue (C. Chapple, *Br. Med. Journal* 304: 1198-1199 (1992)) it is a treatment which is directed to the static and dynamic components of BPH. However, this surgical treatment is associated with rates of mortality (1%) and adverse event (incontinence 2-4%, infection 5-10%, and impotence 5-10%). A non-invasive alternative treatment would thus be highly desirable.

The incidental clinical observation that urinary incontinence developed in women during antihypertensive treatment with prazosin (T. Thien, K. P. Delacre, F. M. J. Debruyne, R. A. P. Koene, *Br. Med. Journal*, 622-623 (1978)) and the experimental work of Caine (*op cit.*) contributed to the recognition of the potential role of selective α -1 adrenoreceptor blockade in diseases of the lower urinary tract. Subsequent studies by several groups have documented the functional role of α -1 adrenoreceptors relative to α -2 adrenoreceptors in the stromal compartment of the prostate, thereby providing a putative molecular basis for the use of specific α -1 adrenoreceptor blockers in the non-surgical management of BPH (C. R. Chapple, M. L.

Aubry, S. James, M. Greengrass, G. Burnstock, R. T. Turner-Warwick, *Br. J. Urol.* **63**: 487-496 (1989)). Clinical efficacy of α -1 antagonists in BPH has been demonstrated with several non-selective α -1 blockers, including terazosin (Hytrin®), prazosin, and doxazosin. Treatment periods as short as two to four weeks with α -1 adrenoreceptor blockers have shown objective improvements in the mean and maximum urinary flow rates (14-96%) with subjective improvements in patients' symptom scores (R. A. Janknegt, C. R. Chapple, *Eur. Urol.* **24**: 319-326 (1993)). Longer term studies with terazosin, indoramin, prazosin, and doxazosin have similarly demonstrated significant improvements in urinary flow rates and subjective symptom scores (R. A. Janknegt, op. cit., H. Lepor, G. Knapp-Maloney, *J. Urol.* **145**: 263A (1991), W. Chow, D. Hahn, D. Sandhu, *Br. J. Urol.* **65**: 36-38 (1990) and C. R. Chapple, T. J. Christmas, E. J. G. Milroy, *Urol. Int.* **45**: 47-55 (1990)). However, these agents possess similar dose limiting side effects: hypotension, dizziness, and muscle fatigue.


In recent years, it has become clear that BPH and bladder outlet obstruction (BOO) are clinically differentiable, and that the severity of clinical BPH is related to many factors in addition to BOO (Lepor, H., Alpha Blockade for the Treatment of Benign Prostatic Hyperplasia, *Urol. Clin. N. Amer.*, **22**: 375-386, 1995.). For example, BOO may be related to other urological symptoms such as detrusor instability (Rosier, P.F.W.M., J.J.M.C.H. de la Rosette, H. Wijkstra, Ph.E.V. Van Kerrebroeck and F.M.J. Debruyne, Is Detrusor Instability in Elderly Males Related to the Grade of Obstruction?, *Neurourol. Urodynam.*, **14**: 625-633, 1995). In addition, the role of extraprostatic α -1 adrenoreceptors has been postulated as important in the etiology of lower urinary tract symptoms, such that antagonism of these receptors in spinal cord, ganglia, nerve terminals, bladder and bladder neck or the external urethral sphincter could be important in pharmacotherapy of urological conditions such as BOO and neurogenic bladder (Andersson, K-E., Prostatic and extraprostatic α -adrenoceptors: Contributions to the Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia, *Scand. J. Urol. and Nephrol.*, **30**: 105-111, 1996). The recognition that women possess paraurethral glands which have anatomical, histological and biochemical similarities to the male prostate (Gittes, R.F. and R.M. Nakamura, Female urethral syndrome: A female prostatitis?, *Western J. Medicine*, **164**: 435-438, 1996) suggests a potential role for α -1 adrenoreceptor antagonist pharmacotherapy for amelioration of some symptoms of female urethral syndromes. In addition, α -adrenoreceptors are functionally important to smooth muscle contraction in the uterus (Miller, M.D. and J.M. Marshall, Uterine response to nerve stimulation: relation to hormonal status and catecholamines, *Am. J. Physiol.*, **209**: 859-863, 1965) and the modulation of sympathetic responses to catecholamines is enhanced by elevations in the levels of estrogens (Miller and Marshall, Uterine response to nerve stimulation: relation to hormonal status and catecholamines, *Am. J. Physiol.*, **209**: 859-863, 1965). Consistent with this observation are

data showing increasing levels of α -adrenoreceptor responses and receptor density following estrogen administration to animals (Hoffman, B.B., T.N. Lavin, R.J. Lefkowitz and R.R. Ruffolo, Jr., Alpha adrenergic receptor subtypes in rabbit uterus: Mediation of myometrial contraction and regulation by estrogens, J. Pharmacol. Exp. Ther., 219: 290-295, 1981, and Roberts, J.M., P.A. Insel and A. Goldfein, Regulation of myometrial adrenoreceptors and adrenergic response by sex steroids, Mol. Pharmacol., 20: 52-58, 1981). Thus hormonal regulation of α -1 adrenoreceptor sensitivity could play a role in enhanced uterine contractions in dysmenorrhea, a condition for which selective α -1 adrenoreceptor antagonists could have therapeutic potential.

There thus exists a need for a "uroselective" α -1 antagonist with reduced side effect liabilities.


Summary of the Invention


In its principle embodiment, the present invention provides certain benzopyranopyrrole and benzopyranopyridine compounds and intermediates of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, and R₃ is selected from the group consisting of,





5

wherein G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl,

10 Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent,

V and V' are independently selected from the group of nitrogen and methine, and U is a ring that is fused to its adjacent ring and is selected from the group consisting of (a) an
 15 unsubstituted or substituted five member ring having five carbon atoms; (b) an unsubstituted or substituted five membered ring having four carbon atoms and one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; (c) an unsubstituted or substituted five membered ring having three carbon atoms and two heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; (d) a substituted or unsubstituted six
 20 membered ring having six carbon atoms; (e) a substituted or unsubstituted six membered ring having 5 carbon atoms and one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; (f) a substituted or unsubstituted 6 membered ring having 4 carbon atoms and two heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; and (g)
 25 a substituted or unsubstituted 6 membered ring having three carbon atoms and three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. The five membered rings constituting U may contain 0, 1, or 2 double bonds. The six membered rings constituting U may contain 0, 1, 2, or 3 double bonds. The rings (a)-(g) of the group constituting U may be mono or di-substituted with substituents independently selected from the group consisting of


alkyl, alkoxy, cyano, nitro, carboxy, alkoxycarbonyl of two to eight carbon atoms, halogen, cycloalkyl, aryl, and heterocyclic.

The present invention also relates to pharmaceutical compositions which comprise a therapeutically effective amount of a compound of formula I in combination with a pharmaceutically effective carrier.


The present invention also relates to a method of antagonizing alpha-1 adrenoreceptor binding in a host mammal, in particular humans, by administering a therapeutically effective amount of a composition comprising a compound of formula I. In particular, the present invention relates to a method of treating BPH in a mammal, in particular humans, by administering to a mammal an effective amount of a compound of formula I.


Detailed Description of the Invention

In one embodiment, the present invention provides a compound of the formula I,



or a pharmaceutically acceptable salt thereof, wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, and R₃ is selected from the group consisting of,






wherein G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl,

Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent,

V and V' are independently selected from the group of nitrogen and methine, and U is a ring that is fused to its adjacent ring and is selected from the group consisting of (a) an unsubstituted or substituted five member ring having five carbon atoms; (b) an unsubstituted or substituted five membered ring having four carbon atoms and one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; (c) an unsubstituted or substituted five membered ring having three carbon atoms and two heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; (d) a substituted or unsubstituted six membered ring having six carbon atoms; (e) a substituted or unsubstituted six membered ring having 5 carbon atoms and one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; (f) a substituted or unsubstituted 6 membered ring having 4 carbon atoms and two heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; and (g)

a substituted or unsubstituted 6 membered ring having three carbon atoms and three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. The five membered rings constituting U may contain 0,1, or 2 double bonds. The six membered rings constituting U may contain 0,1,2, or 3 double bonds. The rings (a)- (g) of the group constituting U may be mono or di-substituted with substituents independently selected from the group consisting of alkyl, alkoxy, cyano, nitro, carboxy, alkoxycarbonyl of two to eight carbon atoms, halogen, cycloalkyl, aryl, and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

In a preferred embodiment, the present invention provides a compound of formula II:




II

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl,

Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent,

P', Q, S', and T are independently selected from the group consisting of nitrogen and methine, with the proviso that no more than two of P', Q, S', and T can be nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


In another preferred embodiment, the present invention provides a compound of the formula III:



III

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, P' and T are nitrogen, Q and S' are methine, and R_4 and R_5 are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof..

In yet another preferred embodiment, the present invention provides a compound of formula IV:




IV

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting

hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, P' is nitrogen, Q, S', and T are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof..


In yet another preferred embodiment, the present invention provides a compound of formula V:



V

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, Q is nitrogen, P', S', and T are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof..


In yet another preferred embodiment, the present invention provides a compound of formula VI:



VI

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, S' is nitrogen, P', Q, and T are methine, and R_4 and R_5 are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

In yet another preferred embodiment, the present invention provides a compound of formula VII:




VII

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are

independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, T is nitrogen, P', Q, and S' are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


In yet another preferred embodiment, the present invention provides a compound of formula VIII:



VIII

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, P', Q, S', and T are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


In yet another preferred embodiment, the present invention provides a compound of formula IX:



IX

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 1, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, P', Q, S', are methine, T is nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


In yet another preferred embodiment, the present invention provides a compound of formula X:



X

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 2, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, P', Q, and S' are methine, T is nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


In yet another preferred embodiment, the present invention provides a compound of formula XI:



XI

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 2, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, Q and S' are methine, P' and T are nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


In yet another preferred embodiment, the present invention provides a compound of formula XII:



XII

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 1, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, Q and S' are methine, P' and T are nitrogen, and R_4 and R_5 are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


In yet another preferred embodiment, the present invention provides a compound of formula XIII:



XIII

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 1, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, Q, S' , and T are methine, P' is nitrogen, and R_4 and R_5 are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


In yet another preferred embodiment, the present invention provides a compound of formula XIV:



XIV

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, Y is nitrogen, G is hydrogen, Y' is sulphur, P' and T are nitrogen, Q is methine, and S' is carbon; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


The present invention also relates to compounds or their salts which are useful as intermediates of Formulae I - XIV. One compound which is useful as an intermediate is a compound of formula XV:



XV

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, and n is 1 or 0.


Another compound which is useful as an intermediate is a compound of formula XVI:



XVI

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, and n is 1 or 0.


Another compound which is useful as an intermediate is a compound of formula XVII:



XVII

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, m is from 2 to 10, and n is 1 or 0.

A more preferred compound which is useful as an intermediate is a compound of formula XVIII:




XVIII

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, and n is 1 or 0. In addition, a more

preferred compound of Formula XVIII is one having an absolute stereochemistry which is 3aR and 9bR.


Another more preferred compound which is useful as an intermediate is a compound of formula XIX:



XIX

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, and n is 1 or 0. In addition, a more preferred compound of Formula XIX is one having an absolute stereochemistry which is 3aR and 9bR.


Another more preferred compound which is useful as an intermediate is a compound of formula XX:



XX

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, m is from 2 to 10, and n is 1 or 0. In addition, a more preferred compound of Formula XX is one having an absolute stereochemistry which is 3aR and 9bR.


Another compound which is useful as an intermediate is a compound of formula XXI:



XXI

5 wherein U, Y', G' are as defined in formulae I-XIV and R is alkyl.


Another compound which is useful as an intermediate is a compound of formula XXII:



XXII

10 wherein U, Y', G' are as defined in formulae I-XIV and R is alkyl.


Another compound which is useful as an intermediate is a compound of formula XXIII:



XXIII


15 wherein U, Y', G', and m are as defined in formulae I-XIV and R is alkyl.

Another compound which is useful as an intermediate is a compound of formula XXIV:




XXIV, wherein Rz is alkyl.

Another compound which is useful as an intermediate is a compound of formula XXV:




XXV, wherein R_z is alkyl.

Another compound which is useful as an intermediate is a compound of formula XXVI:




XXVI, wherein X is halogen and R is selected from alkyl and arylalkyl.

Another compound which is useful as an intermediate is a compound of formula XXVII:




XXVII.

Another compound which is useful as an intermediate is a compound of formula XXVIII:




XXVIII.

Another compound which is useful as an intermediate is a compound of formula XXIX:




XXIX.

The present invention also relates to a process for preparing a compound of the formula




or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R_1 , R_2 , A, n, W, Y, G, Y', G', P, Q, S, T, R_4 , and R_5 are as previously defined; comprising the steps of:

a) reacting a compound of the formula



wherein Ra is aminoalkyl,

b), with a compound of the formula



wherein R is alkyl.

The present invention also relates to pharmaceutical compositions which comprise a therapeutically effective amount of a compound of formulae I - XIV in combination with a pharmaceutically acceptable carrier.

The invention further relates to a method of antagonizing α -1 adrenoreceptors in a host mammal, in particular humans, in need of such treatment by administering a therapeutically effective amount of a compound of formulae I - XIV.

The invention still further relates to a method of treating BPH in a host mammal, in particular humans, in need of such treatment by administering a therapeutically effective amount of a compound of formulae I - XIV.

The invention still further relates to a method of treating bladder outlet obstruction (BOO) in a host mammal, in particular humans, in need of such treatment by administering a therapeutically effective amount of a compound of formulae I - XIV.

The invention still further relates to a method of treating neurogenic bladder in a host mammal, in particular humans, in need of such treatment by administering a therapeutically effective amount of a compound of formulae I - XIV.

The invention still further relates to a method of treating uterine smooth muscle contraction in a female host mammal, in particular humans, in need of such treatment by administering a therapeutically effective amount of a compound of formulae I - XIV.

As used throughout this specification and the appended claims, the following terms have the following meanings:

The term "alkenyl" as used herein refers to a hydrocarbon containing at least one carbon-carbon double bond. Alkenyl groups include, for example, vinyl (ethenyl), allyl (propenyl), butenyl, 1-methyl-2-buten-1-yl and the like.

The terms "alkyl" or "loweralkyl" as used herein refer to straight or branched chain alkyl radicals containing from 1 to 6 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl and the like.

The term "alkylamino" as used herein refers to $R_{10}NH$ - wherein R_{10} is an alkyl group, for example, ethylamino, butylamino, and the like.

The term "alkylene" denotes a divalent group derived from a straight or branched chain saturated hydrocarbon of from 2 to 10 carbon atoms by the removal of two hydrogen atoms, for example methylene, 1,2-ethylene, 1,1-ethylene, 1,3-propylene, 2,2-dimethylpropylene, and the like.

The term "alkoxy" as used herein refers to $R_{11}O$ - wherein R_{11} is an alkyl group, as defined above. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, tert-butoxy, and the like.

The term "alkoxyalkyl" as used herein refers to an alkoxy group as previously defined appended to an alkyl radical as previously defined. Examples of alkoxyalkyl include, but are not limited to, methoxymethyl, methoxyethyl, isopropoxymethyl and the like.

The term "alkoxyalkoxy" refers to $R_{12}O-R_{13}O$ - wherein R_{12} is alkyl R_{13} is alkylene. Examples of alkoxyalkoxy include methoxymethoxy, methoxyethoxy and the like.

The term "alkoxycarbonyl" as used herein refers to $R_{14}O-C(O)$ - wherein R_{14} is an alkyl group. Examples of alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl and the like.

The term "alkylsulfonyl" refers to $R_{15}S(O)_2$ - wherein R_{15} is an alkyl group.

The term "alkynyl" refers to a straight or branched chain hydrocarbon containing a carbon-carbon triple bond. Examples of alkynyl include $-C\equiv C-$, $-C\equiv C-CH_2-$, $-C\equiv C-CH(CH_3)-$ and the like.

The term "amino" as used herein refers to $-NH_2$.

The term "aminoalkyl" as used herein refers to an alkyl radical to which is appended an amino group ($-NH_2$).

The term "aryl" as used herein refers to a mono- or bicyclic carbocyclic ring system having one or more aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like. Aryl groups can be unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, haloalkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, nitro, carboxy, alkoxycarbonyl and carboxamide.

The term "arylalkyl" as used herein refers to an aryl appended to the parent molecular moiety through an alkyl radical.

The term "carboxamide" as used herein refers to $-C(O)NH_2$ wherein the carboxylic acid hydroxy moiety has been replaced by an amine.

The term "carboxyalkyl" as used herein refers to a carboxy group (-C(O)OH) appended to an alkyl radical as previously defined. Examples of carboxyalkyl include carboxymethyl, carboxyethyl and the like.

5 The term "cyanoalkyl" as used herein refers to a cyano group (-CN) appended to the parent molecular moiety through an alkyl radical.

The term "dialkylamino" as used herein refers to R₁₆R₁₇N- wherein R₁₆ and R₁₇ are independently alkyl, for example diethylamino, methyl propylamino, and the like.

The term "carboxy" as used herein refers to a carboxylic acid radical, -C(O)OH.

10 The term "cycloalkyl" as used herein refers to an aliphatic ring system having 3 to 10 carbon atoms and 1 to 3 rings including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, adamantyl, and the like. Cycloalkyl groups can be unsubstituted or substituted with one, two or three substituents independently selected from alkyl, haloalkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl and carboxamide.

15 The term "halogen" or "halo" as used herein refers to I, Br, Cl, or F.

The term "haloalkyl" as used herein refers to a lower alkyl radical, as defined above, bearing at least one halogen substituent, for example, chloromethyl, fluoroethyl or trifluoromethyl and the like.

20 The terms "heterocyclic ring" or "heterocyclic" or "heterocycle" as used herein refers to any 3- or 4-membered ring containing a heteroatom selected from oxygen, nitrogen and sulfur; or a 5-, 6- or 7-membered ring containing one, two or three heteroatoms wherein the heteroatoms are independently selected from nitrogen, oxygen and sulfur. The 5-membered ring has from 0-2 double bonds and the 6- and 7-membered ring have from 0-3 double bonds. The nitrogen heteroatoms can be optionally quaternized. The term "heterocyclic" also includes
25 bicyclic groups in which any of the above heterocyclic rings is fused to a benzene ring or a cyclohexane ring or another heterocyclic ring (for example, indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl or benzothienyl and the like). Heterocyclics include: azetidyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl,
30 pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl and benzothienyl.

Heterocyclics can be unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (=O), alkylimino (R₁₈N= wherein R₁₈ is a
35 loweralkyl group), amino, alkylamino, dialkylamino, alkoxy, alkoxylalkoxy, haloalkyl,

cycloalkyl, aryl, arylalkyl, -COOH, -SO₃H and loweralkyl. In addition, nitrogen containing heterocycles can be N-protected.

The term "(heterocyclic)alkyl" as used herein refers to a heterocyclic group as defined above appended to a loweralkyl radical as defined above.

5 The term "hydroxy" as used herein refers to -OH.

The term "hydroxyalkyl" as used herein refers to alkyl radical which is appended to an hydroxy group.

The term "methine" as used herein refers to -CH=.

The term "nitro" as used herein refers to -NO₂.

10 The term "thioalkoxy" as used herein refers to R₁₉S- wherein R₁₉ is alkyl. Examples of thioalkoxy include, but are not limited to, methylthio, ethylthio and the like.

By "pharmaceutically acceptable salt" is meant those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S.M. Berge, *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharm. Sciences*, 66: 1-19 (1977), which is hereby incorporated by reference. The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. These salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, *p*-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

35 Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Basic

addition salts can be prepared *in situ* during the final isolation and purification of the compounds of formula (I), or separately by reacting the carboxylic acid function with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia, or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, aluminum salts and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Other representative organic amines useful for the formation of base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.

The term "pharmaceutically acceptable ester" as used herein refers to esters which hydrolyze *in vivo* and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters includes formates, acetates, propionates, butyates, acrylates and ethylsuccinates.

The term "pharmaceutically acceptable prodrug" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed *in vivo* to provide the parent compound having the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

As used throughout this specification and the appended claims, the term metabolically cleavable group denotes a moiety which is readily cleaved *in vivo* from the compound bearing it, wherein said compound, after cleavage remains or becomes pharmacologically active. Metabolically cleavable groups form a class of groups reactive with the carboxyl group of the

compounds of this invention are well known to practitioners of the art. They include, but are not limited to groups such as, for example, alkanoyl, such as acetyl, propionyl, butyryl, and the like; unsubstituted and substituted aroyl, such as benzoyl and substituted benzoyl; alkoxy carbonyl, such as ethoxycarbonyl; trialkylsilyl, such as trimethyl- and triethylsilyl; monoesters formed with dicarboxylic acids, such as succinyl, and the like. Because of the ease with which the metabolically cleavable groups of the compounds of this invention are cleaved *in vivo*, the compounds bearing such groups act as pro-drugs of α -1 adrenoreceptor antagonist compounds. The compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group.

Compounds of the present invention include compounds which result from non-natural or synthetic preparations, including *in vitro* and *in situ* preparations, or as a result of *in vivo* preparation, e.g., *in vivo* metabolism.

Asymmetric centers may exist in the compounds of the present invention. The present invention contemplates the various stereoisomers and mixtures thereof. Individual stereoisomers of compounds of the present invention are made by synthesis from starting materials containing the chiral centers or by preparation of mixtures of enantiomeric products followed by separation as, for example, by conversion to a mixture of diastereomers followed by separation by recrystallization or chromatographic techniques, or by direct separation of the optical enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or are made by the methods detailed below and resolved by techniques well known in the organic chemical arts.

Representative compounds falling within the scope of formula I include:

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bS)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

10 3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

15 3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-1-(2-Methoxyethyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

20 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

25 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 10 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[5-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)pentyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[5-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)pentyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 15 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 25 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methyl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

10 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

20 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

25 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methyl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-methoxy-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-chloro-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

10 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-isopropoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

20 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

25 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-furyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[2-((±)-cis-7-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

10 3-[3-((±)-cis-7-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)propyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[2-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[3-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)propyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

15 3-[2-((±)-cis-6-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[3-((±)-cis-6-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)propyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

20 3-[2-((±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((±)-trans-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

25 3-[4-((±)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((±)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[4-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[3-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)propyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

10 3-[2-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione,

3-[4-((±)-trans-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione,

15 3-[4-((±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione,

3-[4-((±)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione,

20 3-[3-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione,

3-[3-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

25 3-[4-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione,

3-[4-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[3-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[2-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[2-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)ethyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione,

10 3-[3-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[3-((4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

15 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

20 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

25 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

10 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

15 3-[4-(-cis-7-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-6-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(2-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

25 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, and

30 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(4-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

or a pharmaceutically acceptable salt, ester, or prodrug thereof..

Preferred compounds falling within the scope of formula (I) include:

- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 5 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 10 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
- 25 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-isopropoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[3-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

10 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

15 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

20 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

25 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

30 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-furyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

10 3-[4-(-cis-7-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-6-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(2-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

and

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(4-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

or a pharmaceutically acceptable salt, ester, or prodrug thereof.

The following compounds may be prepared by the methods described in the synthetic Schemes and Examples contained herein:

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2,3-g]quinazoline-2,4(1H,3H)-dione,

- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,4-g]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4,3-g]quinazoline-2,4(1H,3H)-dione,
5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,2-g]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2,3-f]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,4-f]quinazoline-2,4(1H,3H)-dione,
10 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,2-f]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4,3-f]quinazoline-2,4(1H,3H)-dione,
15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2,3-h]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,4-h]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,2-h]quinazoline-2,4(1H,3H)-dione,
20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4,3-h]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-benz[g]quinazoline-2,4(1H,3H)-dione,
25 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-benz[h]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-benz[f]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2,3-f]quinazoline-2,4(1H,3H)-dione,
30 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2,3-g]quinazoline-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2,3-h]quinazoline-2,4(1H,3H)-dione,
35 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[3,4-f]quinazoline-2,4(1H,3H)-dione.

- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,3-f]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,5-f]quinazoline-2,4(1H,3H)-dione,
- 5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[3,4-g]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,3-g]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,5-g]quinazoline-2,4(1H,3H)-dione,
- 10 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[3,4-h]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,3-h]quinazoline-2,4(1H,3H)-dione,
- 15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,5-h]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[4,5-f]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[5,4-f]quinazoline-2,4(1H,3H)-dione,
- 20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[4,5-g]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[5,4-g]quinazoline-2,4(1H,3H)-dione,
- 25 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[4,5-h]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[5,4-h]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2,3-g]quinazoline-2,4(1H,3H)-dione,
- 30 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,4-g]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4,3-g]quinazoline-2,4(1H,3H)-dione,
- 35 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,2-g]quinazoline-2,4(1H,3H)-dione,

- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2,3-f]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,4-f]quinazoline-2,4(1H,3H)-dione,
- 5 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,2-f]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4,3-f]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2,3-h]quinazoline-2,4(1H,3H)-dione,
- 10 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,4-h]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3,2-h]quinazoline-2,4(1H,3H)-dione,
- 15 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4,3-h]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-benz[g]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-benz[h]quinazoline-2,4(1H,3H)-dione,
- 20 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-benz[f]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2,3-f]quinazoline-2,4(1H,3H)-dione,
- 25 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2,3-g]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2,3-h]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[3,4-f]quinazoline-2,4(1H,3H)-dione,
- 30 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,3-f]quinazoline-2,4(1H,3H)-dione,
- 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,5-f]quinazoline-2,4(1H,3H)-dione,
- 35 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[3,4-g]quinazoline-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,3-g]quinazoline-2,4(1H,3H)-dione,
 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,5-g]quinazoline-2,4(1H,3H)-dione,
 5 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[3,4-h]quinazoline-2,4(1H,3H)-dione,
 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,3-h]quinazoline-2,4(1H,3H)-dione,
 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyridazino[4,5-h]quinazoline-2,4(1H,3H)-dione,
 10 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[4,5-f]quinazoline-2,4(1H,3H)-dione,
 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[5,4-f]quinazoline-2,4(1H,3H)-dione,
 15 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[4,5-g]quinazoline-2,4(1H,3H)-dione,
 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[5,4-g]quinazoline-2,4(1H,3H)-dione,
 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[4,5-h]quinazoline-2,4(1H,3H)-dione, and
 20 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrimidino[5,4-h]quinazoline-2,4(1H,3H)-dione,

or a pharmaceutically acceptable salt, ester, or prodrug thereof.

Representative compounds of the present invention were evaluated for their ability to displace prazosin from its adrenoreceptor.

In vitro Binding Assays

In the following, for purposes of discussing alpha-1 adrenoreceptor subtypes, the IUPHAR convention of using lower case letters to define molecular clones and upper case letters to indicate pharmacologically defined adrenoreceptors has been followed. Moreover, the newly recommended nomenclature for alpha-1 (α_{1a} , α_{1b} , α_{1d}) has been used.

Representative compounds of the invention were evaluated for α -adrenoreceptor binding affinity in vitro using [3 H]-prazosin as the radioligand and three cloned α -1 adrenoreceptors expressed in LTK cells: α -1a (bovine), α -1b (hamster), and α -1d (rat). Additionally, binding

affinity against the pharmacologically defined α -1A adrenoreceptor (rat submaxillary gland) was measured.

The cDNA clones encoding the α -1 adrenoreceptors (α -1a, α -1b, and α -1d) were obtained from TULCO (Triangle Universities Licensing Consortium, Research Triangle Park, NC) and inserted into the eukaryotic expression vector SnaB30. In this vector, expression of the adrenoreceptor gene is under the transcriptional control of an SV40 early promoter. Positive drug selection is provided by a neomycin-resistance gene. Mouse fibroblast cells (LTK) were transfected with the α ₁ expression plasmids and grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum and 30 μ M G418. Stable G418-resistant parental lines were generated, with successful expression of adrenoreceptor protein monitored using radioligand binding techniques. Stable single cell clones derived from the parental lines were screened in adrenoreceptor binding assays to identify clones having high adrenoreceptor density. Roller bottle cultures of the cloned lines were used to provide cell membranes for subsequent adrenoreceptor binding characterization studies. A cell line containing the SnaB30 vector expressing the human erythropoietin gene served as a negative control.

For adrenoreceptor binding assays, large scale membrane preparations were utilized in which 6 million cells were seeded into small (450 cm²) Corning tissue culture roller bottles. 200 mL of DMEM containing 10% fetal calf serum and 300 μ M G418 were added to each roller bottle. A 95% air / 5% CO₂ gas mixture (sterile) was injected into each roller bottle prior to sealing. The bottles were then incubated at 37 °C on a roller rack for 5 days. Cells were re-fed with fresh medium after 3 days in culture.

On the fifth day of culture, growth medium was removed from cells grown in roller bottles, and the cells were washed twice with PBS (Sigma, 120 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄-NaH₂PO₄, pH = 7.4). Cells were detached from the roller bottles by incubating for 15 minutes at 37 °C in a Tris-EDTA solution (10 mM Tris, 100 mM NaCl, 1 mM EDTA, pH = 7.4). The cell suspension from each roller bottle was decanted into tared centrifuge tubes and kept on ice. An aliquot of each cell suspension was generally taken for cell counting. Cells were centrifuged at 3000 X G for 5 min at 2-4 °C, washed with PBS and recentrifuged. The supernatant was decanted and the pellet weighed to determine the wet weight of cells. Cells were washed a final time in 40 vol 5 mM Tris-HCl, 5 mM EDTA, pH = 7.7, and centrifuged at 40,000 X G for 10 minutes. Cells were homogenized in 10 mL of 50 mM Tris-HCl, 5 mM EDTA (pH = 7.4) and diluted to 40 mL/tube. Homogenates were centrifuged at 40,000 X G for 10 minutes. The supernatant was decanted and the pellets rehomogenized in 50 mM Tris-HCl (pH = 7.4) and centrifuged as before. The supernatant was decanted and the homogenate resuspended in 6.25 volumes (per gram wet weight) of 50 mM Tris-HCl and aliquots of the pooled homogenates frozen in liquid N₂ and stored at -70 °C until the time of assay. Rat

submaxillary glands were used for α -1A adrenoreceptors and were prepared essentially as described (Michel, A. D., Loury, D. N. and Whiting, R. L., *Brit. J. Pharmacol.* **98**: 83-889 (1989)).

Receptor binding assays for α -1 adrenoreceptors were performed essentially as described by Greengrass and Bremner (*Eur. J. Pharmacol.* **55**: 323-326 (1979)). Briefly, plastic BioblocksTM (DBM Scientific, Valencia, CA) were incubated at 25 °C for 50 minutes with 500 μ L of membrane homogenate (diluted with an additional 96 volumes [for cloned adrenoreceptors, 12 volumes for submaxillary gland] in 50 mM Tris-HCl buffer (pH = 7.7 at the time of assay), 450 μ L of [³H]prazosin (0.2 nM final concentration, 75-85 Ci/mmol, DuPont-NEN Corp., Boston, MA) and 50 μ L of either water (for total binding) or 10 μ M phentolamine (final concentration, for non-specific binding). Following equilibration, bound radioligand was separated from free on GF/B filters (presoaked in 0.5% polyethyleneimine) using either a Brandel or Packard cell harvester. Radioactivity was determined by standard liquid scintillation techniques. Data were analyzed as previously described (Hancock, A. A., Kyncl, J. J., Martin, Y. C. and DeBernardis, J. F., *J. Receptor Res.* **8**: 23-46 (1988)).

Canine prostate strips were used *in vitro* as previously described (Hieble, J.P., Boyce, A.J. and Caine, M., *Fed. Proc.*, **45**: 2609-2614 (1986)), to determine antagonist potencies against phenylephrine-induced contractions.

The results are shown in Table 1. The results show that the compounds of the invention bind to the α -1 adrenoreceptor and show varying degrees of specificity for the α -1a adrenoreceptor.

Table 1
In Vitro Data for Binding to α -1 Adrenoceptors

	Radioligand Binding			
	(K _i , nM)			
	1A (Rat)	1a (Bovine)	1b (Hamster)	1d (Rat)
1	0.045	0.024	1.144	0.223
2	0.95	0.193	9.23	2.716
3	0.026	0.02	0.286	0.041
4	0.097	0.049	0.867	0.377
5	0.268	0.086	2.008	0.638
6	0.409	0.173	1.997	0.302
7	0.53	0.215	1.606	0.438
8	0.762	0.362	4.187	1.419
9	2.267	0.325	17.75	1.551

10	0.662	0.406	10.45	1.597
11	0.374	0.243	3.784	1.461
12	0.52	0.375	5.255	2.167
13	0.1	0.041	2.492	0.112
14	0.105	0.038	1.37	0.145
15	0.227	0.068	4.406	0.928
16	0.373	0.073	8.636	0.729
17	0.175	0.068	1.2475	0.19
18	0.284	0.069	5.055	0.79
19	0.059	0.025	1.13	0.108
20	0.208	0.038	3.505	0.439
21	0.03	0.018	0.326	0.03
22	0.196	0.031	1.163	0.138
23	0.743	0.046	0.973	0.639
24	5.37	0.616	5.557	4.512
25	0.061	0.03	0.591	0.039
26	0.09	0.022	0.376	0.017
27	0.121	0.044	0.974	0.094
28	0.273	0.092	3.694	0.195
29	0.252	0.095	3.69	0.466
30	0.264	0.066	2.673	0.222
31	0.224	0.06	4.787	0.344
32	1.011	0.093	9.952	0.86
33	0.811	0.082	10.451	0.701
34	0.474	0.079	3.367	0.339
35	0.312	0.057	5.121	0.436
36	0.539	0.124	2.854	0.36
37	0.264	0.069	3.343	0.195
38	0.376	0.057	5.63	0.897
39	0.343	0.226	31.915	2.145
40	22.845	3.015	33.778	7.123
41	0.069	0.031	0.603	0.041
42	0.073	0.028	0.829	0.066
43	0.114	0.037	1.485	0.063
44	0.043	0.043	0.622	0.081
45	0.125	0.066	1.341	0.104

46	0.353	0.033	2.577	0.114
47	0.245	0.038	2.402	0.189
49	0.037	0.007	0.129	0.019
48	0.475	0.048	5.749	0.467
50	1.934	0.335	20.787	0.391
51	1.188	0.064	0.868	0.371
52	3.981	1.083	13.575	0.597
53	0.872	0.037	9.419	0.664
54	0.077	0.187	1.004	0.173
55	0.111	0.103	1.458	0.02
56	0.614	0.078	10.202	1.307
57	0.682	0.078	19.3	0.507
58	0.273	0.188	2.079	0.039
59	0.166	0.049	6.74	0.257
60	0.187	0.078	14.155	1.821
61	0.152	0.15	8.851	0.336
62	982.857	52.015	1147.067	411.328
63	51.225	11.213	92.216	70.056
64	4.198	1.633	9.298	10.356
65	15.023	1.821	20.715	25.011
66	214.086	24.756	532.739	87.712
67	115.856	77.208	247.773	64.982
68	40.585	7.82	23.6	42.499
69	0.665	0.344	4.347	1.63
70	0.17	0.082	0.724	0.482
71	0.065	0.068	0.634	0.169
72	0.107	0.133	3.543	0.804
73	0.087	0.038	1.312	0.187
74	3.286	1.532	14.325	2.939
75	5.727	1.893	52.108	18.34
76	11.652	6.213	78.559	12.922
77	99.715	26.984	10000	105.832
78	0.297	0.122	1.883	0.478
79	0.199	0.174	0.821	0.361
80	0.442	0.17	2.504	0.765
81	0.045	0.052	0.192	0.108

82	0.577	0.361	4.898	1.577
83	0.383	0.217	3.069	0.807
84	0.479	0.617	4.916	1.123
85	0.419	0.336	1.886	0.566
86	0.54	0.202	1.707	0.398
87	0.371	0.227	2.857	0.704
88	0.188	0.11	0.791	0.259
89	0.133	0.038	0.111	0.061
90	0.323	0.135	2.294	0.439
91	0.102	0.066	1.459	0.495
92	3.845	2.196	45.066	18.494
93	4.044	1.204	3.667	11.524
94	0.185	0.097	1.967	0.361
95	8.834	1.804	21.594	23.036
96	0.816	0.211	10.382	0.816
97	0.892	0.097	4.696	0.247
98	1.023	0.121	2.654	0.324
99	14.939	1.726	57.075	5.808
100	30.546	5.826	26.984	7.59
101	1.267	0.063	8.415	0.597
102	1.894	0.113	6.26	0.651
103	0.909	0.115	3.327	0.243
104	3.59	0.427	266	5.20
105	26.3	6.42	1620	55.9
Prazosin	0.112	0.195	0.223	0.054
Terazosin	0.829	3.311	2.027	0.689
Doxazosin	0.423	0.912	0.793	0.231

Functional Antagonism at α -1 Adrenoceptors

Functional assays indicative of pharmacologically defined α -1 adrenoceptors were used to further characterize compounds. Inhibition of phenylephrine (PE)-induced contraction of canine prostate smooth muscle can be correlated with α -1A adrenoceptor activation.

5 Inhibition of PE-induced contraction of rat spleen is representative of α -1B adrenoceptor antagonism and inhibition of PE-induced contraction of rat vas deferens correlates with α -1A adrenoceptor antagonism (R. P. Burt, C. R. Chapple and I. Marshall, *Br. J. Pharmacol.* **107**: P324 (1992)). For each of these models, agonist dose response curves were repeated against increasing concentrations of test agent to derive a Schild plot [$\log (EC_{50} - 1)$ against \log

10 (molarity of test agent)] to determine the pA_2 . Data for prazosin, terazosin and doxazosin actually demonstrate a more potent effect on spleen smooth muscle by approximately an order of magnitude.

Canine prostate strips were used *in vitro* as previously described (Hieble, J.P., Boyce, A.J. and Caine, M., *Fed. Proc.*, **45**: 2609-2614 (1986)), to determine antagonist potencies

15 against phenylephrine-induced contractions.

The results are shown in Tables 2. The results show that the compounds of the invention exhibit functional antagonism of α -1 adrenoceptors.

Table 2.

In Vitro Data for Functional Antagonism at α -1 Adrenoceptors

In Vitro Characterization (pA_2)				
Ex. No	Rat Vas	Rat Spleen	Dog Prostate	Rat Aorta
1			8.69	
2			7.95	
3			9.43	
13	9.8	8.39	9.91	10.39
17	9.95	7.96		9.2
18	9.13	7.71		9.34
25	9.92	8.7		10.86
26	10.34	8.5	9.15	10.18
28	9.39	8.36		9.71
29	9.36	7.91		9.3
30	9.6	7.67		9.33
31	9.64	7.85		9.1
32	9.46	7.24		9.31

33	9.02	7.83		9.15
34	9.23	8.12		9.19
35	8.9	7.96		9.13
36	9.27	8.09		9.43
37	9.69	8.03		9.64
38	9.55	7.71		8.94
39	9.79	6.83	8.52	7.89
40	8.52	6.12		8.35
41	9.45	8.4		10.77
42	9.59	8.56		10.41
43		7.66		
44	9.96	8.35		10.4
45	9.59	8.89		9.68
46	9.79	8.12		9.81
47	8.95	7.95		9.69
49		8.14		
48		7.4		
50	10.35	6.5	8.45	9.41
51	9.2	7.47		9.74
53	9.31	7.2		8.97
54		7.31		
63			6.65	
64			6.92	
65			7.76	
66			7.48	
67		6.83	7.33	
68			7.02	
69			6.91	
70	8.2	7.06		
74	9.1	8.19	9.03	
81		7.41		
85			8.6	
87	8.67	7.14		
88	8.74	7.14	8.09	
95		7.72	8.58	
97	8.81	7.76	8.6	

Prazosin	8.78	10.02	8.46	9.35
Terazosin	8.04	8.60	7.44	8.65
Doxazosin	8.69	9.51	7.59	8.97

In Vivo Determination of Intraurethral Pressure (IUP) in Canines

The intraurethral pressure (IUP) model in aged canines is an accepted model of measuring the effect of prostate smooth muscle contraction on urethral tone. Canines also have an enclosed prostate covering the urethral shaft thus providing an anatomical correlate with humans.

Beagle dogs (Marshall Farms) greater than 2 years of age and weighing between 12 and 15 kg were pre-anesthetized with thiopental sodium 15 mg/kg i.v. (Pentothal™, Abbott) and then placed under general anesthesia (isoflurane). A 7F Swan-Ganz balloon catheter (Multiflex - list no. 41224-01, Abbott) was lubricated with a water soluble jelly, inserted into the urethral orifice and advanced approximately 40 cm in male dogs (considerably less in females) until the balloon tip was placed well inside the bladder. The balloon was then inflated with 1 mL of room air and the catheter slowly withdrawn just past the first resistance that is felt at the bladder neck. Preliminary experiments in which dogs were sacrificed after such placement confirmed that this technique results in consistent positioning of the balloon within the prostatic urethra in males or the corresponding location in females. The balloon port of the catheter was connected to a Gould Statham P23Dd pressure transducer interfaced to a computerized data acquisition system (Modular Instruments, Inc., Malvern, PA) for the measurement of intraurethral pressure (IUP).

Dogs were then treated with propranolol to block the β -adrenoreceptor agonist effects of test agonists. Dose-response curves of the intraurethral pressor effect of epinephrine (EPI) were obtained before and after each of up to 3 increasing doses of a test antagonist (i.v.). Fifteen minutes was allowed after each antagonist dose for equilibration before the next agonist dose-response was initiated. The increase in IUP caused by a given agonist dose was allowed to return to baseline before the next dose was given. The estimated antagonist dissociation constant (*in vivo* pseudo pA_2) was determined by Schild analysis (Brune, et al., Drug Development Research, 34:267-275 (1995)).

The results are shown in Table 3. The results indicate that the compounds of the invention inhibit EPI induced increases in IUP.

Table 3
Inhibition of EPI Induced Increase in Canine IUP

In Vivo Characterization (pseudo pA2)	
Ex. No.	IUP
13	8.61
26	8.22
39	8.10
67	6.70
Prazosin	7.88
Terazosin	6.91
Doxazosin	6.90

5
Spontaneously Hypertensive Rat (SHR) Model

10 The SHR model historically has been used as a predictor for the hypotensive effects of α -1 adrenoreceptor antagonists. Male spontaneously hypertensive rats were anesthetized and the left femoral artery and vein catheterized for the measurement of mean arterial pressure (MAP) and drug administration respectively. The arterial catheter was connected to a Gould Statham p23ID transducer and the pressure waveform was recorded. MAP (mm Hg) and heart rate (HR, beats/min.) were determined on-line using a BUXCO Cardiovascular Analyzer. After a 30 minute pre-dose control period, each rat was given one dose of a test antagonist i.v. and the MAP and HR were monitored for an additional 2.5 hours. The area under the hypotensive response curve up to 60 minutes post dosing (T_{60} AUC) was determined using a trapezoidal rule integration of the percent change from control arterial pressure dataset. The results are expressed as a pED₅₀ value, which is defined as the negative log of the dose that produced a hypotensive response of -1250, which constitutes 50% of the area under the curve between SHR and normotensive rats.

20 The results are shown in Table 4. The results show that the compounds of the invention are weakly hypotensive.

Table 4
Spontaneously Hypertensive Rat (SHR) Assay

In Vivo Characterization (pseudo pA2)	
Ex. No.	SHR
13	6.15
26	6.4
39	5.2
67	4
97	5.9
Prazosin	7.4
Terazosin	6.59
Doxazosin	6.74

5

Pharmaceutical Compositions

The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.

10

The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray. The term "parenteral" administration as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

15

Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

20
25

These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium

lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Compositions for rectal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable

lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidylcholines (lecithins), both natural and synthetic.

5 Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 *et seq.*

Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or
10 propellants which may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of
15 administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

20 Generally dosage levels of about 0.01 to about 50, more preferably of about 0.05 to about 5 mg of active compound per kilogram of body weight per day are administered orally to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.

25 Methods for preparing the compounds of the invention are shown in Schemes 1-9. In the following Schemes, R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl. In the following schemes, n=1 or 2, m=1-6, R= alkyl, and Y, G, G', U, and U' are as defined previously.

30 Scheme 1 illustrates the general procedure for the preparation of the compounds of this invention. The secondary amine 1 is elaborated to the compounds of this invention (7) by one of two general methods. Alkylation of 1 with a haloalkyl nitrile in the presence of a non-nucleophilic base, such as ethyldiisopropylamine, K₂CO₃, or the like to yield an intermediate nitrile (2) which is then reduced using LiAlH₄, AlH₃, BH₃, catalytic hydrogenation, or the like produces the intermediate aminoalkyl substituted analog 3. Treatment of this amine with a
35 heterocyclic isocyanate of the general formula 5 yields an intermediate urea, which either spontaneously cyclizes to the pyrimidinedione product 7, or does so under base catalysis.

Alternatively, when R is other than H, the carbamoyl chloride 6 replaces the isocyanate 5. Alternatively, the secondary amine 1 can be reacted with the haloalkyl heterocyclic urea of the general formula 4 in the presence of a non-nucleophilic base such as ethyldiisopropylamine, K_2CO_3 , or the like to the yield the title compounds of the invention (7) directly.

5 The amine 1, where $n=1$, is prepared as outlined in Scheme 2 (for cis ring fusion) and Scheme 3 (for trans ring fusion). For the cis fused product, treatment of the appropriately substituted coumarin 8 with the azomethine ylide precursor N-trimethylsilylmethyl-N-methoxymethyl-benzylamine 9 produces the cyclized product 10 selectively as the cis isomer. Reduction of the lactone with $LiAlH_4$, BH_3 , AlH_3 , $LiBH_4$, or the like yield the alcohol 11.

10 Activation of the primary alcohol as a chloride 12, bromide, mesylate, or the like, followed by treatment with a base, such as $KOtBu$, $NaOMe$, $NaOH$, K_2CO_3 , or the like results in cyclization to the cis fused benzopyranopyrrole nucleus 13. Removal of the benzyl group from the amine, most conveniently achieved by catalytic hydrogenation, yields the cis fused secondary amine 14.

15 For the trans fused product, treatment of the appropriately substituted trans cinnamate 15 (Scheme 3) with the azomethine ylide precursor N-trimethylsilylmethyl-N-methoxymethyl-benzylamine 9 produces the cyclized product 16 selectively as the trans isomer. Reduction of the ester with $LiAlH_4$, BH_3 , AlH_3 or the like, followed by hydrolysis of the phenol protecting group, yields the alcohol 17. Activation of the primary alcohol as a chloride 18, bromide, mesylate, or the like, followed by treatment with a base, such as $KOtBu$, $NaOMe$, $NaOH$, K_2CO_3 , or the like results in cyclization to the trans fused benzopyranopyrrole nucleus 19.

20 Removal of the benzyl group from the amine, most conveniently achieved by catalytic hydrogenation, yields the trans fused secondary amine 20.

25 In a preferred embodiment of this invention, substitution of the azomethine ylide precursor 21, derived from (R)- α -methylbenzyl amine, for 9, derived from benzyl amine, allows for synthesis of the preferred (3aR, 9bR) amine 22 from 5-methoxycoumarin (Scheme 4), and the preferred (3aS, 9bR) amine 23 from the ethyl 2-methoxy-6-methoxymethyl-trans-cinnamate (Scheme 5). In Scheme 4, the reagents PPh_3/CCl_4 may be replaced using methanesulfonyl chloride and triethylamine.

30 In another preferred embodiment of this invention, a precursor of a compound of formula 1 wherein $n=2$, (4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyridine (28) is prepared as show in Scheme 6. The imide 24 is prepared from ethyl 2-methoxy-6-methoxymethyl cinnamate and ethyl N-benzylamidomalonate according to the method of Faruk and Martin, U. S. Patent No. 4,902,801. Reduction with $LiAlH_4$, AlH_3 , BH_3 , or the like, followed by conversion of the primary alcohol to a suitable leaving group, such as chloro, bromo, mesylate, or the like; hydrolysis of the protected phenol, and

35


intramolecular cyclization, followed by debenzylation yields the racemic *trans*-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyridine 25. Reaction of the secondary amine with a chiral chloroformate, such as menthyl chloroformate, yields a mixture of diastereomeric carbamates, which can then be separated chromatographically. Removal of the carbamate group by treatment with *n*-BuLi then yields the enantiomerically resolved secondary amine 28.

In another preferred embodiment of the present invention, the compounds of Formulae I-XIV and Formulae XXI-XXV may be prepared as shown in Scheme 7. Condensation of phenylglyoxal mono oxime (30) with 2-aminomalononitrile tosylate salt (31) followed by reduction of the resulting pyrazine N-oxide (32) with triethylphosphite, sodium bisulfite, triphenylphosphine, or the like, regioselectivity yields 33. Diazotization of the amino functionality, followed by displacement with CuBr, CuCl or the like, yields the intermediate chloro- or bromopyrazine (34), which upon base promoted condensation with methylthioglycolate yields the thienopyrazine intermediate (35). Use of other alkylthioglycolates such as ethyl, *n*-propyl, *n*-alkyl, or substituted alkyls would yield alternative thienopyrazine intermediates with differentiated alkyl groups on the ester. Reaction of the thienopyrazine intermediate (35) with phosgene, diphosgene, triphosgene, or the like, in the presence of an inert solvent produces the isocyanate (36) of Formula XXV.


In another preferred embodiment of the present invention, a compound of XV-XX may be prepared according to the method outlined in Scheme 8. Activation of the free hydroxyl of (37) as a methanesulfonate, toluenesulfonate, benzenesulfonate, or the like, or as a halide, followed by nucleophilic displacement with 2-bromo- or 2-iodoresorcinol mono methyl ether yields the ether intermediate (40). The ether intermediate (40) where X=Br or I may be cyclized by forming the enolate of the lactam with a metal amide (such as KHMDS, LiHMDS, LDA, NaNH₂, KNH₂, or the like) and exposing to a metal salt (Cu⁺, Cu²⁺, Mn²⁺, Fe²⁺, Fe³⁺, and the like) similar to the work of McKillop (McKillop, J. Chem. Soc., Perkin Trans, I., 1993, 2433), herein incorporated entirely by reference. Alternatively, a metal enolate of the lactam (40) can be exposed to a transition metal complex (such as Pd/C or Pd(PPh₃)₄) or a transition metal salt complex (salts of Pd²⁺ that may or may not be complexed to phosphines, amines, or nitriles) in order to make the compound (41) where R is an unsubstituted benzyl group. Deprotection of 41 can be accomplished using catalytic hydrogenation conditions. The alkylation of 42 with a haloalkyl nitrile in the presence of a non-nucleophilic base, such as ethyldiisopropylamine, K₂Co₃, or the like, to yield an intermediate nitrile (43) which is then reduced using LiAlH₄, AlH₃, BH₃, catalytic hydrogenation, or the like, produces the intermediate aminoalkyl substituted analog (44).

In another embodiment of the present invention, a lactam intermediate may be prepared as shown in Scheme 9 by reacting 1-hydroxy-2-formaldehyde-3-methoxybenzene (45) in a protic solvent, such as iso-propyl alcohol or the like, with a tertiary amine base, such as DABCO or the like, and methyl acrylate to produce the chromene (47). Condensation of the chromene with nitromethane in the presence of a non-nucleophilic base such as DBU or potassium tert-butoxide or the like yields the intermediate nitroester (48) which is then reduced to the lactam (49) using catalytic hydrogenation and a base such as sodium methoxide or the like.


Scheme 1




Scheme 2




Scheme 3




Scheme 4




Scheme 5




Scheme 6




Scheme 7




Scheme 7b



Scheme 8



Scheme 9



5 The foregoing may be better understood by reference to the following examples which are provided for illustration and not intended to limit the scope of the inventive concept.

The following abbreviations are used: K_2CO_3 for potassium carbonate, $LiAlH_4$ for lithium aluminum hydride, AlH_3 for aluminum hydride, BH_3 for borane, BH_3 -DMS for borane dimethylsulfide complex, DABCO for 1,4-diazabicyclo[2.2.2]octane, DBU for 1,8-diazabicyclo[5.4.0]undec-7-ene, DMF for dimethylformamide, DMSO for dimethylsulfoxide, Et_3N for triethylamine, Et_2O for diethyl ether, EtOAc for ethyl acetate, EtOH for ethanol, $KOtBu$ for potassium tert-butoxide, LDA for lithium diisopropylamide, MeOH for methanol, NaOMe for sodium methoxide, NaOH for sodium hydroxide, HCl for hydrochloric acid, H_2/Pd for hydrogen and a palladium catalyst, iPrOH for isopropyl alcohol and THF for tetrahydrofuran, cat. TFA for catalytic trifluoroacetic acid, PPh_3/CCl_4 for triphenyl phosphine/carbon tetrachloride, and n-BuLi for n-butyllithium.

Example 1

20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1,1-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 1A(3aR,9bR)-cis-9-Methoxy-2-(R)- α -methylbenzyl-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-4-one

5
10
15
5-Methoxycoumarin (22.3 g, 126 mmol) and trifluoroacetic acid (0.97 mL, 12.6 mmol) were combined in CH₂Cl₂ (200 mL) and cooled to 0° C. To the stirred solution was added N-methoxymethyl-N-trimethylsilylmethyl-(R)- α -methylbenzylamine (63.4 g, 252 mmol) over 30 min. The reaction was stirred an additional 30 min at 0° C, and then 1 hr at 25° C. The reaction mixture was washed with 5% NaHCO₃, the organic layer was dried and evaporated. The resulting oil was suspended in diethyl ether, and after 2 hr, the title compound was collected by filtration, (15.4 g, 38%). ¹H NMR (300 MHz, CDCl₃) δ 1.36 (d, 3H), 2.41 (dd, 1H), 3.04 (d, 1H), 3.05-3.15 (m, 2H), 3.23 (m, 1H), 3.32 (t, 1H), 3.75 (m, 1H), 3.79 (s, 3H), 6.61 (d, 1H), 6.67 (d, 1H), 7.18 (t, 1H), 7.20-7.35 (m, 5H).

Example 1B(3aR,9bR)-cis-9-Methoxy-2-(R)- α -methylbenzyl-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrole

20
25
30
The resulting product from Example 1A (15.3 g, 47 mmol) in THF (200 mL) was added to a suspension of LiAlH₄ (3.6 g, 94 mol) in THF (200 mL) over 15 min. After 2 hr at 25° C, the reaction was quenched (Fieser workup), and the intermediate alcohol isolated by evaporation of solvent. The alcohol (15.2 g, 46 mmol) was combined with triphenylphosphine (24.3 g, 93 mmol) in a 4:1 mixture of acetonitrile and CCl₄, and the resulting solution was heated to reflux for 1 hr. The solvent was evaporated and the resulting product was isolated as a mixture of the title compound and an intermediate chlorophenol. The mixture was treated with 1 M potassium t-butoxide (12 mmol) in THF (50 mL). Solvent was evaporated and the product was partitioned between dil aq. NaOH and ethyl acetate. The organic phase was dried and evaporated to yield, after chromatographic purification, 11.9 g (84%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.36 (d, 3H), 2.23-2.31 (m, 2H), 2.59 (m, 1H), 3.04 (dd, 1H), 3.20 (q, 1H), 3.23 (q, 1H), 3.38 (q, 1H), 3.77 (s, 3H), 3.81 (q, 1H), 4.01 (q, 1H), 6.41 (d, 1H), 6.52 (d, 1H), 7.04 (t, 1H), 7.20-7.35 (m, 5H).

Example 1C(3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[11]-benzopyrano[3,4-c]pyrrole

The product from Example 1B (7.7 g, 24.9 mmol) was dissolved in methanol (300 mL) and palladium hydroxide on charcoal (1.5 g) was added. The reaction was stirred rapidly under one atmosphere of H₂ for 18 hr. The reaction was filtered and evaporated to yield the title compound (4.6 g, 90%): ¹H NMR (300 MHz, CDCl₃) δ 2.55 (m, 1H), 2.67 (dd, 1H), 2.80 (dd, 1H), 3.21 (q, 1H), 3.32 (dd, 1H), 3.62 (dd, 1H), 3.70 (m, 1H), 3.81 (s, 3H), 4.10 (dd, 1H), 6.46 (d, 1H), 6.55 (d, 1H), 7.17 (t, 1H); [α]_D -95.7° (MeOH).

Example 1D(3aR,9bR)-cis-2-(3-cyanopropyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[11]-benzopyrano[3,4-c]pyrrole

The product from Example 1C (7.0 g, 34 mmol) was combined with 4-bromobutyronitrile (5.6 g, 37.5 mmol) and ethyldiisopropylamine (8.9 mL, 51 mmol) in acetonitrile (50 mL), and the reaction was stirred at 80° C for 4 hr. The reaction was quenched in 5% aq. NaHCO₃ and extracted with CH₂Cl₂. The organic extracts were washed with brine, dried and evaporated. The resulting product was purified by column chromatography to yield the title compound (7.5 g, 81%): ¹H NMR (300 MHz, CDCl₃) δ 1.82 (m, 2H), 2.30 (m, 2H), 2.43 (t, 2H), 2.45-2.65 (m, 3H), 3.04 (dd, 1H), 3.23-3.42 (m, 2H), 3.79 (dd, 1H), 3.82 (s, 3H), 4.06 (dd, 1H), 6.46 (d, 1H), 6.54 (d, 1H), 7.07 (t, 1H).

Example 1E(3aR,9bR)-cis-2-(4-aminobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[11]-benzopyrano[3,4-c]pyrrole

LiAlH₄ (7.8 g, 207 mmol) was suspended in THF (200 mL) and cooled to 0° C. To the suspension was added AlCl₃ (9.2 g, 69 mmol) in small portions over 15 min. The product from Example 1D (7.5 g, 27.5 mmol) in THF (50 mL) was then added over 15 min, and the reaction was allowed to warm to 25° C and stir for 1.5 hr. The reaction was quenched by the addition of 10.5 mL H₂O, 10.5 mL 15% aq. KOH, and 42 mL H₂O. The reaction was filtered through celite, and the solvent evaporated to yield the title compound (6.6 g, 87%): ¹H NMR (300 MHz, CDCl₃) δ 1.65-1.80 (m, 4H), 2.19 (m, 1H), 2.25 (dd, 1H), 2.42 (m, 1H), 2.52 (t, 2H), 3.14 (dd, 1H), 3.18-3.30 (m, 2H), 3.79 (dd, 1H), 3.80 (s, 3H), 4.04 (dd, 1H), 6.46 (d, 1H), 6.54 (d, 1H), 7.07 (t, 1H).

Example 1F

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 Methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate, prepared by the procedure described in *J. Heterocyclic Chem.*, **24**: 85 (1987), (0.624 g, 3.00 mmol) and triethylamine (0.84 mL, 6.0 mmol) were dissolved in THF (20 mL), and to the solution was added 1.7 mL of a 1.93 M solution of phosgene in toluene (3.3 mmol). After 2h, the product from Example 1E (0.78 g, 2.8 mmol) was added. After 4h, the reaction was quenched in aq. 5% NaHCO₃, and
 10 extracted with CH₂Cl₂. The organic extracts were dried, and evaporated. The resulting urea was dissolved in toluene (100 mL) and heated to reflux for 18 h. The cooled reaction mixture was filtered, and the resulting free base of the title compound was treated with anhydrous HCl in ethanol. Addition of diethyl ether resulted in crystallization of the title compound (0.76 g, 57%): m.p. 241-243° (dec); ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.56-1.99 (m, 2H),
 15 1.71-1.83 (m, 2H), 2.26 (t, J=9 Hz, 1H), 2.34 (dd, J=6, 10 Hz, 1H), 2.50-2.70 (m, 3H), 3.26 (dd, J=7, 10 Hz, 1H), 3.43 (q, J=8 Hz, 1H), 3.63 (t, J=8 Hz, 1H), 3.79 (s, 3H), 3.76-3.86 (m, 1H), 4.01 (dd, J=4, 11 Hz, 1H), 4.11 (t, J=7 Hz, 1H), 6.43 (d, J=8 Hz, 1H), 6.49 (d, J=8 Hz, 1H), 7.04 (t, J=8 Hz, 1H), 7.49 (dd, J=4, 8 Hz, 1H), 8.23 (dd, J=1, 8 Hz, 1H), 8.78 (dd, J=1, 4 Hz, 1H); MS (DCI(NH₃)) m/e 479 (M+H)⁺; Analysis calc'd for C₂₅H₂₆N₄O₄S·HCl·(H₂O)_{0.25}: C, 57.80; H, 5.34; N, 10.78; found: C, 57.72; H, 5.46; N, 10.58.

Example 1G

Alternative synthesis of (3aR,9bR)-cis-2-(4-aminobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

25 To a solution of 5-methoxycoumarin in THF at 15°C, was added trifluoroacetic acid. To this was added a solution of N- methoxymethyl-N trimethylsilylmethyl-(R)-α-methylbenzylamine in t-butylmethyl ether. After the addition was complete, the mixture was stirred at 25°C for 1 hour and then concentrated in-vacuo. The residue was diluted with ethyl acetate, stirred for 1.5 hours at 5 C, and filtered. The filtercake was washed with ethyl acetate and dried to yield (3aR,9bR)-cis-9-Methoxy-2-(R)-α-methylbenzyl-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-4-one.

35 Lithium borohydride and tetrahydrofuran were combined and cooled to less than -10°C. A solution of pyrrolidine lactone in tetrahydrofuran was slowly added while keeping the temperature below 0°C. The solution was stirred at approx 5°C for 1 hour and then distilled

under vacuum. Methanol was added to the residue and the contents were refluxed for 2 hours. A solution of ammonium chloride in water was added and the reaction mixture was distilled under vacuum at less than 55°C. The residue was extracted with toluene and the toluene layer was washed with distilled water. The washed toluene layer was then distilled down under vacuum at less than 55°C.

Tetrahydrofuran was added to the toluene and cooled to 0±10°C and triethylamine was added. Methanesulfonyl chloride in toluene was added and the mixture was stirred at 0±10°C for 1 hour. A solution of potassium t-butoxide in tetrahydrofuran was added and stirred below 10°C for not less than 1 hour. Toluene was added and the layers were washed with ammonium chloride in water followed by distilled water. A sample of the solution may then be concentrated in-vacuo.

Alternatively, the material could be purified by concentrating in-vacuo to an oil, adding isopropanol and then anhydrous hydrogen chloride in isopropanol. The solution was stirred for 3 hours at room temperature and the resultant slurry was filtered. The filter cake was washed with isopropanol and dried in an oven at 35°C for 16 hours to yield the hydrochloride salt (3aR,9bR)-cis-9-Methoxy-2-(R)-α-methylbenzyl-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole.

To a solution of (3aR,9bR)-cis-9-methoxy-2-(R)-α-methylbenzyl-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole hydrochloride in ethanol was added 50% wet 5% palladium on carbon. The flask was purged with hydrogen and heated to 50°C at 50psi for 16 hours. The catalyst was filtered and the solvent removed under vacuum at approx. 40°C to yield the hydrochloride salt of (3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole.

The product from Example 1C (7.0 g, 34 mmol) was combined with 4-bromobutyronitrile (5.6 g, 37.5 mmol) and ethyldiisopropylamine (8.9 mL, 51 mmol) in acetonitrile (50 mL), and the reaction was stirred at 80°C for 4 hr. The reaction was quenched in 5% aq. NaHCO₃ and extracted with CH₂Cl₂. The organic extracts were washed with brine, dried and evaporated. The resulting product was purified by column chromatography to yield (3aR,9bR)-cis-2-(3-cyanopropyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole.

Alternative to the process in Example 1E, a nitrogen purged hydrogenator was charged with Raney Nickel and methanol. The slurry was stirred and allowed to settle. The supernate was removed via a dip tube. The residue was then slurried again with methanol and the supernate again removed with a dip tube. This was repeated a third and fourth time. The Raney Nickel was then slurried with methanol and a solution of the product from example 1D in methanol was added. The internal temperature was cooled to approx. 0°C and ammonia added.

The hydrogenator was pressure purged three times with hydrogen and pressurized to 50psi. The solution was hydrogenated at approx. 25°C for 2 hours. Once the reaction was complete, the catalyst was filtered through a bed of celite and the filtercake washed with methanol. The combined filtrates were then charged to another reactor and distilled under vacuum at less than 40°C to a residue. Toluene was added, followed by a solution of sodium hydroxide in water. The biphasic solution was filtered through a pad of celite into another reactor and the layers separated. The organics were washed with water and the toluene distilled under vacuum at less than 45°C to yield the primary amine.

Example 1H

Synthesis of Compound 40 in Scheme 8

To a solution of water (500mL) and itaconic acid (108.9g, 0.83mol) was added phenethylamine (101.4g, 0.83mol). This was heated to reflux for 24h, cooled to room temperature, and the liquid decanted. The solid was then dissolved into 40% aqueous ethanol (800mL) at reflux. The solution was slowly cooled to room temperature and filtered. The filtercake was washed with water (200mL), twice with ethanol (200mL each), and dried to give 82.1g of a white solid.

A solution of the white solid (82g, 0.35mol) in methanol (500mL) was heated to reflux with trimethylorthoformate (37.3g, 0.35mol) and sulfuric acid (ca 0.5g) for 16h. This was cooled to room temperature and sodium borohydride (26.48g, 0.7mol) was added portionwise. The solution was then heated to reflux for 2h, concentrated *in-vacuo* ca 300mL. The solution was diluted with aqueous ammonium chloride (200mL) and extracted with ethyl acetate (once with 500mL, 3 times with 300mL). The combined organic layers were concentrated *in-vacuo* to an oil (34g) of the compound (37) that was comparable to the previously reported compound (Domagala, *J. Med. Chem.*, 1987, 30, 1711).

To a solution of alcohol, compound (37) (30g, 0.137mol) in THF (300mL), was added triethylamine (13.84g, 0.137mol) followed by tosyl chloride (26.08g, 0.137mol). This was stirred 14h at room temperature. The reaction was diluted with ethyl acetate (300mL) and washed with 5% sodium bicarbonate (400mL), and twice with 1% sodium bicarbonate (300mL), dried over sodium sulfate, and concentrated *in-vacuo* to an oil of the compound (38): ¹HNMR (CDCl₃) δ 7.78 (d, 2H, J=8Hz), 7.4-7.2 (m, 7H), 5.45 (q, 1H, J=6.5Hz), 4.0-3.9 (m, 2H), 3.1-3.0 (m, 2H), 2.65-2.5 (m, 1H), 2.4 (d, 1H, J=12Hz), 2.45 (s, 3H), 2.15-2.05 (m, 1H), 1.43 (d, 3H, J=7Hz).

To a solution of 3-methoxyphenol (100g, 0.81mol) in methylene chloride (500mL) was added dihydropyran (184mL, 2.01mol) and pyridinium p-toluenesulfonate (10.1g, 0.04mol) at room temperature. This solution was stirred at room temperature for 5h before quenching with

saturated sodium bicarbonate (250mL). The organics were separated and the aqueous extracted twice with methylene chloride (250mL). The combined organics were then washed with saturated NaCl (250mL), dried over sodium sulfate and concentrated *in-vacuo* to an oil (184g).

To the resulting oil (10.45g, 50mmol) in heptane (210mL) at 0°C, was added 1.6M butyl-lithium (45mL, 72mmol). This was stirred for 3 hours and then quenched with a solution of iodine (22.1g 8.7mmol) in ether (250mL). The reaction mixture was then stirred for 30min at 0°C, quenched with sat. sodium bisulfate (200mL) and extracted with ether (3x250mL). The combined organics were washed with sat. sodium bisulfate (200mL), sat. NaCl (200mL), and dried over sodium sulfate. Concentration *in-vacuo* yielded an oil. The crude oil was dissolved in ethanol (250mL) and pyridinium p-toluenesulfonate was added. The mixture was heated to 70°C for 1.5h, cooled to room temperature, diluted with ethyl acetate (250mL) and washed with sat. NaCl (250mL). The aqueous was extracted again twice with ethyl acetate (250mL). The organics were combined, dried over sodium sulfate, and concentrated *in-vacuo* to an oil of the compound (39): MS (CI) *m/z* (rel intensity 250 ([M+I]⁺100).

To a solution of the 2-bromophenol (1.73g, 10mmol) in DMF (20mL) at 0°C was added potassium tertbutoxide (1.12g, 10mmol). This was stirred for 15min at 0°C before adding the compound from example 38 (3.73g, 10mmol). This was heated to 60°C for 16h, cooled to room temperature, diluted with ethyl acetate (200mL) and washed twice with water (1x200mL, 1x100mL). The organics were dried over sodium sulfate and concentrated *in-vacuo* to approx. 20mL. This was diluted 1:1 (v/v) with heptane and passed through a pad of silica (1.5g). The eluent was concentrated *in-vacuo* to give the compound (40) (3g, 80%) as an oil.

Example 2

3-[4-((3aS,9bS)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 2A

(3aS,9bS)-cis-9-Methoxy-2-(S)- α -methylbenzyl-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-4-one

5-Methoxycoumarin and N-methoxymethyl-N-trimethylsilylmethyl-(S)- α -methylbenzylamine were treated in an analogous manner as described in Example 1A. ¹H NMR (300 MHz, CDCl₃) δ 1.36 (d, 3H), 2.41 (dd, 1H), 3.04 (d, 1H), 3.05-3.15 (m, 2H), 3.23 (m, 1H), 3.32 (t, 1H), 3.75 (m, 1H), 3.79 (s, 3H), 6.61 (d, 1H), 6.67 (d, 1H), 7.18 (t, 1H), 7.20-7.35 (m, 5H).

Example 2B

(3aS,9bS)-cis-9-Methoxy-2-(S)- α -methylbenzyl-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

The resulting product from Example 2A was treated in an analogous manner as described in Example 1B. ^1H NMR (300 MHz, CDCl_3) δ 1.36 (d, 3H), 2.23-2.31 (m, 2H), 2.59 (m, 1H), 3.04 (dd, 1H), 3.20 (q, 1H), 3.23 (q, 1H), 3.38 (q, 1H), 3.77 (s, 3H), 3.81 (q, 1H), 4.01 (q, 1H), 6.41 (d, 1H), 6.52 (d, 1H), 7.04 (t, 1H), 7.20-7.35 (m, 5H).

Example 2C

(3aS,9bS)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

The product from Example 2B was treated in an analogous manner as described in Example 1C. ^1H NMR (300 MHz, CDCl_3) δ 2.55 (m, 1H), 2.67 (dd, 1H), 2.80 (dd, 1H), 3.21 (q, 1H), 3.32 (dd, 1H), 3.62 (dd, 1H), 3.70 (m, 1H), 3.81 (s, 3H), 4.10 (dd, 1H), 6.46 (d, 1H), 6.55 (d, 1H), 7.17 (t, 1H); $[\alpha]_D^{25}$ MeOH +95.2°.

Example 2D

(3aS,9bS)-cis-2-(3-cyanopropyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

The product from Example 2C was treated in an analogous manner as described in Example 1D. ^1H NMR (300 MHz, CDCl_3) δ 1.82 (m, 2H), 2.30 (m, 2H), 2.43 (t, 2H), 2.45-2.65 (m, 3H), 3.04 (dd, 1H), 3.23-3.42 (m, 2H), 3.79 (dd, 1H), 3.82 (s, 3H), 4.06 (dd, 1H), 6.46 (d, 1H), 6.54 (d, 1H), 7.07 (t, 1H).

Example 2E

(3aS,9bS)-cis-2-(4-aminobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

The product from Example 2D was treated in an analogous manner as described in Example 1E. ^1H NMR (300 MHz, CDCl_3) δ 1.65-1.80 (m, 4H), 2.19 (m, 1H), 2.25 (dd, 1H), 2.42 (m, 1H), 2.52 (t, 2H), 3.14 (dd, 1H), 3.18-3.30 (m, 2H), 3.79 (dd, 1H), 3.80 (s, 3H), 4.04 (dd, 1H), 6.46 (d, 1H), 6.54 (d, 1H), 7.07 (t, 1H).

Example 2F

3-[4-((3aS,9bS)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 2E (0.800 g, 2.9 mmol) and methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.624 g, 3.00 mmol) were treated as described in Example 1F to yield 1.1 g (79 %) of the title compound: m.p. 241-243° (dec); ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.56-1.99 (m, 2H), 1.71-1.83 (m, 2H), 2.26 (t, J=9 Hz, 1H), 2.34 (dd, J=6, 10 Hz, 1H), 2.50-2.70 (m, 3H), 3.26 (dd, J=7, 10 Hz, 1H), 3.43 (q, J=8 Hz, 1H), 3.63 (t, J=8 Hz, 1H), 3.79 (s, 3H), 3.76-3.86 (m, 1H), 4.01 (dd, J=4, 11 Hz, 1H), 4.11 (t, J=7 Hz, 1H), 6.43 (d, J=8 Hz, 1H), 6.49 (d, J=8 Hz, 1H), 7.04 (t, J=8 Hz, 1H), 7.49 (dd, J=4, 8 Hz, 1H), 8.23 (dd, J=1, 8 Hz, 1H), 8.78 (dd, J=1, 4 Hz, 1H); MS (DCI(NH₃)) *m/e* 479 (M+H)⁺; Analysis calc'd for C₂₅H₂₆N₄O₄S•HCl•(H₂O)_{0.25}: C, 57.80; H, 5.34; N, 10.78; found: C, 57.85; H, 5.46; N, 10.65.

Example 3

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 3A

3-(R)-(2-Hydroxy-6-methoxy)phenyl-4-(S)-hydroxymethyl-N-(R)-α-methylbenzyl-pyrrolidine

25 Ethyl 2-methoxy-6-methoxymethyl-cinnamate (36 g, 160 mmol) and trifluoroacetic acid (1.23 mL, 16 mmol) were combined in CH₂Cl₂ (800 mL) and cooled to 0° C. To the stirred solution was added N-methoxymethyl-N-trimethylsilylmethyl-(R)-α-methylbenzylamine (80 g, 320 mmol) in 200 mL CH₂Cl₂ over 30 min. The reaction was stirred an additional 2.5 hr at 0° C. The reaction mixture was washed with 5% NaHCO₃, the organic layer was dried and evaporated. The crude product was dissolved in THF (150 mL) and added to a stirred suspension of LiAlH₄ (12.1 g, 320 mmol). The reaction was quenched, (Fieser workup), 30 filtered through celite, and evaporated. The product was dissolved in methanol (850 mL) and 4N HCl (120 mL) was added. After heating at reflux for 2h, the solvent was evaporated, and the residue was partitioned between sat. NaHCO₃ solution and ethyl acetate. The organic extracts were dried and evaporated. The crude product was purified by chromatography, eluting 2:1 diethyl ether:hexane to yield 22.1 g (42%) of the title compound as the faster moving 35 diastereomer: ¹H NMR (300 MHz, CDCl₃) δ 1.48 (d, 3H), 1.81 (t, 1H), 2.16 (m, 1H), 2.36

(m, 1H), 2.58 (t, 1H), 3.05 (t, 1H), 3.40 (m, 2H), 3.53 (m, 2H), 3.80 (dd, 1H), 3.83 (s, 3H), 6.38 (d, 1H), 6.60 (d, 1H), 7.05 (t, 1H), 7.22-7.40 (m, 5H), 12.62 (br s, 1H).

Example 3B

(3aS,9bR)-trans-9-Methoxy-2-(R)- α -methylbenzyl]-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

The product from Example 3A (22.1 g, 67.0 mmol) was dissolved in 290 mL of a 4:1 mixture of acetonitrile and CCl_4 . To the solution was added triphenylphosphine (35.4 g, 135 mmol) and the reaction was heated to 80°C for 20 min. The reaction was concentrated, and passed through a silica gel column, eluting with 1:1 hexane:diethyl ether. The product, which contained a mixture of the title compound and the chloro intermediate, was dissolved in THF (300 mL) and 41 mL of 1.0M potassium t-butoxide in THF was added. After 18 hr, the THF was evaporated and the resulting product partitioned between 1N NaOH and diethyl ether. The organic extracts were dried and evaporated, and the resulting product was chromatographed over silica gel, eluting 1:1 hexane:diethyl ether to yield 13.2 g (63%) of the title compound: ^1H NMR (300 MHz, CDCl_3) δ 1.45 (d, 3H), 2.28 (m, 1H), 2.44 (dd, 1H), 2.70-2.90 (m, 2H), 3.54 (m, 1H), 3.69 (s, 3H), 3.70 (q, 1H), 3.99 (dd, 1H), 4.38 (dd, 1H), 6.37 (d, 1H), 6.47 (d, 1H), 7.04 (t, 1H), 7.20-7.40 (m, 5H).

Example 3C

(3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3.4-c]pyrrole

The product from Example 3B (13.0 g, 42 mmol) was treated as described in Example 1C to yield 8.08 g (94%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 2.07 (br s, 1H), 2.24 (m, 1H), 2.70 (m, 2H), 2.84 (t, 1H), 3.21 (dd, 1H), 3.77 (s, 3H), 3.83 (dd, 1H), 4.07 (dd, 1H), 4.53 (dd, 1H), 6.40 (d, 1H), 6.51 (d, 1H), 7.06 (t, 1H); [α]_D MeOH -94.8°.

Example 3D

(3aS,9bR)-trans-2-(3-cyanopropyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1,1-benzopyrano[3,4-c]pyrrole

The product from Example 3C (8.0 g, 39 mmol), 4-bromobutyronitrile (6.3 g, 43 mmol), and diisopropylethylamine (7.6 g, 58 mmol) were treated as described in Example 1D to yield 7.1 g (67%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.84 (m, 2H), 2.30

(m, 1H), 2.46 (t, 2H), 2.55 (dd, 1H), 2.70-2.85 (m, 4H), 2.91 (dd, 1H), 3.52 (m, 1H), 3.78 (s, 3H), 4.06 (dd, 1H), 4.45 (dd, 1H), 6.39 (d, 1H), 6.49 (d, 1H), 7.05 (t, 1H).

Example 3E

(3aS,9bR)-trans-2-(4-aminobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

The product from Example 3D (7.1 g, 26 mmol) was treated as described in Example 1E to yield 6.29 g (87%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.40-1.80 (m, 4H), 2.32 (m, 1H), 2.57 (t, 1H), 2.62-2.90 (m, 4H), 2.95 (t, 1H), 3.60 (m, 1H), 3.78 (s, 3H), 4.06 (dd, 1H), 4.45 (dd, 1H), 6.40 (d, 1H), 6.49 (d, 1H), 7.04 (t, 1H).

Example 3F

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 3E (0.800 g, 2.9 mmol) and methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.624 g, 3.00 mmol) were treated as described in Example 1F to yield 0.70 g (50 %) of the title compound: m.p. > 255°; ¹H NMR (300 MHz, DMSO-d₆ (free base)) δ 1.42-1.54 (m, 2H), 1.60-1.72 (m, 2H), 2.04-2.18 (m, 1H), 2.25-2.89 (m, 4H), 3.10-3.48 (m, 3H), 3.68 (s, 3H), 3.95 (t, J=7 Hz, 2H), 4.02 (dd, J=10, 12 Hz, 1H), 4.39 (dd, J=4, 10 Hz, 1H), 6.39 (dd, J=1, 8 Hz, 1H), 6.44 (dd, J=1, 8 Hz, 1H), 7.01 (t, J=8 Hz, 1H), 7.64 (dd, J=5, 8 Hz, 1H), 8.63 (dd, J=1, 8 Hz, 1H), 8.83 (dd, J=1, 5 Hz, 1H); MS (DCI(NH₃)) m/e 479 (M+H)⁺; Analysis calc'd for C₂₅H₂₆N₄O₄S•HCl•(H₂O)_{0.5}: C, 57.30; H, 5.39; N, 10.69; found: C, 57.08; H, 5.43; N, 10.80.

Example 4

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 4A

(3aR,9bS)-trans-2-(4-aminobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

Ethyl 2-methoxy-6-methoxymethyl-cinnamate and N-methoxymethyl-N-trimethylsilylmethyl-(S)-α-methylbenzylamine were treated, in an analogous manner as

described in Examples 3A-E: ^1H NMR (300 MHz, CDCl_3) δ 1.40-1.80 (m, 4H), 2.32 (m, 1H), 2.57 (t, 1H), 2.62-2.90 (m, 4H), 2.95 (t, 1H), 3.60 (m, 1H), 3.78 (s, 3H), 4.06 (dd, 1H), 4.45 (dd, 1H), 6.40 (d, 1H), 6.49 (d, 1H), 7.04 (t, 1H).

5

Example 4B

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 4A (680 mg, 2.5 mmol) and methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (520 mg, 2.5 mmol) were treated as described in Example 1F to yield 0.75 g (63 %): m.p. > 255°; ^1H NMR (300 MHz, DMSO- d_6 (free base)) δ 1.42-1.54 (m, 2H), 1.60-1.72 (m, 2H), 2.04-2.18 (m, 1H), 2.25-2.89 (m, 4H), 3.10-3.48 (m, 3H), 3.68 (s, 3H), 3.95 (t, J=7 Hz, 2H), 4.02 (dd, J=10, 12 Hz, 1H), 4.39 (dd, J=4, 10 Hz, 1H), 6.39 (dd, J=1, 8 Hz, 1H), 6.44 (dd, J=1, 8 Hz, 1H), 7.01 (t, J=8 Hz, 1H), 7.64 (dd, J=5, 8 Hz, 1H), 8.63 (dd, J=1, 8 Hz, 1H), 8.83 (dd, J=1, 5 Hz, 1H); MS (DCI(NH_3)) m/e 479 ($\text{M}+\text{H}^+$); Analysis calc'd for $\text{C}_{25}\text{H}_{26}\text{N}_4\text{O}_4\text{S}\cdot\text{HCl}\cdot(\text{H}_2\text{O})_{0.25}$: C, 57.80; H, 5.34; N, 10.78; found: C, 57.45; H, 5.35; N, 10.80.

20

Example 5

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

25

Example 5A

Methyl 3-amino-5-chlorothieno[3,2-b]pyridine-2-carboxylate and Methyl 3-amino-7-chlorothieno[3,2-b]pyridine-2-carboxylate

To a solution of 3-chloro-2-cyanopyridine (40g, 0.29 mol) in 500 mL acetic acid was added hydrogen peroxide (30 %, 52 g, 0.45 mol) dropwise. After stirring at 90°C for 18 h, the reaction is cooled to 25°C and a solution of sodium sulfite (57 g, 0.45 mol) in H_2O was added dropwise. The reaction was concentrated to remove the bulk of the acetic acid and the residue is partitioned between 1 M NaOH and CH_2Cl_2 . The CH_2Cl_2 layer was dried (MgSO_4), filtered, concentrated, and recrystallized from EtOAc to provide 23 g (51 %) of 3-chloro-2-cyanopyridine-N-oxide. The resulting N-oxide (12.2 g, 79 mmol) was dissolved in DMF (160 mL) at 0°C. Methyl thioglycolate (7.1 mL, 79 mmol) was added followed by sodium methoxide (8.5 g, 160 mmol) in portions. The reaction was stirred for 1 h. The reaction was

poured onto ice and the resulting solid was collected by filtration, washed with water, dissolved in CH₂Cl₂, dried (MgSO₄), filtered, concentrated, and recrystallized from EtOAc. 10.6 g (60 %) of methyl 3-amino-thieno[3,2-b]pyridine-4-oxide carboxylate was obtained. The pyridine-N-oxide (10.6 g, 47 mmol) was mixed with phosphorous oxychloride (100 mL). The reaction was heated to 80°C for 30 min. The reaction was concentrated and partitioned between CH₂Cl₂ and 5% aq. NaHCO₃ solution. The CH₂Cl₂ layer was dried (MgSO₄), filtered, concentrated, and chromatographed (5:1 hex:EtOAc) to yield methyl 3-amino-5-chloro-thieno[3,2-b]pyridine-2-carboxylate (8.3g, 73 %): ¹H NMR (300 MHz, CDCl₃) δ 3.92 (s, 3H), 6.15 (bs, 2H), 7.37 (d, 1H), 7.99 (d, 1H); MS (DCI/NH₃) m/e 243 (M+H)⁺; followed by methyl 3-amino-7-chloro-thieno[3,2-b]pyridine-2-carboxylate (2.0 g, 18 %): ¹H NMR (300 MHz, CDCl₃) δ 3.93 (s, 3H), 6.20 (bs, 2H), 7.41 (d, 1H), 8.54 (db, 1H); MS (DCI/NH₃) m/e 243 (M+H)⁺.

Example 5B

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[2',3':4,5]thienol[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 4A (0.27g, 1.0 mmol) and methyl 3-amino-7-chloro-thieno[3,2-b]pyridine-2-carboxylate were treated as described in Example 1F to yield 0.12g (24%) of the title compound: m.p. 265-267°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.63 (d, 1H), 7.51 (d, 1H), 7.08 (t, 1H), 6.48 (d, 1H), 6.38 (d, 1H), 4.93 (dd, 1H), 4.02-4.18 (m, 3H), 3.99 (m, 1H), 3.38 (t, 1H), 2.88-3.12 (m, 5H), 2.45 (m, 1H), 1.8 (m, 4H); MS (DCI/NH₃) m/e 513(M+H)⁺; Analysis calc'd for C₂₅H₂₅N₄O₄SCl·2HCl: C, 51.25; H, 4.64; N, 9.56; found: C, 51.28; H, 4.96; N, 9.45.

Example 6

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thienol[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 4A (0.27g, 1.0 mmol) and methyl 3-amino-5-chloro-thieno[3,2-b]pyridine-2-carboxylate were treated as described in Example 1F to yield 0.10 g (19%) of the title compound: m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.1 (d, 1H), 7.41 (d, 1H), 7.05 (t, 1H), 6.48 (d, 1H), 6.35 (d, 1H), 4.57 (dd, 1H), 4.11 (m, 3H), 3.95 (m, 1H), 3.73 (s, 3H), 3.37 (m, 2H), 2.9-3.1 (m, 4H), 2.48 (m, 1H), 1.8 (m, 4H); MS

(DCI/NH₃) *m/e* 513(M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·2HCl: C, 51.25; H, 4.64; N, 9.56; found: C, 51.22; H, 4.77; N, 9.32.

Example 7

5 3-[4-((3aR,9bS)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

Example 7A

10 3-Amino-5-methoxy-thieno[3,2-b]pyridine-2-carboxylate

A solution of 3-amino-5-chloro-thieno[3,2-b]pyridine-2-carboxylate, (5g, 21 mmol) and sodium methoxide (4.5 g, 82 mmol) in MeOH (150 mL) were refluxed for 18 h. The reaction was concentrated and partitioned between EtOAc and NaHCO₃ solution. The EtOAc layer was
15 dried (MgSO₄), filtered, concentrated, and chromatographed (5:1 hex: EtOAc) to yield 2.5 g (51%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 3.80 (s, 3H), 4.02 (s, 3H), 6.05 (bs, 2H), 6.89 (d, 1H), 7.88 (d, 1H); MS (DCI/NH₃) *m/e* 239 (M+H)⁺.

Example 7B

20 3-[4-((3aR,9bS)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

To 0.10 g (0.42 mmol) of the product from Example 7A, dissolved in 10mL of dry
25 THF and cooled to 0° C was add 2.2 equiv. of triethylamine (0.142 ml), followed by 0.23 ml of 1.93M solution of phosgene in toluene. The reaction was stirred for 3 hr and then 0.10 g (0.36 mmol) of the product from Example 4A was added. The reaction was stirred at room temperature overnight, and then partitioned between aq. NaHCO₃ and CH₂Cl₂. The organic phase was dried, concentrated, and dissolved in THF. Potassium t-butoxide (0.8 mmol in
30 THF) was added. The reaction was stirred at room temperature for 2 hours, and then partitioned between aq. NaHCO₃ and CH₂Cl₂. After chromatographic purification and conversion to the hydrochloride salt, 0.09 g (48%) of the title compound was isolated: m.p. 238-240°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.06 (d, 1H), 7.05 (t, 1H), 6.9 (d, 1H), 6.48 (d, 1H), 6.39 (d, 1H), 4.45 (dd, 1H), 4.12 (t, 1H), 4.03 (s, 3H), 4.02 (m, 1H), 3.76 (s,
35 3H), 3.59 (q, 1H), 2.96 (q, 1H), 2.78 (m, 4H), 2.56 (m, 1H), 2.31 (m, 1H), 1.79 (m, 2H), 1.63 (m, 2H); MS (DCI/NH₃) *m/e* 509(M+H)⁺; Analysis calc'd for

$\text{C}_{26}\text{H}_{28}\text{N}_4\text{O}_5\text{S}\cdot\text{HCl}\cdot 0.5\text{H}_2\text{O}$: C, 56.36; H, 5.46; N, 10.11; found: C, 56.56; H, 5.41; N, 9.97.

Example 8

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-6-methoxy-pyrido[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Example 8A

3-Amino-7-methoxy-thieno[3,2-b]pyridine-2-carboxylate

Following the procedure described in Example 7A, 3-amino-7-chloro-thieno[3,2-b]pyridine-2-carboxylate (2.0 g, 8.2 mmol) provided 1.1 g (56 %) of the title compound after chromatography with 1:1 hex:EtOAc. ¹H NMR (300 MHz, CDCl₃) δ 3.92 (s, 3H), 4.05 (s, 3H), 6.18 (bs, 2H), 6.81 (d, 2H), 8.52 (d, 2H); MS (DCI/NH₃) *m/e* 239 (M+H)⁺.

Example 8B

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

To 0.24 g (1mmol) of the product from Example 8A, dissolved in 10ml of dry THF and cooled to 0° C was added 2.2 equiv. of triethylamine (0.37ml), followed by 0.6ml of 1.93M solution of phosgene in toluene. The reaction was stirred for 3 hr and then 0.276 g (1.00 mmol) of the product from Example 4A was added. The reaction was stirred at room temperature overnight, and then partitioned between aq. NaHCO₃ and CH₂Cl₂. The organic phase was dried, concentrated, and dissolved in THF. Potassium t-butoxide (1 mmol in THF) was added. The reaction was stirred at room temperature for 2 hours, and then partitioned between aq. NaHCO₃ and CH₂Cl₂. After chromatographic purification and conversion to the dihydrochloride salt, 0.26g (49%) of the title compound was isolated: m.p. 191-193°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.63 (d, 1H), 7.1 (t, 1H), 6.92 (d, 1H), 6.5 (d, 1H), 6.4 (d, 1H), 4.51 (dd, 1H), 4.15 (m, 6H), 3.78 (s, 3H), 3.6 (m, 1H), 3.0-3.3 (m, 6H), 2.52 (m, 1H), 1.85 (m, 4H); MS (DCI/NH₃) *m/e* 509(M+H)⁺; Analysis calc'd for C₂₆H₂₈N₄O₅·2HCl·H₂O: C, 52.09; H, 5.38; N, 9.34; found: C, 51.85; H, 5.47; N, 9.00.

Example 9

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 9A

2-Chloro-3-cyano-5-phenylpyrazine and 2-chloro-3-cyano-6-phenylpyrazine

A mixture of 5- and 6- phenyl regioisomers of 2-hydroxy-3-carboxamidopyrazines (7.2g, 33.5 mmol) prepared by the method of R.G. Jones, *J. Am. Chem. Soc.* 71:78 (1949) was combined with phosphorous oxychloride (56 ml, 586 mmol) and triethylamine (9.3 mL, 67 mmol) and heated to reflux for 2 h. The mixture was evaporated to give a black oil which was extracted with ether (3 x 100 ml); the combined extracts were washed with 300 ml of 10% Na₂CO₃, after which the aqueous layer was back-extracted with ether. The combined organic layers were decolorized with activated carbon and filtered through Celite, then evaporated to give a white solid as a 60:40 mixture of the 5 and 6-phenyl isomers; mp: (mixture) 121-125 °C. ¹H NMR (300 MHz CDCl₃) δ 7.52 (m, 5H major and minor), 8.02 (d, 2H (major), 8.11 (d, 2H (minor)), 9.0 (s, 1H (major)), 9.05 (s, 1H (minor)). MS (DCI/NH₃) m/e 215 (M)+.

Example 9B

Methyl 7-amino-3-phenylthienof[2,3-b]pyrazine-6-carboxylate

The product from Example 9A (1.20 g, 5.58 mmol) was treated sequentially with methyl thioglycolate (0.65 g, 6.14 mmol), and sodium methoxide (0.60 g, 11.2 mmol) in anhydrous DMF (5 ml) and the reaction was stirred at 25° for 1h. The reaction mixture was diluted with water, the product collected by filtration and purified by column chromatography on silica gel eluting with CH₂Cl₂ to yield 0.80 g (first eluting isomer) (47%) of the title compound as a yellow solid: ¹H NMR (300 MHz, CDCl₃) δ 3.75 (s, 3H), 6.25 (br s, 2H), 7.53 (m, 3H), 8.09 (d, 2H), 9.09 (s, 1H). MS (DCI/NH₃) m/e 286 (M+H)+.

Example 9C

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 4A (0.10 g, 0.42 mmol) and the product from Example 9B (0.14 g, 0.43 mmol) were treated as described in Example 1F to yield 0.03 g (13%) of the title compound: m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 9.18 (s, 1H), 8.11 (m, 2H), 7.6 (m, 3H), 7.1 (t, 1H), 6.5 (d, 1H), 6.38 (d, 1H), 4.5 (dd, 1H), 4.18 (m, 3H), 4.1 (m, 1H), 3.8 (s, 3H), 3.18 (m, 6H), 2.5 (m, 1H), 1.7-1.9 (m, 4H); MS (DCI/NH₃) *m/e* 556(M+H)⁺; Analysis calc'd for C₃₀H₂₉N₅O₄S·HCl·2H₂O: C, 57.36; H, 5.46; N, 11.15; found: C, 57.40; H, 5.27; N, 10.79.

Example 9DAlternative Synthesis of Methyl 7-amino-3-phenylthieno[2,3-b]pyrazine-6-carboxylate

15 To a flask was charged phenylglyoxime, 30 (44g, 0.3mol) and aminomalnonitrile tosylate salt, 31 (75g, 0.3mol) and 518mL isopropanol. This was stirred at ambient temperature for 2 days. The reaction was then cooled to 0°C for 4 hours, and the solid collected by filtration. The product was washed with 400mL cold isopropanol and dried in the oven at 20 50°C for 14hrs to give 60g (95% yield) of the pyrazine (32): ¹HNMR (300 MHz, DMSO d₆) δ 9.18 (s, 1H), 8.08 (br s, 2H), 7.99-7.92 (m, 2H), 7.52-7.40 (m, 3H); ¹³CNMR (75.5 MHz, DMSO-d₆) δ 149.6, 142.2, 134.2, 131.3, 129.3, 128.8, 125.7, 115.2, 111.1.

To a flask was charged compound 32 (60g, 0.28mol) and 230mL (1.34mol) triethyl phosphite. This was heated to 100°C for 7.5 hours. The solution was then cooled to ambient 25 temperature and quenched with 480mL water. The slurry was stirred for 12 hours and filtered. The filtercake was washed with 200mL of 10% ethanolic water and dried in a vacuum oven at 40°C for 24 hours to yield 53g (95% yield) of the compound (33); ¹HNMR (300 MHz, CDCl₃) δ 8.96 (s, 1H), 8.05-7.95 (m, 2H), 7.55-7.4 (m, 5H); ¹³CNMR (75.5 MHz, CDCl₃) δ 155.9, 145.0, 140.9, 135.2, 128.9, 128.6, 125.2, 116.1, 110.0; mp 181.5°C.

30 To a flask was charged copper(II) bromide (67.3g, 0.3mol), DMF (300mL). This was heated to approx. 60°C. To the heated solution was added 46.5g (0.45mol) t-butylisonitrite. After stirring for approx. 2-5 minutes, compound 33 (58.85g, 0.3mol) was added portionwise. This was stirred at 60°C for 20 minutes. The contents were then cooled to approx. 15°C and transferred into 2.5L of 5% hydrochloric acid precooled to 5°C. This was stirred for 20 minutes 35 and extracted with 600mL methylene chloride. The aqueous was extracted again with 100mL methylene chloride and the organics combined. The organics were washed 4x1L water, and

300mL brine. 100gr sodium sulfate and 50gr silica were then charged to the organics. This was stirred and filtered. The filtercake was rinsed with methylene chloride to remove product. The combined filtrate and washes were then distilled at not more than 40°C to a solid. Drying at 30°C under vacuum gave 56.5g (72% yield) of the compound(34): ¹H NMR (300 MHz, DMSO-d₆) δ 8.95 (s, 1H), 8.04-8.01 (m, 2H), 7.58-7.51 (m, 3H); ¹³CNMR (75.5 MHz, DMSO-d₆) δ 151.8, 143.8, 140.4, 133.2, 132.2, 131.5, 129.5, 127.1, 114.8.

To a flask was charged sodium carbonate (5.03g, 0.05mol), methylthioglycolate (5.03g, 0.05mol), and 400mL methanol. To this is added compound 34 (13.01g, 0.05mol). This was stirred at ambient temperature for 1h and then heated to 50°C for 1.5h before cooling to 4°C for 2h. The solid was collected by filtration and washed with cold methanol (40mL) and dried to give 15.6g of the title compound impure. The solid was mixed with silica gel (29g) and washed with approx. 1.5L of methylene chloride. The organics were concentrated in-vacuo to give the title compound (35) (10.5 1g): ¹H NMR (300 MHz, DMSO-d₆) δ 9.42 (s, 1H), 8.41-8.35 (m, 2H), 7.6-7.5 (m, 3H), 7.2 (br s, 2H), 3.87 (s, 3H); mp 197-198°C.

Example 9E

Alternative Synthesis of Methyl 7-amino-3-phenylthieno[2,3-b]pyrazine-6-carboxylate

To a slurry of distilled water (25mL), malononitrile (72g, 1.09mol), and acetic acid (2.18g, 0.036mol) was added sodium nitrite (75.3g, 1.09mol) dissolved in water (300mL). The reaction mixture was stirred for 2h and then slowly transferred into a solution of toluenesulfonyl chloride (200g, 1.05mol) dissolved in acetonitrile (463g) cooled to 12°C. After the addition was complete, the reaction mixture was slowly quenched into water (2.6L). The resultant slurry was stirred for at room temperature and then the solid formed was filtered, washed with water (2x1L) followed by heptane (200mL). The solids were dried under vacuum to give the compound (50) (242g, 92%) ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, J=7 Hz), 7.35 (d, J=7 Hz), 2.41 (s 3H).

Pyrrolidine (10g, 0.14mole) and sodium sulfate (5g) were added to a flask and cooled to <0°C. Phenylacetaldehyde (2.4g, 0.02mol) was added slowly to the flask to keep temperature <2°C. The mixture was stirred at 0°C for 1 hour. The reaction was filtered and the solids was washed with 10ml heptane. The combined filtrates were distilled (<40°C) under vacuum to an oil. Heptane (30ml) was added and then distilled again to an oil. The final oil was mixed with dimethylformamide (6ml) and triethylamine (6.06g, 0.06moles). The mixture was then slowly added into a flask containing compound 50 (4.98g, 0.02moles) in DMF (20ml) at 0°C±3°C. This reaction mixture was stirred at 0°C for 30 minutes and then thiophenol (2.4g, 0.022moles) was added. This mixture was stirred for 3 hours at ambient temperature before adding water (100 ml). This was stirred for 20 minutes at room temperature and the solid filtered. The

filtercake was slurried with 50ml methanol and stirred for 20min and filtered. The solid was washed with 10ml of methanol and dried to give a grayish solid of compound (51)(2.98g, 51%). ¹HNMR (300 Mhz, CDCl₃) δ 8.9 (s, 1H), 8.0-7.9 (m, 2H), 7.7-7.6 (m, 2H), 7.6-7.45 (m, 6H).

5 To a solution of compound (51) (2.89g, 1 Ommol) in acetic anhydride (25mL) and chloroacetic acid (10g, 106mmol) was added 30% aqueous hydrogen peroxide (10g, 88mmol) at 0°C. The solution was stirred at room temperature for 1h and then heated to 35°C for 6h. The mixture was cooled to room temperature, diluted with water (25mL) and methanol (25mL), stirred at room temperature for 30min, and filtered. The filtercake was washed with 50%
10 aqueous methanol (40mL) and dried to give compound (52).(2.9g, 90%): ¹HNMR(DMSO-d₆) δ 9.60 (1H, s), 8.21 (2H, dd, J=7.6, 1Hz), 8.07 (2H, dd, J=7.6, 1Hz), 7.83 (1H, dt, J=7.6, 1Hz), 7.73(2H, m), 7.60(3H, m); ¹³CNMR(DMSO-d₆); δ 113.96, 126.13, 128.04, 129.01, 129.39, 129.81, 132.20, 132.91, 135.24, 136.97, 144.72, 153.14, 154.21.

15 A suspension of sulfone (52) (30mg, 0.09mmol), sodium carbonate (0.1g, 0.9mmol), and methyl thioglycolate (20mg, 0.19mmol) in methanol (3mL) was stirred at ambient temperature for 30min and then at 50°C for 2h. After concentration in-vacuo, the residue was blended with silica (1.5g) and eluted with methylene chloride (50mL). Concentration *in-vacuo* yielded the title compound (15mg, 58%).

Example 10

3-[4-((3aR,9bS)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

Example 10A

2-Chloro-3-cyano-pyrazine-4-oxide

2-Chloro-3-cyanopyrazine (5.00 g, 35.94 mmol) was dissolved in 35 ml concentrated
30 H₂SO₄ under nitrogen and cooled to 0 °C. To this was added 11.65 g (43.95 mmol) K₂S₂O₈ portionwise. The flask was fitted with a CaCl₂ drying tube, the reaction mixture allowed to warm to rt and stir for 24 h. After partitioning between CHCl₃ and ice water, the separated aqueous phase was extracted with CHCl₃. The combined organics were washed with water, saturated NaHCO₃, brine and dried over MgSO₄. Concentration gave 2.01 g (36%) of the title
35 compound as an off-white solid. ¹H NMR (300 MHz, CDCl₃) δ 8.12 (d, 1H), 8.38 (d, 1H). MS (DCI/NH₃) m/e 173 (M+NH₄)⁺.

Example 10BEthyl-7-aminothieno[2,3-b]pyrazine-6-carboxylate-1-oxide

5 The compound resulting from Example 10A (2.90 g, 18.64 mmol) was dissolved in 100 ml DMF under nitrogen and treated with ethyl thioglycolate (2.24 g, 18.64 mmol). After cooling the solution to 0 °C, it was treated with solid NaOEt (2.54 g, 37.29 mmol) allowed to warm to rt and then stirred for 13 h. The reaction mixture was partitioned between ethyl acetate and brine and the layers separated. After extracting the aqueous phase with ethyl acetate, the
10 combined organics were washed with water, brine and dried over MgSO₄. Concentration gave a yellow solid that was purified by column chromatography on silica gel eluting with 2:1 then 1:1 hexanes:ethyl acetate to yield 3.50 g (78%) of the title compound as a yellow solid: mp: 126-127° C; ¹H NMR (300 MHz, CDCl₃) δ 1.40 (t, 3H), 4.38 (q, 2H), 7.25 (br s, 2H), 8.02 (d, 1H), 8.41 (d, 1H); MS (DCI/NH₃) m/e 240 (M+H)⁺, 257 (M+NH₄)⁺; Analysis calc'd.
15 for C₉H₉N₃O₃S: C, 45.18; H, 3.79; N, 17.56; Found: C, 44.94; H, 3.77; N, 17.47.

Example 10CEthyl-7-amino-2-chloro-thieno[2,3-b]pyrazine-6-carboxylate

20 The compound resulting from Example 88B (0.88 g, 3.68 mmol) was dissolved in 50 ml POCl₃ under nitrogen and heated to 95 °C for 3 h. The reaction mixture was concentrated and partitioned between ethyl acetate and water. After extracting the aqueous phase with ethyl acetate, the combined organics were washed with water, saturated NaHCO₃, brine and dried over Na₂SO₄. Concentration gave a two component mixture that was separated by column
25 chromatography on silica gel using a gradient elution from 10:1 to 1:1 hexanes:ethyl acetate to give 0.56 g (59%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.41 (t, 3H), 4.40 (q, 2H), 6.11 (br s, 2H), 8.60 (s, 1H); MS (DCI/NH₃) m/e 258 (M+H)⁺, 275 (M+NH₄)⁺.

Example 10D

30 3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[11]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

The product resulting from Example 4A (0.25 g, 0.95 mmol) and the product from
35 Example 10C (0.25 g, 1.1 mmol) were treated as described in Example 1F to yield 0.15 g (29%) of the title compound: m.p. 266-267°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 8.7 (d,

1H), 7.53 (d, 1H), 7.1 (t, 1H), 6.5 (d, 1H), 6.4 (d, 1H), 4.51 (dd, 1H), 4.14 (t, 2H), 3.78 (s, 3H), 3.68 (m, 1H), 3.55 (m, 1H), 3.02-3.32 (m, 5H), 2.58 (m, 2H), 1.85 (m, 4H); MS (DCI/NH₃) *m/e* 514(M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·HCl·1.5H₂O: C, 52.09; H, 5.07; N, 9.72; found: C, 52.21; H, 4.87; N, 9.60.

Example 11

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-1-(2-Methoxyethyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 11A

Ethyl 7-(N-(2-methoxyethyl)amino)thieno[2,3-b]pyrazine-6-carboxylate

Ethyl 7-amino-thieno[2,3-b]pyrazine-6-carboxylate (1.0 g, 4.48 mmol) prepared by the method of Schneller and Clough, J. Het. Chem., 12: 513 (1975), was treated with potassium bis(trimethylsilyl)amide (0.5 M in toluene, 8.96 ml) in 15 ml THF at -70° C, and allowed to warm to room temperature. 2-Bromoethyl methyl ether (0.454 ml, 4.70 mmol) was added, and the reaction was stirred under N₂ at 60° C overnight. The mixture was cooled and evaporated, then purified by column chromatography on silica gel eluting with 1:9 ethyl acetate:hexanes to yield 0.640 g (51%) of the title compound as a yellow solid: ¹H NMR (300 MHz, DMSO-d₆) δ 1.32 (t, 3H), 3.3 (s, 3H), 3.56 (t, 2H), 4.25 (q, 2H), 4.32 (t, 2H), 7.70 (br t, 1H), 8.76 (s, 1H), 8.77 (s, 1H); MS (DCI/NH₃) m/e 282 (M+H)⁺.

Example 11B

Ethyl 7-(N-(2-methoxyethyl)-N-chlorocarbamoylamino)thieno[2,3-b]pyrazine-6-carboxylate

The product from Example 11A (0.620 g, 2.20 mmol) was reacted with phosgene (1.93M in toluene, 3.41 ml, 6.6 mmol) and triethylamine (0.767 ml, 5.5 mmol) to yield the title compound (0.582 g, 81%) as a yellow oil: ¹H NMR (300 MHz DMSO-d₆) δ 1.31 (t, 3H), 3.3 (s, 3H), 3.56 (t, 2H), 4.23 (q, 2H), 4.3 (q, 2H), 8.78 (2 singlets, 2H); MS (DCI/NH₃) 344 (M+H)⁺.

Example 11C

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-1-(2-Methoxyethyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 4A (0.25g, 0.95mmol) was refluxed overnight with 0.1ml of triethylamine and 0.27g (0.82 mmol) of the product from Example 11B. After workup and chromatography, 0.3g (68%) of the title compound was isolated as its free base. The product was converted to its HCl-salt and recrystallized from ethanol/ether to yield the title compound: m.p. 200-202°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.78 (d, 1H), 8.7 (d, 1H), 7.1 (t, 1H), 6.5 (d, 1H), 6.4 (d, 1H), 5.12 (t, 2H), 4.5 (dd, 1H), 4.05-4.2 (m, 4H), 3.8 (m, 5H), 3.5 (m, 1H), 3.12 (m, 5H), 2.5 (m, 1H), 1.85 (m, 4H); MS (DCI/NH₃) m/e 538(M+H)⁺; Analysis calc'd for C₂₇H₃₁N₅O₅S·HCl·0.75H₂O: C, 55.19; H, 5.75; N, 11.92; found: C, 55.19; H, 5.49; N, 11.88.

Example 12

3-[4-((3aR,9bS)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Ethyl 7-amino-thieno[2,3-b]pyrazine-6-carboxylate (0.32 g, 1.35 mmol) prepared by the method of Schneller and Clough, *J. Het. Chem.*, 12: 513 (1975) and the product from Example 4A (0.31 g, 1.13 mmol) were treated as described in Example 1F to yield 0.28 g of the title compound as its free base. The product was converted to its HCl salt and recrystallized from ethanol/ether to yield the title compound: m.p. >250°; ¹H NMR (300 MHz, DMSO-d₆(free base)) δ 8.98 (d, 1H), 8.89 (d, 1H), 7.11 (t, 1H), 6.52 (d, 1H), 6.45 (d, 1H), 4.5 (dd, 1H), 4.2 (m, 1H), 4.1 (m, 1H), 3.92 (m, 2H), 3.73 (s, 3H), 3.0 (m, 1H), 2.6 (m, 5H), 2.3 (m, 1H), 1.8 (m, 4H); MS (DCI/NH₃) m/e 480(M+H)⁺; Analysis calc'd for C₂₄H₂₅N₅O₄S·2HCl·0.5H₂O: C, 51.34; H, 5.03; N, 12.47; found: C, 51.34; H, 4.95; N, 12.32.

Example 13

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 10C (0.27 g, 1.0 mmol) and the product from Example 3E (0.22 g, 0.8 mmol) were treated as described in Example 1F to yield 0.22 g (66%) of the title compound: m.p. >270°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.61 (s, 1H), 7.05 (t, 1H), 6.48 (d, 1H), 6.45 (d, 1H), 4.6 (m, 1H), 4.45 (dd, 1H), 4.18 (m, 3H), 3.71 (s, 3H), 3.52 (m, 1H), 3.3 (m, 1H), 3.1 (m, 2H), 2.9 (m, 2H), 2.5 (m, 1H), 1.8 (m, 4H); MS (DCI/NH₃) m/e 514(M+H)⁺; Analysis calc'd for C₂₄H₂₄ClN₅O₄S·HCl·0.5H₂O: C, 51.52; H, 4.68; N, 12.52; found: C, 51.89; H, 4.38; N, 12.17.

Example 14

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Ethyl 7-amino-thieno[2,3-b]pyrazine-6-carboxylate (0.24 g, 1.0 mmol) prepared by the method of Schneller and Clough, *J. Het. Chem.*, 12: 513 (1975) and the product from Example 3E (0.22 g, 0.8 mmol) were treated as described in Example 1F to yield 0.16 g (43%) of the title compound: m.p. 219-222°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 8.62 (s, 1H), 8.45 (s, 1H), 7.05 (t, 1H), 6.48 (d, 1H), 6.4 (d, 1H), 4.5 (dd, 1H), 4.2 (m, 1H), 4.1 (m, 3H), 3.72 (s, 1H), 7.7 (m, 1H), 3.3 (m, 2H), 3.2 (m, 1H), 3.05 (m, 2H), 2.52 (m, 1H), 1.8 (m, 4H); MS (DCI/NH₃) m/e 480(M+H)⁺; Analysis calc'd for C₂₄H₂₅N₅O₄S·2HCl·0.5H₂O: C, 51.34; H, 4.96; N, 12.25; found: C, 51.45; H, 4.96; N, 12.25.

Example 15

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Ethyl 7-amino-thieno[2,3-b]pyrazine-6-carboxylate (0.24 g, 1.0 mmol) prepared by the method of Schneller and Clough, *J. Het. Chem.*, 12: 513 (1975) and the product from Example 1E (0.2 g, 0.75 mmol) were treated as described in Example 1F to yield 0.11 g (32%) of the title compound: m.p. 220-222°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.7 (d, 1H), 8.6 (d, 1H), 7.02 (t, 1H), 6.4 (t, 2H), 4.1 (m, 2H), 3.7-4.0 (m, 4H), 3.7 (s, 3H), 3.52 (m,

2H), 2.6-2.9 (m, 4H), 1.6-1.82 (m, 4H); MS (DCI/NH₃) *m/e* 480(M+H)⁺; Analysis calc'd for C₂₄H₂₅N₅O₄S·2HCl: C, 52.18; H, 4.93; N, 12.68; found: C, 52.56; H, 4.99; N, 12.64.

Example 16

5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

10 The product from Example 10 C (0.27 g, 1.0 mmol) and the product from Example 1E (0.20 g, 0.73 mmol) were treated as described in Example 1F to yield 0.29 g (77%) of the title compound: m.p. 220-222°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.68 (s, 1H), 7.0 (t, 1H), 6.48 (d, 1H), 6.45 (d, 1H), 4.28 (m, 1H), 4.12 (m, 3H), 4.0 (m, 2H), 3.75 (s, 3H), 3.6 (m, 1H), 3.08 (m, 3H), 2.9 (m, 2H), 1.75 (m, 4H); MS (DCI/NH₃) *m/e* 514(M+H)⁺; Analysis calc'd for C₂₄H₂₄ClN₅O₄S·HCl·0.75H₂O: C, 51.11; H, 4.74; N, 12.42; found: C, 51.09; H, 4.75; N, 12.43.

Example 17

20 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

25 The product from Example 8A (0.24 g, 1.0 mmol) and the product from Example 3E (0.276 g, 1.0 mmol) were treated as described in Example 1F to yield 0.26 g (51%) of the title compound: m.p. 173-174°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.64 (d, 1H), 7.08 (t, 1H), 6.92 (d, 1H), 6.5 (d, 1H), 6.4 (d, 1H), 6.5 (dd, 1H), 4.5 (dd, 1H), 4.12 (m, 8H), 3.76 (s, 3H), 3.02 (m, 4H), 2.45 (m, 2H), 1.82 (m, 4H); MS (DCI/NH₃) *m/e* 509(M+H)⁺; Analysis calc'd for C₂₆H₂₈N₄O₅S·2HCl·0.25H₂O: C, 60.86; H, 5.60; N, 10.92; found: C, 60.84; H, 5.41; N, 10.62.

Example 18

30 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

35 The product from Example 8A (0.30 g, 1.26 mmol) and the product from Example 1E (0.345 g, 1.25 mmol) were treated as described in Example 1F to yield 0.37 g (58%) of the title

compound: m.p. 204-206°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.64 (d, 1H), 7.05 (t, 1H), 6.92 (d, 1H), 6.51 (d, 1H), 6.44 (d, 1H), 4.0-4.18 (m, 6H), 3.8 (s, 4H), 3.6 (m, 1H), 3.44 (m, 1H), 3.24 (m, 1H), 2.6 (m, 3H), 2.3 (m, 2H), 1.78 (m, 2H), 1.64 (m, 2H); MS (DCI/NH₃) *m/e* 509(M+H)⁺; Analysis calc'd for C₂₆H₂₈N₄O₅S·2HCl·2H₂O: C, 50.57; H, 5.55; N, 9.07; found: C, 50.59; H, 5.74; N, 9.05.

Example 19

3-[4-((3aS,9bR)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 5A (0.24 g, 1.0 mmol) and the product from Example 3E (0.27 g, 1.0 mmol) were treated as described in Example 1F to yield 0.08 g (15%) of the title compound: m.p. 266-267°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.7 (d, 1H), 7.53 (d, 1H), 7.1 (t, 1H), 6.5 (d, 1H), 6.4 (d, 1H), 4.51 (dd, 1H), 4.14 (t, 2H), 3.78 (s, 3H), 3.68 (m, 1H), 3.55 (m, 1H), 3.02-3.32 (m, 5H), 2.58 (m, 2H), 1.85 (m, 4H); MS (DCI/NH₃) *m/e* 514(M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·HCl·1.5H₂O: C, 52.09; H, 5.07; N, 9.72; found: C, 52.21; H, 4.87; N, 9.60.

Example 20

3-[4-((3aR,9bR)-*cis*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 5A (0.24 g, 1.0 mmol) and the product from Example 1E (0.27 g, 1.0 mmol) were treated as described in Example 1F to yield 0.125 g (25%) of the title compound: m.p. 180-182°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.63 (d, 1H), 7.51 (d, 1H), 7.05 (t, 1H), 6.48 (d, 1H), 6.42 (d, 1H), 4.1 (t, 2H), 4.0 (dd, 1H), 3.73 (m, 1H), 3.7 (s, 3H), 3.48 (q, 2H), 3.38 (m, 1H), 3.25 (m, 1H), 2.7 (m, 3H), 2.5 (m, 1H), 2.4 (m, 1H), 1.78 (m, 1H), 1.65 (m, 1H); MS (DCI/NH₃) *m/e* 513(M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·HCl·0.75H₂O: C, 53.34; H, 4.92; N, 9.95; found: C, 53.42; H, 4.65; N, 9.55.

Example 21

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 Methyl-3-amino-benzo[b]thiophene-2-carboxylate (0.24 g, 0.97 mmol) and the product from Example 3E (0.18 g, 0.6 mmol) were treated as described in Example 1F to yield 0.22 g (77%) of the title compound: m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.28 (d, 1H), 7.39 (d, 1H), 7.56 (m, 2H), 7.04 (t, 1H), 6.46 (d, 1H), 6.38 (d, 1H), 4.4 (dd, 1H), 4.24 (t, 2H), 4.0 (t, 1H), 3.71 (s, 3H), 3.65 (m, 1H), 3.0 (t, 1H), 2.81 (m, 4H), 2.58 (t, 1H),
10 2.3 (m, 1H), 1.88 (m, 2H); MS (DCI/NH₃) m/e 478(M+H)⁺; Analysis calc'd for C₂₆H₂₇N₃O₄S·HCl: C, 60.75; H, 5.49; N, 8.17; found: C, 60.65; H, 5.31; N, 8.03.

Example 22

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

15 Methyl-3-amino-benzo[b]thiophene-2-carboxylate (0.13 g, 0.52 mmol) and the product from Example 1E (0.10 g, 0.36 mmol) were treated as described in Example 1F to yield 0.11 g (64%) of the title compound: m.p. 198-199°; ¹H NMR (300 MHz, CDCl₃) δ 8.22 (d, 1H), 8.4 (d, 1H), 7.55 (m, 2H), 7.04 (t, 1H), 6.5 (d, 1H), 6.43 (d, 1H), 4.22 (t, 2H), 4.0 (dd, 1H),
20 3.78 (s, 3H), 3.72 (m, 1H), 3.48 (m, 1H), 3.39 (m, 1H), 3.11 (m, 1H), 2.55 (m, 3H), 2.2 (m, 2H), 1.86 (m, 2H), 1.69 (m, 2H); MS (DCI/NH₃) m/e 478(M+H)⁺; Analysis calc'd for C₂₆H₂₇N₃O₄S·HCl: C, 60.75; H, 5.49; N, 8.17; found: C, 60.62; H, 5.27; N, 8.03.

Example 23

3-[5-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)pentyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 23A

30 (3aS,9bR)-trans-2-(4-cyanobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

The product from Example 3C (0.12 g, 0.6 mmol), 5-chlorovaleronitrile (0.08g, 0.69 mmol) and 1.0 mL ethyldiisopropylamine were heated to reflux in 5 mL acetonitrile for 6 h.
35 Solvent was evaporated, and the product partitioned between ethyl acetate and water. The organic layer was dried, evaporated, and purified by silica gel column chromatography to yield

0.11 g(64%) of the title compound: ^1H NMR (300 MHz, CDCl_3) δ 7.05 (t, 1H), 6.49(d,1H), 6.39(d,1H), 4.46(dd,1H), 3.77(s,3H), 3.56(q,1H), 2.92(q,1H), 2.68-2.88(m,4H), 2.57(q,1H), 2.42(t,2H), 2.32(m,1H), 1.71(m,4H); MS (DCI/NH_3) m/e 287($\text{M}+\text{H}$) $^+$

Example 23B

(3aS,9bR)-trans-2-(5-aminopentyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrole

Lithium aluminum hydride (0.11g, 2.88mmol) was suspended in ether, and a solution of 0.13g (0.96mmol) of aluminum chloride in ether was added. To the reaction was then added a solution of the product from Example 23A (0.11g, 0.38mmol). The reaction was stirred at 25° for 3 h, and then isolated (Fieser workup) to yield 0.10 g (90%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 7.05 (t, 1H), 6.49 (d, 1H), 6.39 (d, 1H), 4.45 (dd, 1H), 4.05 (q, 1H), 3.77 (s, 3H), 3.58 (q, 1H), 2.93 (q, 1H), 2.61-2.88 (m, 6H), 2.56 (m, 1H), 2.3 (m, 1H), 1.5 (m, 2H), 1.48 (m, 2H); MS (DCI/NH₃) *m/e* 291 (M+H)⁺.

Example 23C

3-[5-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)pentyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Methyl-3-amino-benzo[b]thiophene-2-carboxylate (0.10 g, 0.40 mmol) and the product from Example 23B (0.11 g, 0.38 mmol) were treated as described in Example 1F to yield 0.11 g (60%) of the title compound: m.p. 196-198°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.22 (d, 1H), 7.89 (d, 1H), 7.53 (m, 2H), 7.03 (t, 1H), 6.48 (d, 1H), 6.38 (d, 1H), 4.41 (dd, 1H), 4.21 (t, 2H), 4.02 (dd, 1H), 3.71 (s, 3H), 3.56 (m, 1H), 2.92 (m, 1H), 2.63-2.86 (m, 3H), 2.52 (m, 1H), 2.3 (m, 1H), 1.87 (m, 2H), 1.62 (m, 2H), 1.55 (m, 2H), 1.4 (m, 1H); MS (DCI/NH₃) *m/e* 492(M+H)⁺; Analysis calc'd for C₂₇H₂₉N₃O₄S·HCl·H₂O: C, 59.39; H, 5.91; N, 7.69; found: C, 59.83; H, 5.71; N, 7.48.

Example 24

3-[5-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)pentyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 24A

(3aR,9bR)-cis-2-(4-cyanobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

5 The product from Example 1C (0.10 g, 0.5 mmol), 5-chlorovaleronitrile (0.067g, 0.57 mmol) and 1.0 mL ethyldiisopropylamine were heated to reflux in 5 mL acetonitrile for 6 h. Solvent was evaporated, and the product partitioned between ethyl acetate and water. The organic layer was dried, evaporated, and purified by silica gel column chromatography to yield 0.08 g (58%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 7.08 (t, 1H), 6.51 (d, 1H), 6.45 (d, 1H), 4.04 (dd, 1H), 3.82 (s, 3H), 3.78 (m, 1H), 3.4 (m, 2H), 3.06 (q, 1H), 2.6 (m, 1H), 2.48 (q, 2H), 2.39 (t, 2H), 2.25 (m, 2H), 1.71 (m, 4H); MS (DCI/NH₃) m/e 287(M+H)⁺

Example 24B

15 (3aR,9bR)-cis-2-(5-aminopentyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

20 Lithium aluminum hydride (0.10g, 2.63 mmol) was suspended in ether, and a solution of 0.11 g (0.82 mmol) of aluminum chloride in ether was added. To the reaction was then added a solution of the product from Example 24A (0.08g, 0.28mmol). The reaction was stirred at 25° for 3 h, and then isolated (Fieser workup) to yield 0.07 g (86%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 7.08 (t, 1H), 6.51 (d, 1H), 6.45 (d, 1H), 4.03 (dd, 1H), 3.8 (s, 3H), 3.78 (m, 1H), 3.45 (m, 2H), 3.12 (q, 1H), 2.68 (t, 2H), 2.6 (m, 1H), 2.43 (m, 2H), 2.18 (m, 2H), 1.5 (m, 2H), 1.38 (m, 2H); MS (DCI/NH₃) m/e 291(M+H)⁺.

Example 24C

25 3-[5-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)pentyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

30 Methyl 3-amino-benzo[b]thiophene-2-carboxylate (0.10 g, 0.40 mmol) and the product from Example 24B (0.07 g, 0.24 mmol) were treated as described in Example 1F to yield 0.08 g (69%) of the title compound: m.p. 128-130°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.12 (d, 1H), 7.72 (d, 1H), 7.4 (m, 2H), 7.08 (t, 1H), 6.52 (d, 1H), 6.47 (d, 1H), 4.4 (m, 2H), 4.3 (m, 1H), 4.04 (dd, 1H), 3.7 (s, 3H), 3.5 (m, 1H), 3.32 (m, 2H), 3.2 (m, 1H), 2.7 (m, 1H), 2.52 (m, 2H), 2.35 (m, 2H), 1.88 (m, 1H), 1.62 (m, 4H); MS (DCI/NH₃) m/e 492(M+H)⁺; Analysis calc'd for C₂₇H₂₉N₃O₄S·HCl·H₂O: C, 59.39; H, 5.91; N, 7.69; found: C, 59.47; H, 5.94; N, 7.52.

Example 25

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Methyl 3-amino-5-chloro-thieno[3,2-b]pyridine-2-carboxylate, prepared as described in Example 6A (0.24 g, 1.0 mmol) and the product from Example 3E (0.20 g, 0.7 mmol) were treated as described in Example 1F to yield 0.18 g (50%) of the title compound: m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.1 (d, 1H), 7.21 (d, 1H), 7.02 (t, 1H), 6.48 (d, 1H), 6.38 (d, 1H), 4.56 (dd, 1H), 4.1 (m, 2H), 3.88 (m, 1H), 3.73 (s, 3H), 3.3 (m, 2H), 2.85-3.12 (m, 4H), 2.44 (m, 2H), 1.8 (m, 4H); MS (DCI/NH₃) m/e 513(M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·2HCl: C, 51.25; H, 4.64; N, 9.56; found: C, 51.04; H, 4.58; N, 9.27.

Example 26

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

Methyl 3-amino-5-methoxy-thieno[3,2-b]pyridine-2-carboxylate, prepared as described in Example 7A (0.20 g, 0.84 mmol) and the product from Example 3E (0.23 g, 0.84 mmol) were treated as described in Example 1F to yield 0.30 g (70%) of the title compound: m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.06 (d, 1H), 7.05 (t, 1H), 6.9 (d, 1H), 6.48 (d, 1H), 6.39 (d, 1H), 4.45 (dd, 1H), 4.12 (t, 1H), 4.03 (s, 3H), 4.02 (m, 1H), 3.76 (s, 3H), 3.59 (q, 1H), 2.96 (q, 1H), 2.78 (m, 4H); MS (DCI/NH₃) m/e 509(M+H)⁺; Analysis calc'd for C₂₆H₂₈N₄O₅S·HCl·0.25H₂O: C, 56.82; H, 5.41; N, 10.19; found: C, 56.68; H, 5.19; N, 10.09.

Example 27

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

Example 27A2-Cyano-3,5-dichloropyridine

3,5-Dichloropyridine-N-oxide (10.0 g, 61 mmol), trimethylsilylcyanide (25 mL, 183 mmol) and triethylamine (17 mL, 122 mmol) combined in acetonitrile (60 mL) and heated to reflux for 6 hr. The solvent was evaporated and the residue was partitioned between diethyl ether and 5% aq. NaHCO₃. The organic phase was dried (MgSO₄), evaporated, and the product purified by chromatography over silica gel to yield 10.0 g (97%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 7.92 (d, 1H), 8.58 (d, 1H).

Example 27B3-Chloro-2-cyano-5-methoxypyridine

The product from Example 27A (0.865 g, 5.0 mmol) was dissolved in THF (10 mL) and 0.27 g NaOMe was added. After 3h and 25° C, the reaction was quenched in 5% aq. NaHCO₃ solution and extracted with diethyl ether. The organic phase was dried, evaporated, and the residue purified by column chromatography, eluting with 70:30 hexanes:ethyl acetate to yield 0.27 g (32%, second eluting component) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 3.95 (s, 3H), 7.29 (d, 1H), 8.28 (d, 1H).

Example 27CMethyl 3-amino-6-methoxy-thieno[3,2-b]pyridine-2-carboxylate

The product from Example 27B (0.168 g, 1.0 mmol) and methyl thioglycolate (0.09 mL, 1.0 mmol) were combined in DMF (2 mL). To the solution was added 0.054 g NaOMe. After 1 hr, and additional 0.07 g NaOMe was added. After an additional 1 hr, the reaction was quenched in sat. aq. NH₄Cl and extracted with ethyl acetate. The organic phase was dried (MgSO₄), and evaporated to yield 0.17 g of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 3.90 (s, 3H), 3.93 (s, 3H), 6.15 (br s, 2H), 7.44 (d, 1H), 8.36 (d, 1H).

Example 27D

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 27C (0.12 g, 0.50 mmol) and the product from Example 3E (0.15 g, 0.47 mmol) were treated as described in Example 1F to yield 0.12 g (47%) of the title compound: m.p. 235-237°; ¹H NMR (300 MHz, CDCl₃((free base))) δ 8.45 (d, 1H), 7.6 (d, 1H), 7.05 (t, 1H), 6.48 (d, 1H), 6.38 (d, 1H), 4.45 (dd, 1H), 4.1 (t, 2H), 4.05 (m, 1H), 3.98 (s, 3H), 3.78 (s, 3H), 3.72 (m, 1H), 3.05 (m, 1H), 2.85 (m, 4H), 2.65 (m, 1H), 2.38 (m, 1H), 1.8 (m, 2H), 1.7 (m, 2H); MS (DCI/NH₃) *m/e* 509(M+H)⁺; Analysis calc'd for C₂₆H₂₈N₄O₅S·HCl·H₂O: C, 55.46; H, 5.55; N, 9.95; found: C, 55.22; H, 5.30; N, 9.75.

Example 28

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 1E (400 mg, 1.5 mmol), 3-amino-2-carbomethoxythieno[3,2-c]pyridine (.33 g, 1.6 mmol) (*J. Heterocyclic Chem.*, **24**, 85 (1987)), Et₃N (.50 mL, 3.6 mmol), and phosgene (0.82 mL 1.93 M solution in toluene, 1.6 mmol) were treated as described in Example 1F to yield 0.38 g (55%) of the title compound: m.p. 207-210°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.62-1.75 (m, 2H), 1.80-1.92 (m, 2H), 2.20-2.33 (m, 2H), 2.49-2.65 (m, 3H), 3.15 (bt, J=8 Hz, 1H), 3.39 (q, J=8 Hz, 1H), 3.50 (t, J=8 Hz, 1H), 3.70-3.79 (m, 1H), 3.75 (s, 3H), 3.98 (dd, J=4, 9 Hz, 1H), 4.22 (t, J=7 Hz, 2H), 6.41 (dd, J=1, 8 Hz, 1H), 6.47 (dd, J=1, 8 Hz, 1H), 7.03 (t, J=8 Hz, 1H), 7.82 (dd, J=1, 5 Hz, 1H), 8.65 (d, J=5 Hz, 1H), 9.55 (s, 1H); MS (DCI(NH₃)) *m/e* 479 (M+H)⁺; Analysis calc'd for C₂₅H₂₆N₄O₄S·(HCl)₂·(H₂O)_{0.75}: C, 53.15; H, 5.26; N, 9.22; found: C, 53.37; H, 5.11; N, 9.74.

Example 29

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 1E (400 mg, 1.5 mmol), 3-amino-2-carbomethoxythieno[2,3-c]pyridine (.33 g, 1.6 mmol) (*J. Heterocyclic Chem.*, **24**, 85 (1987)), Et₃N (.50 mL, 3.6 mmol), and phosgene (0.82 mL 1.93 M solution in toluene, 1.6 mmol)

were treated as described in Example 1F to yield 0.50 g (72%) of the title compound: m.p. 212-214°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.61-1.76 (m, 2H), 1.81-1.93 (m, 2H), 2.21-2.31 (m, 2H), 2.50-2.67 (m, 3H), 3.15 (dd, J=7, 9 Hz, 1H), 3.36-3.55 (m, 2H), 3.73-3.82 (m, 1H), 3.78 (s, 3H), 4.00 (dd, J=5, 11 Hz, 1H), 4.23 (t, J=7 Hz, 2H), 6.42 (d, J=8 Hz, 1H), 6.48 (d, J=8 Hz, 1H), 7.04 (t, J=8 Hz, 1H), 8.12 (d, J=6 Hz, 1H), 8.71 (d, J=6 Hz, 1H), 9.24 (s, 1H); MS (DCI(NH₃)) *m/e* 479 (M+H)⁺; Analysis calc'd for C₂₅H₂₆N₄O₄S•(HCl)₂: C, 54.45; H, 5.12; N, 10.16; found: C, 54.05; H, 5.24; N, 10.05.

Example 30

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 7A (0.30 g, 1.26 mmol) and the product from Example 1E (0.35 g, 1.26 mmol) were treated as described in Example 1F to yield 0.37 g (58%) of the title compound: m.p. 195-197°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.3 (d, 1H), 7.07 (t, 1H), 6.98 (d, 1H), 6.52 (d, 1H), 6.46 (d, 1H), 4.05 (t, 2H), 4.03 (m, 1H), 4.02 (s, 3H), 3.83 (m, 1H), 3.81 (s, 3H), 3.5 (m, 2H), 3.25 (m, 1H), 2.65 (m, 3H), 2.3 (m, 2H), 1.78 (m, 2H), 1.58 (m, 2H); MS (DCI/NH₃) *m/e* 509(M+H)⁺; Analysis calc'd for C₂₆H₂₈N₄O₅S•HCl•H₂O: C, 55.46; H, 5.55; N, 9.95; found: C, 55.40; H, 5.62; N, 9.58.

Example 31

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 31A

Ethyl 7-amino-2-methoxy-thienof[2,3-b]pyrazine-6-carboxylate

The compound from Example 10C (0.700 g, 2.72 mmol) was dissolved in 75 ml MeOH, treated with solid NaOMe (1.47 g, 27.2 mmol) and the resulting solution refluxed for 12h. The reaction mixture was partitioned between saturated NH₄Cl and CHCl₃. After extracting the aqueous phase with CHCl₃, the combined organics were washed with water then brine and dried over Na₂SO₄. Concentration gave 0.500 g (77%) pure title compound as a yellow solid: mp: 181-182 °C; ¹H NMR (300 MHz, CDCl₃) δ 3.92 (s, 3H), 4.05 (s, 3H),

6.02 (br s, 2H), 8.30 (s, 1H); MS (DCI/NH₃) m/e 240 (M+H)⁺, 257 (M+NH₄)⁺. Analysis calc'd. for C₉H₉N₃O₃S: C, 45.18; H, 3.79; N, 17.56; Found: C, 45.25; H, 3.48; N, 17.41.

Example 31B

5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

10 The product from Example 31A (0.30 g, 1.26 mmol) and the product from Example 1E (0.35 g, 1.26 mmol) were treated as described in Example 1F to yield 0.33 g (52%) of the title compound: m.p. 182-184°; ¹H NMR (300 MHz, DMSO-d₆(free base)) δ 8.58 (s, 1H), 7.13 (t, 1H), 6.61 (d, 1H), 6.52 (d, 1H), 4.1 (m, 1H), 4.08 (s, 3H), 3.96 (t, 2H), 3.85 (m, 1H), 3.8 (s, 3H), 3.42 (m, 2H), 3.1 (m, 1H), 2.85 (m, 3H), 2.75 (m, 2H), 1.68 (m, 4H); MS (DCI/NH₃) m/e 510(M+H)⁺; Analysis calc'd for C₂₅H₂₇N₅O₅S·HCl·2H₂O: C, 51.59; H, 5.54; N, 12.03; found: C, 51.67; H, 5.43; N, 11.84.

Example 32

20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 32A

Methyl 3-amino-5-chloro-thieno[2,3-b]pyridine-2-carboxylate

25 3-Cyano-2,6-dichloropyridine (5.19 g, 30 mmol) and 2.7 mL (30 mmol) methyl thioglycolate were combined in DMF (25 mL) and the solution was cooled to 0° C. To the reaction was added KOH (3.0 g, 54 mmol) in 12 mL H₂O. After 1.5 h at 0° C the reaction was diluted with H₂O (50 mL) and the precipitate collected. The product was recrystallized from ethyl acetate/hexane to yield 1.49 g (20%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 3.92 (s, 3H), 5.90 (br s, 2H), 7.33 (d, 1H), 7.87 (d, 1H).

Example 32B

30 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

35 The product from Example 1E (0.414 g, 1.5 mmol) and the product from Example 32A (0.382 g, 1.57 mmol) were treated as described in Example 1F to yield 0.30 g (25%) of the title

compound.: m.p. 201-205°; ¹H NMR (300 MHz, CDCl₃) δ 1.6-1.9 (m, 4H), 2.2-2.44 (m, 2H), 2.5-5.8 (m, 4H), 3.1-3.9 (m, 4H), 3.78 (s, 3H), 4.02 (dd, 1H), 4.18 (t, 2H), 6.42 (d, 1H), 6.49 (d, 1H), 7.05 (t, 1H), 7.49 (d, 1H), 8.49 (d, 1H); MS (DCI/NH₃) *m/e* 513 (515 (M+H)⁺); Analysis calc'd for C₂₅H₂₆Cl₂N₄O₄S·H₂O: C, 52.91; H, 4.97; N, 9.87; Cl, 12.49; found: C, 53.17; H, 4.87; N, 9.52; Cl, 12.43.

Example 33

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

Example 33A

Methyl 3-amino-5-methoxy-thienof[2,3-b]pyridine-2-carboxylate

Sodium metal (0.46 g, 20 mmol) was added to methanol (20 mL) and allowed to react until metallic sodium was consumed. To the solution was added the product from Example 32A (0.485 g, 2.0 mmol) and the reaction was heated to reflux for 2h. The reaction was quenched in sat. aq. NH₄Cl and extracted with ethyl acetate. The organic phase was dried (MgSO₄) and evaporated to yield 0.410 g (86%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 3.88 (s, 3H), 4.02 (s, 3H), 6.74 (d, 1H), 7.77 (d, 1H).

Example 33B

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

The product from Example 1E (0.414 g, 1.5 mmol) and the product from Example 33A (0.375 g, 1.57 mmol) were treated as described in Example 1F to yield 0.480 g (51%) of the title compound.: m.p. 210-14°; ¹H NMR (300 MHz, CDCl₃) δ 1.64-1.88 (m, 4H), 2.2-2.4 (m, 2H), 2.5-2.8 (m, 4H), 3.1-3.9 (m, 4H), 3.78 (s, 3H), 4.02 (dd, 1H), 4.07 (s, 3H), 4.15 (t, 2H), 6.44 (d, 1H), 6.53 (d, 1H), 6.88 (d, 1H), 7.07 (t, 1H), 8.54 (d, 1H); MS (DCI/NH₃) *m/e* 509 (M+H)⁺; Analysis calc'd for C₂₅H₂₉ClN₄O₅S·H₂O: C, 55.46; H, 5.55; N, 9.95; Cl, 6.30; found: C, 55.64; H, 5.35; N, 9.91; Cl, 6.24.

Example 34

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 1E (0.414 g, 1.5 mmol) and methyl 3-amino-thieno[2,3-b]pyridine-2-carboxylate (0.328 g, 1.57 mmol) were treated as described in Example 1F to yield 0.26 g (34%) of the title compound.: m.p. 195-200°; ¹H NMR (300 MHz, CDCl₃) δ 1.68-1.9 (m, 4H), 2.3-2.5 (m, 2H), 2.5-2.85 (m, 4H), 3.2-3.9 (m, 4H), 3.79 (s, 3H), 4.01 (dd, 1H), 4.19 (t, 2H), 6.42 (d, 1H), 6.52 (d, 1H), 7.07 (t, 1H), 7.48 (dd, 1H), 8.57 (m, 1H), 8.77 (dd, 1H); MS (DCI/NH₃) *m/e* 497 (M+H)⁺; Analysis calc'd for C₂₅H₂₇ClN₄O₄S·H₂O: C, 56.33; H, 5.48; N, 10.51; Cl, 6.65; found: C, 56.32; H, 5.36; N, 10.42; Cl, 6.54.

Example 35

15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methyl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 35A

Methyl 3-amino-5-methyl-thieno[2,3-b]pyridine-2-carboxylate

20 2-Chloro-3-cyano-6-methyl pyridine (1.5 g, 9.8 mmol) and methyl thioglycolate (0.88 mL, 9.8 mmol) were dissolved in DMF (7 mL). To the solution was added 1.0 g KOH in 5 mL H₂O over 30 min. The reaction was then quenched by the addition of ice water, and the product collected by filtration to yield 1.72 g (79%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 2.88 (s, 3H), 3.91 (s, 3H), 5.90 (br s, 2H), 7.17 (d, 1H), 7.82 (d, 1H).

Example 35B

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

30 The product from Example 1E (0.414 g, 1.5 mmol) and the product from Example 35A (0.350 g, 1.57 mmol) were treated as described in Example 1F to yield 0.27 g (34%) of the title compound.: m.p. 215-20°; ¹H NMR (300 MHz, CDCl₃) δ 1.68-1.9 (m, 4H), 2.3-2.5 (m, 2H), 2.5-2.8 (m, 4H), 2.71 (s, 3H), 3.2-3.9 (m, 4H), 3.77 (s, 3H), 4.02 (dd, 1H), 4.17 (t, 2H), 6.44 (d, 1H), 6.53 (d, 1H), 7.07 (t, 1H), 7.34 (d, 1H), 8.41 (d, 1H); MS (DCI/NH₃)

m/e 493 (M+H)⁺; Analysis calc'd for C₂₆H₂₉ClN₄O₄S·1.5H₂O: C, 56.16; H, 5.80; N, 10.08; Cl, 6.38; found: C, 56.00; H, 5.37; N, 10.01; Cl, 5.99.

Example 36

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 36A

Methyl 3-amino-4-methoxy-thieno[2,3-b]pyridine-2-carboxylate

To 2-chloro-3-cyano-4-methoxypyridine (2.02 g) and methyl thioglycolate (1.1 mL) in DMF (24 mL) at 5°C was added a 1.0 M solution of KOtBu/THF (14.6 mL). The reaction was stirred 20 min at 5°, then 1 h at RT, quenched in saturated NH₄Cl, the solid collected, washed with water and sucked dry. This was recrystallized from EtOAc to give 0.89 g of the title compound.

Example 36B

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 1E (0.414 g, 1.5 mmol) and the product from Example 36A (0.350 g, 1.57 mmol) were treated as described in Example 1F to yield 0.40 g (44%) of the title compound: m.p. 180-200°; ¹H NMR (300 MHz, CDCl₃) δ 1.61 (2H, br), 1.78 (2H, m), 2.23 (2H, br), 2.60 (3H, br), 3.20 (1H, br), 3.45 (2H, br), 3.75 (1H, m), 3.81 (3H, s), 4.03 (1H, dd), 4.10 (1H, t), 4.14 (3H, s), 6.44 (1H, d), 6.51 (1H, d), 6.82 (1H, d), 7.04 (1H, t), 8.60 (1H, d), 8.90 (1H, br s); MS (DCI/NH₃) *m/e* 509; Analysis calc'd for C₂₆H₂₉ClN₄O₅S·HCl·(H₂O)₂·(C₄H₈O₂)_{0.5}: C, 53.80; H, 5.97; N, 8.96; Cl, 5.67; found: C, 53.54; H, 5.68; N, 8.92; Cl, 5.73.

Example 37

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 1E (0.357 g, 1.25 mmol) and the product from Example 6A (0.30 g, 1.24 mmol) were treated as described in Example 1F to yield 0.30 g (47%) of the title compound: m.p. 196-198°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.15 (d, 1H), 7.47 (d, 1H), 7.05 (t, 1H), 6.48 (d, 1H), 6.42 (d, 1H), 4.08 (t, 2H), 4.02 (dd, 1H), 3.85 (m, 1H), 3.78 (s, 3H), 3.5 (m, 2H), 2.78 (m, 4H), 2.5 (m, 2H), 1.76 (m, 4H); MS (DCI/NH₃) m/e 513(M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·HCl·2H₂O: C, 51.09; H, 5.28; N, 9.25; found: C, 51.20; H, 5.33; N, 9.55.

Example 38

15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 38A

Methyl 3-amino-6-chloro-thieno[3,2-b]pyridine-2-carboxylate

20 The product from Example 27A (3.46 g, 20 mmol) and methyl thioglycolate (1.8 mL, 20 mmol) were combined in 40 mL THF. To the solution was added 1.08 g NaOMe (20 mmol). After 1.5 h, and additional 1.08 g NaOMe was added, and then after an additional 2h, the reaction was quenched in 5% aq. NaHCO₃ and extracted with diethyl ether. The organic extracts were dried (MgSO₄), evaporated, and the product was purified by silica gel column chromatography to yield 1.23 g (25%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 3.92 (s, 3H), 6.20 (br s, 2H), 8.04 (d, 1H), 8.54 (d, 1H).

Example 38B

30 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 1E (0.357 g, 1.25 mmol) and the product from Example 38A (0.30 g, 1.24 mmol) were treated as described in Example 1F to yield 0.29 g (46%) of the title compound: m.p. 224-226°; ¹H NMR (300 MHz, DMSO-d₆) δ 8.88 (m, 2H), 7.13 (t, 1H), 6.62 (d, 1H), 6.5 (d, 1H), 4.05 (dd, 1H), 3.96 (t, 2H), 3.82 (m, 1H), 3.8 (s, 3H), 3.2 (m, 2H), 2.95 (m, 1H), 2.85 (m, 3H), 2.3 (m, 2H), 1.7 (m, 4H); Analysis calc'd for

C₂₅H₂₅ClN₄O₄S·HCl·0.75H₂O: C, 53.22; H, 5.16; N, 9.39; found: C, 53.24; H, 5.04; N, 9.93.

Example 39

5 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

10 The product from Example 1E (0.357 g, 1.25 mmol) and the product from Example 9B (0.356 g, 1.25 mmol) were treated as described in Example 1F to yield, after recrystallization from methanol, 0.35 g (63%) of the title compound: m.p. 291°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 9.08 (s, 1H), 8.07 (dd, 2H), 7.58 (m, 3H), 6.88 (t, 1H), 6.30 (d, 1H), 6.20 (d, 1H), 4.18 (m, 2H), 3.88 (dd, 1H), 3.72 (s, 3H), 3.63 (m, 2H), 3.38 (m, 2H), 2.72 (m, 3H), 2.6 (m, 1H), 2.5 (m, 1H), 1.8 (m, 4H); MS (DCI/NH₃) m/e 556(M+H⁺); Analysis
15 calc'd for C₃₀H₂₉N₅SO₄·HCl: C, 60.85; H, 5.10; N, 11.82; Cl, 5.98. Found C, 60.50; H, 5.20; N, 11.69; Cl, 6.07.

Example 40

20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

Example 40A

3-Cyano-2-chloro-6-phenylpyrazine

25 3-Carboxamido-2-hydroxy-6-phenylpyrazine (7.56 g, 35.13 mmol), prepared by the method of Dick and Wood, *J. Chem. Soc.*, 1379 (1955), was suspended in triethylamine (7.11 g, 70.26 mmol), cooled to 0 °C and dissolved in 50 ml POCl₃. The mixture was refluxed for 3 h before concentrating *in vacuo*. The resulting black oil was extracted 5 x 100 ml Et₂O and the
30 combined extracts treated with 250 ml cold 10 % Na₂CO₃. The layers were separated and the organic phase washed with water, brine and dried over Na₂SO₄. Concentration gave the title compound (3.20 g, 42%) as a tan solid. mp: 143-145 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.57 (m, 3H), 8.10 (m, 2H), 9.05 (s, 1H); MS (DCI/NH₃) m/e 233 (M+NH₄)⁺.

Example 40BEthyl-7-amino-3-phenyl-thieno[2,3-b]pyrazine-6-carboxylate

The compound resulting from Example 40A (1.00 g, 4.65 mmol) was treated with ethyl thioglycolate (0.56 g, 4.65 mmol) and Na₂CO₃ (0.49 g, 4.65 mmol) in 20 ml EtOH. Recrystallization of the crude product from EtOH/H₂O gave the title compound (1.19 g, 86%) as a yellow-green solid. mp: 173-175 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.42 (t, 3H), 4.41 (q, 2H), 6.18 (br s, 2H), 7.55 (m, 3H), 8.12 (m, 2H), 9.03 (s, 1H). MS (DCI/NH₃) m/e 300 (M+H)⁺.

Example 40C3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-7-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 1E (0.357 g, 1.25 mmol) and the product from Example 40B (0.356 g, 1.25 mmol) were treated as described in Example 1F to yield 0.30 g (59%) of the title compound: ¹H NMR (300 MHz, CDCl₃(free base)) δ 9.13 (s, 1H), 8.18 (dd, 2H), 7.79 (m, 3H), 7.04 (t, 1H), 6.45 (t, 2H), 4.12 (t, 2H), 4.01 (dd, 1H), 3.88 (m, 1H), 3.81 (s, 3H), 3.55 (m, 2H), 3.45 (m, 1H), 2.78 (m, 3H), 2.62 (m, 2H), 1.78 (m, 4H); MS (DCI/NH₃) m/e 556(M+H)⁺; Analysis calc'd for C₃₀H₂₉N₅SO₄·HCl·1.5H₂O: C, 58.20; H, 5.37; N, 11.31; found: C, 58.51; H, 5.31; N, 11.33.

Example 413-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 3E (210 mg, 0.75 mmol), 3-amino-2-carbomethoxythieno[3,2-c]pyridine (.17 g, .83 mmol) (*J. Heterocyclic Chem.*, **24**, 85 (1987)), Et₃N (.40 mL, 2.9 mmol), and phosgene (0.43 mL 1.93 M solution in toluene, .83 mmol) were treated as described in Example 1F to yield 0.20 g (56%) of the title compound: m.p. > 250°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.72-1.93 (m, 4H), 2.29-2.43 (m, 1H), 2.74 (t, J=10 Hz, 1H), 2.83-2.98 (m, 4H), 3.16 (dd, J=8, 10 Hz, 1H), 3.73 (s, 3H), 3.75-3.83 (m, 1H), 4.03 (dd, J=1, 10 Hz, 1H), 4.21 (t, J=7 Hz, 2H), 4.43 (dd, J=4, 10 Hz, 1H), 6.36 (dd, J=1, 8 Hz, 1H), 6.46 (dd, J=1, 8 Hz, 1H), 7.05 (t, J=8 Hz, 1H), 7.80 (dd, J=1, 6 Hz, 1H), 8.61 (d, J=6 Hz, 1H), 9.54 (d, J=1 Hz, 1H); MS (DCI(NH₃)) m/e 479 (M+H)⁺;

Analysis calc'd for $C_{25}H_{26}N_4O_4S \cdot (HCl)_2 \cdot H_2O \cdot (CH_3OH)_{0.5}$: C, 52.31; H, 5.51; N, 9.57; found: C, 51.95; H, 5.22; N, 9.27.

Example 42.

5 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 3E (200 mg, 0.72 mmol), 3-amino-2-carbomethoxythieno[2,3-c]pyridine (.16 g, .79 mmol) (*J. Heterocyclic Chem.*, **24**, 85 (1987)),
10 Et_3N (.40 mL, 2.9 mmol), and phosgene (0.41 mL 1.93 M solution in toluene, 0.79 mmol) were treated as described in Example 1F to yield 0.20 g (58%) of the title compound: m.p. 221-223°; 1H NMR (300 MHz, $CDCl_3$ (free base)) δ 1.76-1.96 (m, 4H), 2.37-2.50 (m, 1H), 2.72-2.82 (m, 1H), 2.89-3.11 (m, 4H), 3.18-3.28 (m, 1H), 3.73 (s, 3H), 3.80-3.89 (m, 1H), 4.04 (dd, $J=1$, 9 Hz, 1H), 4.22 (t, $J=7$ Hz, 2H), 4.45 (dd, $J=4$, 10 Hz, 1H), 6.38 (d, $J=8$ Hz,
15 1H), 6.54 (d, $J=8$ Hz, 1H), 7.08 (t, $J=8$ Hz, 1H), 8.10 (d, $J=6$ Hz, 1H), 8.64 (d, $J=6$ Hz, 1H), 9.19 (s, 1H); MS (DCI(NH_3)) m/e 479 ($M+H$) $^+$; Analysis calc'd for $C_{25}H_{26}N_4O_4S \cdot (HCl)_2 \cdot (H_2O)_{0.75}$: C, 53.15; H, 5.26; N, 9.92; found: C, 53.18; H, 5.18; N, 9.70.

Example 43

20 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

25 The product from Example 3E (0.276 g, 1.00 mmol) and the product from Example 31A (0.25 g, 1.05 mmol) were treated as described in Example 1F to yield 0.10 g (50%) of the title compound: 1H NMR (300 MHz, $CDCl_3$ (free base)) δ 8.02 (d, 1H), 7.04 (t, 1H), 6.92 (d, 1H), 6.48 (d, 1H), 6.39 (d, 1H), 5.39 (m, 1H), 4.45 (dd, 1H), 4.11 (t, 2H), 4.04 (m, 1H), 3.76 (s, 3H), 3.59 (q, 1H), 2.96 (q, 1H), 2.76 (m, 4H), 2.58 (m, 1H), 2.3 (m, 1H), 1.77 (m,
30 4H), 1.42 (d, 6H); MS (DCI/ NH_3) m/e 537 ($M+H$) $^+$; Analysis calc'd for $C_{28}H_{32}N_4O_5S \cdot HCl \cdot 1.5H_2O$: C, 56.04; H, 6.05; N, 9.34; found: C, 56.04; H, 5.70; N, 9.14.

Example 44

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 3E (0.276 g, 1.0 mmol) and methyl 3-amino-thieno[2,3-b]pyridine-2-carboxylate (0.229 g, 1.1 mmol), as described in Example 35A, were treated as described in Example 1F to yield 0.185 g (36%) of the title compound: m.p. 217-8°; ¹H NMR (300 MHz, DMSO-d₆) δ 1.6-1.8 (m, 4H), 2.1-2.7 (m, 2H), 2.8-3.5 (m, 5H), 3.78 (s, 3H), 3.97 (m, 2H), 4.10 (q, 1H), 4.47 (m, 1H), 6.46 (d, 1H), 4.56 (d, 1H), 7.13 (t, 1H), 7.65 (dd, 1H), 8.75 (dt, 1H), 8.84 (dd, 1H), 10.55 (br s, 1H), 12.74 (d, 1H); MS (DCI/NH₃) m/e 479(M+H)⁺; Analysis calc'd for C₂₅H₂₇ClN₄O₄S·1.5H₂O: C, 55.39; H, 5.57; N, 10.33; found: C, 55.43; H, 5.17; N, 10.32.

Example 45

15 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methyl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

20 The product from Example 3E (0.276 g, 1.0 mmol) and the product from Example 35A (0.244 g, 1.1 mmol) were treated as described in Example 1F to yield 0.090 g (17%) of the title compound: m.p. 243-5°; ¹H NMR (300 MHz, DMSO-d₆) δ 1.6-1.8 (m, 4H), 2.1-2.7 (m, 3H), 2.66 (s, 3H), 2.8-3.8 (m, 6H), 3.77 (s, 3H), 3.96 (m, 2H), 4.12 (m, 1H), 4.45 (m, 1H), 6.46 (d, 1H), 6.56 (d, 1H), 7.12 (t, 1H), 7.51 (d, 1H), 8.60 (d, 1H); MS (DCI/NH₃) m/e 493 (M+H)⁺; Analysis calc'd for C₂₆H₂₉ClN₄O₄S·H₂O: C, 57.08; H, 5.71; N, 10.24; found: C, 56.93; H, 5.22; N, 9.94.

Example 46

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

30 The product from Example 3E (0.248 g, 0.90 mmol) and the product from Example 33A (0.238 g, 1.0 mmol) were treated as described in Example 1F to yield 0.301 g (61%) of the title compound: m.p. 260-3°; ¹H NMR (300 MHz, DMSO-d₆) δ 1.6-1.8 (m, 4H), 2.1-2.7 (m, 3H), 2.8-3.6 (m, 6H), 3.74 (s, 3H), 3.95 (m, 2H), 3.97 (s, 3H), 4.07 (t, 1H), 4.28 (m, 1H), 6.46 (d, 1H), 6.55 (d, 1H), 7.07 (d, 1H), 7.11 (t, 1H), 8.59 (d, 1H); MS (DCI/NH₃)

m/e 509 (M+H)⁺; Analysis calc'd for C₂₆H₂₉ClN₄O₅S·3/4H₂O: C, 55.91; H, 5.50; N, 10.03; Cl, 6.35; found: C, 55.75; H, 5.32; N, 10.00; Cl, 6.44.

Example 47

5 3-[4-((3aS,9bR)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 3E (0.248 g, 0.90 mmol) and the product from Example 32A (0.242 g, 1.0 mmol) were treated as described in Example 1F to yield 0.285 g (58%) of the title compound: m.p. 245-50°; ¹H NMR (300 MHz, DMSO-d₆) δ 1.6-1.8 (m, 4H), 2.1-2.7 (m, 2H), 2.8-3.6 (m, 5H), 3.77 (s, 3H), 3.8-4.2 (m, 2H), 3.95 (m, 2H), 4.10 (t, 1H), 4.47 (m, 1H), 6.46 (d, 1H), 6.54 (d, 1H), 7.11 (t, 1H), 7.78 (d, 1H), 8.75 (d, 1H); MS (DCI/NH₃) *m/e* 513 (515 (M+H)⁺); Analysis calc'd for C₂₅H₂₆Cl₂N₄O₄S·0.5H₂O·0.1HCl: C, 53.42; H, 4.86; N, 9.97; Cl, 13.24; found: C, 53.25; H, 7.73; N, 9.68; Cl, 13.31.

Example 48

3-[4-((3aR,9bR)-*cis*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-chloro-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 48A

Methyl 3-amino-4-chloro-thienof[3,2-c]pyridine-2-carboxylate

To 3-cyano-2,4-dichloropyridine (653 mg) and methyl thioglycolate (340 µL) in DMF (12 mL) at 5°C was added a solution of 1.0 M KOtBu/THF (4.5 mL). The reaction was stirred 20 min at 5° then 1 h at RT, then quenched in sat'd NH₄Cl, the solid precipitate collected, washed with water and sucked dry to give 800 mg (88%) of the title compound.

Example 48B

3-[4-((3aR,9bR)-*cis*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-chloro-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 1E (0.276 g, 1.0 mmol) and the product from Example 48A (0.242 g, 1.0 mmol) were treated as described in Example 1F to yield 0.280 g (55%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.75 (4H, br m), 2.40 (2H, br), 2.65 (3H, br), 3.30 (1H, br), 3.50 (2H, br), 3.80 (3H, s), 3.86 (1H, br), 4.02 (1H, dd), 4.10 (1H, t), 6.45 (1H, d), 6.52 (1H, d), 7.08 (1H, t), 7.79 (1H, d), 8.40 (1H, d); MS (CI(NH₃)) *m/e* 513

(M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·HCl: C, 52.49; H, 4.89; N, 9.79; found: C, 52.28; H, 4.55; N, 9.44.

Example 49

3-[4-((3aS,9bR)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-methoxy-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione fumarate

Example 49A

Methyl 3-amino-4-methoxy-thieno[3,2-c]pyridine-2-carboxylate

The product from Example 48A (1.2 g, 4.9 mmol) and sodium methoxide (1.0 g, 19 mmol) were refluxed in 30 mL MeOH for 6 h. The reaction was partitioned between water and CH₂Cl₂. The layers were separated and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered, and concentrated. Silica gel chromatography (CH₂Cl₂) yielded 1.1 g (78 %) of the title compound: ¹H NMR (300 MHz, DMSO-d₆) δ 3.79 (s, 3H), 4.05 (s, 3H), 6.96 (bs, 2H), 7.47 (d, J=6 Hz, 1H), 8.07 (d, J=6 Hz, 1H); MS (DCI(NH₃)) *m/e* 239 (M+H)⁺.

Example 49B

3-[4-((3aS,9bR)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-9-methoxy-pyrido[3',4':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione fumarate

The product from Example 1E (0.140 g, 0.50 mmol), the product from Example 49A (0.145 g, 0.61 mmol), Et₃N (0.18 mL, 1.3 mmol), and phosgene (1.1 mL 1.93 M solution in toluene, 2.1 mmol) were treated as described in Example 1F substituting fumaric acid for the salt forming step to yield 0.22 g (87%) of the title compound: m.p. 232-233°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.60-1.84 (m, 4H), 2.24-2.40 (m, 1H), 2.55-2.65 (m, 1H), 2.72-2.90 (m, 4H), 2.95-3.03 (m, 1H), 3.60-3.69 (m, 1H), 3.76 (s, 3H), 4.05 (dd, J=10, 11 Hz, 1H), 4.11 (t, J=7 Hz, 2H), 4.20 (s, 3H), 4.46 (dd, J=4, 9 Hz, 1H), 6.39 (d, J=8 Hz, 1H), 6.48 (d, J=8 Hz, 1H), 7.05 (t, J=8 Hz, 1H), 7.39 (d, J=6 Hz, 1H), 8.16 (d, J=6 Hz, 1H); MS (DCI(NH₃)) *m/e* 509 (M+H)⁺; Analysis calc'd for C₂₆H₂₈N₄O₅S·C₄H₄O₄·(H₂O)_{0.25}: C, 57.27; H, 5.21; N, 8.90; found: C, 56.96; H, 4.95; N, 8.83.

Example 50

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazinol[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 3E (0.276 g, 1.0 mmol) and the product from Example 9B (0.308 g, 1.08 mmol) were treated as described in Example 1F to yield 0.41 g (73%) of the title compound: m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 9.03 (s, 1H), 8.02 (m, 2H), 7.58 (m, 3H), 7.0 (t, 1H), 6.4 (d, 1H), 6.31 (d, 1H), 3.98 (m, 2H), 4.05 (dd, 1H), 3.85
10 (t, 2H), 3.62 (m, 1H), 3.06 (m, 3H), 2.85 (m, 2H), 2.22 (m, 1H), 1.82 (m, 4H); MS (DCI/NH₃) m/e 556(M+H)⁺; Analysis calc'd for C₃₀H₂₉N₅O₄S·HCl·2H₂O: C, 57.36; H, 5.46; N, 11.15; found: C, 57.31; H, 5.23; N, 10.99.

Example 51

15 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-8-isopropoxy-pyridol[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 51A

20 Isopropyl 3-amino-5-isopropoxy-thienol[3,2-b]pyridine-2-carboxylate

Na metal (0.47 g, 20 mmol) was added to 2-propanol (150 mL) and the reaction was heated to reflux until all the sodium was consumed. To the resulting solution was added methyl 3-Amino-7-chloro-thienol[3,2-b]pyridine-2-carboxylate (prepared as described in Example 5A),
25 (0.50 g, 2.06 mmol) and the solution was heated to reflux for 48 h. Solvent was evaporated and the product was partitioned between aq. NH₄Cl and CH₂Cl₂. The organic phase was dried, concentrated, and the product purified by silica gel chromatography to yield 0.11 g (19%) of the title compound: ¹H NMR (300 MHz, CDCl₃) 7.85 (d, 1H), 6.91 (d, 1H), 5.98 (bs, 1H), 5.42 (m, 1H), 5.25 (m, 1H), 1.42 (d, 6H), 1.38 (d, 6H); MS (DCI/NH₃) m/e 295(M+H)⁺;

Example 51B

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-isopropoxy-pyrido[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 3E (0.102 g, 0.37 mmol) and the product from Example 51A (0.11 g, 0.37 mmol) were treated as described in Example 1F to yield 0.10 g (50%) of the title compound: ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.02 (d, 1H), 7.04 (t, 1H), 6.92 (d, 1H), 6.48 (d, 1H), 6.39 (d, 1H), 5.39 (m, 1H), 4.45 (dd, 1H), 4.11 (t, 2H), 4.04 (m, 1H),
10 3.76 (s, 3H), 3.59 (q, 1H), 2.96 (q, 1H), 2.76 (m, 4H), 2.58 (m, 1H), 2.3 (m, 1H), 1.77 (m, 4H), 1.42 (d, 6H); MS (DCI/NH₃) *m/e* 537(M+H)⁺; Analysis calc'd for C₂₈H₃₂N₄O₅S.HCl·1.5H₂O: C, 56.04; H, 6.05; N, 9.34; found: C, 56.04; H, 5.70; N, 9.14.

Example 52

15 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Example 52A

20 Methyl 3-amino-5-phenyl-thienof[3,2-b]pyridine-2-carboxylate

Methyl 3-amino-5-chloro-thienof[3,2-b]pyridine-2-carboxylate, prepared as described in Example 6A (0.243 g, 1.0 mmol), phenylboronic acid (0.134 g, 1.1 mmol) and triethylamine
25 (0.20 mL) were added to 3 mL of DMF containing [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride (1:1 complex with CH₂Cl₂) under N₂. The mixture was stirred at 90°C for 4 h. The reaction was then cooled and diluted with Et₂O. The organic layer was washed with H₂O, brine, dried (MgSO₄), concentrated and chromatographed (2:1 CH₂Cl₂:hexane) to yield the title compound (140 mg, 50 %): ¹H NMR
30 (300 MHz, CDCl₃) δ 3.93 (s, 3H), 6.30 (bs, 2H), 7.41-7.55 (m, 3H), 7.84 (d, J=8 Hz, 1H), 8.07-8.13 (m, 3H); MS (DCI(NH₃)) *m/e* 285 (M+H)⁺.

Example 52B

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

The product from Example 3E (0.21 g, 0.75 mmol), the product from Example 52A (235 mg, 0.83 mmol), Et₃N (0.26 mL, 1.9 mmol), and phosgene (0.5 mL 1.93 M solution in toluene, 0.95 mmol) were treated as described in Example 1F to yield 0.300 g (72%) of the title compound: m.p. > 250°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.59-1.71 (m, 2H), 1.74-1.87 (m, 2H), 2.19-2.34 (m, 1H), 2.59 (dd, J=9, 11 Hz, 1H), 2.72-2.84 (m, 4H), 3.00 (dd, J=7, 9 Hz, 1H), 3.55-3.67 (m, 1H), 3.73 (s, 3H), 4.00 (dd, J=10, 12 Hz, 1H), 4.18 (t, J=7 Hz, 2H), 4.38 (dd, J=4, 10 Hz, 1H), 6.38 (dd, J=1, 8 Hz, 1H), 6.46 (dd, J=1, 8 Hz, 1H), 7.08 (t, J=8 Hz, 1H), 7.44-7.56 (m, 3H), 7.92 (d, J=8 Hz, 1H), 8.04-8.11 (m, 2H), 8.26 (d, J=8 Hz, 1H); MS (DCI(NH₃)) m/e 555 (M+H)⁺; Analysis calc'd for C₃₁H₃₀N₄O₄S•(HCl)₂•(H₂O)_{0.5}: C, 58.49; H, 5.23; N, 8.80; found: C, 58.18; H, 5.23; N, 8.47.

Example 53

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

Example 53A

Methyl-3-amino-7-chloro-thienof[2,3-c]pyridine-2-carboxylate

3-Chloro-4-cyanopyridine, prepared as described in *J. Heterocyclic Chem.*, **15**, 683 (1978), (2.9 g, 21 mmol) was dissolved in acetic acid (15 mL) and 30% H₂O₂ (15 mL) was added over 5 min. The reaction was stirred at 80° for 18 h. After cooling to room temp., the white solid product (2.5 g) was collected by filtration and dried. The N-oxide was then dissolved in DMF (50 mL) and methyl thioglycolate (1.45 mL, 16 mmol) was added. Sodium methoxide (0.86 g, 16 mmol) was then added. The reaction was stirred for 1h, poured into ice/water, and the product collected by filtration, and dried. The resulting solid was suspended in POCl₃ (40 mL) and heated at reflux for 1h. The reaction was quenched on ice, extracted with ether, and the organic extracts washed several times with aq. 5% NaHCO₃. Silica gel column chromatography (85:15 hexane:ethyl acetate) yielded 0.42 g of the minor isomer (methyl-3-amino-5-chloro-thieno[2,3-c]pyridine-2-carboxylate) and 1.05 g of the title compound.

Example 53B

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

The product from Example 1E (0.42 g, 1.5 mmol), the product from Example 53A (0.364 g, 1.5 mmol), Et₃N (0.5 mL, 3.0 mmol), and phosgene (1.6 mL 1.93 M solution in toluene, 3.0 mmol) were treated as described in Example 1F to yield 0.26 g (33%) of the title compound: m.p. 191°; ¹H NMR (300 MHz, CDCl₃) δ 1.7-1.8 (m, 2H), 1.8-1.9 (m, 2H), 2.32-2.55 (m, 2H), 2.60-2.80 (m, 3H), 3.27 (m, 1H), 3.40-3.90 (m, 4H), 3.78 (s, 3H), 4.01 (dd, 1H), 4.19 (t, 2H), 6.43 (d, 1H), 6.48 (d, 1H), 7.06 (t, 1H), 8.04 (d, 1H), 8.46 (d, 1H); MS (DCI/NH₃) m/e 513, 515 (M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·H₂O: C, 56.55; H, 5.12; N, 10.55; found: C, 56.32; H, 5.03; N, 10.44.

Example 54

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6-chloro-pyrido[4',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

The product from Example 3E (0.42 g, 1.5 mmol), the product from Example 53A (0.364 g, 1.5 mmol), Et₃N (0.5 mL, 3.0 mmol), and phosgene (1.6 mL 1.93 M solution in toluene, 3.0 mmol) were treated as described in Example 1F to yield 0.31 g (40%) of the title compound: m.p. 230°; ¹H NMR (300 MHz, CDCl₃) δ 1.50-1.75 (m, 4H), 2.18 (m, 1H), 2.66 (t, 1H), 2.82 (m, 4H), 3.07 (t, 1H), 3.1-3.9 (m, 5H), 3.71 (s, 3H), 3.95 (m, 2H), 4.05 (dd, 1H), 4.42 (dd, 1H), 6.40 (d, 1H), 6.47 (d, 1H), 7.04 (t, 1H), 8.21 (d, 1H), 8.50 (d, 1H); MS (DCI/NH₃) m/e 513, 515 (M+H)⁺; Analysis calc'd for C₂₅H₂₅ClN₄O₄S·0.5H₂O: C, 57.52; H, 5.02; N, 10.73; found: C, 57.33; H, 4.72; N, 10.73.

Example 55

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

Example 55A

Methyl 2-amino-5-methoxy-thieno[2,3-b]pyridine-2-carboxylate

To 2-chloro-3-cyano-5-methoxypyridine (0.53 g) and methyl thioglycolate (280 μL) in DMF (10 mL) at 5°C was added a 1.0 M solution of KOtBu/THF (3.8 mL). The reaction was

stirred 20 min at 5°, then 2 h at RT, quenched in sat'd NH₄Cl, the solid precipitate was collected, washed with water and dried to give 0.53 g (71%) of the title compound.

Example 55B

5 3-[4-((3aS,9bR)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

10 The product from Example 3E (0.223 g, 0.80 mmol) and the product from Example 55A (0.192 g, 0.80 mmol) were treated as described in Example 1F to yield 0.315 g (77%) of the title compound: m.p. 207-213°; ¹H NMR (300 MHz, DMSO-d₆) δ 1.5 (2H, m), 1.65 (2H, m), 2.12 (1H, m), 2.57 (1H), 2.7 (4H, m), 2.9 (1H, t), 3.48 (1H, m), 3.7 (3H, s), 3.92 (3H, s), 3.94 (2H), 4.02 (1H, dd), 4.4 (1H, dd), 6.4 (1H, d), 6.45 (1H, d), 7.02 (1H, t), 8.32 (1H, d), 8.56 (1H, d); MS (CI(NH₃)) *m/e* 509; Analysis calc'd for C₂₆H₂₉ClN₄O₅: C, 54.59; H, 5.64; N, 9.79; found: C, 54.61; H, 5.60; N, 9.72.

Example 56

20 3-[4-((3aR,9bR)-*cis*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Example 56A

Methyl 3-amino-5-(3-pyridyl)thienyl[3,2-b]pyridine-2-carboxylate

25 A solution of the methyl 3-amino-5-chloro-thieno[3,2-b]pyridine-2-carboxylate prepared as described in Example 5A (0.252 g), diethyl 3-pyridyl-borane (0.155 g), Pd(dppf)Cl₂ (0.082 g) and K₂CO₃ (420 mg) in degassed DMF (5 mL) was heated to 95°C for 1.5 h, cooled, quenched in sat'd NH₄Cl, the solid precipitate collected and chromatographed 9:1 hexane/EtOAc to give 0.24 g (81%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 3.95 (3H, s), 6.30 (2H, br s), 7.45 (1H, dd), 7.86 (1H, d), 8.19 (1H, d), 8.42 (1H, dt), 8.70 (1H, dd), 9.32 (1H, br d).

Example 56B

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

5 The product from Example 1E (0.127 g, 0.46 mmol) and the product from Example 56A (0.14 g, 0.49 mmol) were treated as described in Example 1F to yield 0.09 g (33%) of the title compound: m.p. 210-211°; ¹H NMR (300 MHz, CDCl₃) δ 9.3 (d, 1H), 8.73 (dd, 1H), 8.41 (dt, 1H), 8.37 (d, 1H), 7.99 (d, 1H), 7.48 (dd, 1H), 7.12 (t, 1H), 6.53 (d, 1H), 6.48 (d, 1H), 4.12 (t, 2H), 4.0 (dd, 1H), 3.81 (s, 3H), 3.78 (m, 1H), 3.42 (m, 2H), 3.1 (m, 1H), 2.6 (m, 3H), 2.2 (m, 2H), 1.85 (m, 2H), 1.68 (m, 2H); MS (DCI/NH₃) m/e 556(M+H)⁺; Analysis calc'd for C₃₀H₂₉N₅SO₄·2HCl: C, 57.33; H, 4.97; N, 11.14; found: C, 57.04; H, 5.09; N, 10.89.

Example 57

15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Example 57A

20 Methyl 7-amino-2-(3-thienyl)thieno[2,3-b]pyrazine-6-carboxylate

A solution of the methyl 7-amino-2-chloro-thieno[2,3-b]pyrazine-6-carboxylate prepared as described in Example 10C (0.190 g), thiophene-3-boronic acid (0.100 g), Pd(dppf)Cl₂ (0.032 g) and triethylamine (0.22 mL) in degassed DMF was heated to 95°C for 4 h, cooled, quenched in water and extracted with 1:1 Et₂O/EtOAc (3x). The organics were washed 3x with water, brine, dried (Na₂SO₄), filtered and solvent evaporated to give 0.200 g (88%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 3.95 (3H, s), 6.23 (2H, br s), 7.50 (1H, dd), 7.79 (1H, dd), 8.05 (1H, dd), 9.00 (1H, s).

Example 57B

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 1E (0.127 g, 0.46 mmol) and the product from Example 57A (0.13 g, 0.45 mmol) were treated as described in Example 1F to yield 0.09 g (36%) of the title compound: ¹H NMR (300 MHz, CDCl₃(free base)) δ 9.06 (s, 1H), 8.1 (dd, 1H), 7.78 (dd, 1H), 7.53 (dd, 1H), 7.05 (t, 1H), 6.45 (dd, 2H), 4.13 (t, 2H), 4.01 (dd, 1H), 3.83 (m, 1H), 3.8 (s, 3H), 3.52 (m, 2H), 3.3 (m, 1H), 2.72 (m, 3H), 2.45 (m, 2H), 1.85 (m, 2H), 1.68 (m, 2H); MS (DCI/NH₃) m/e 562(M+H)⁺; Analysis calc'd for C₂₈H₂₇N₅O₄S₂·HCl·2H₂O: C, 53.00; H, 5.09; N, 11.04; found: C, 52.78; H, 4.84; N, 10.72.

Example 58

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrido[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione trihydrochloride

The product from Example 3E (0.127 g, 0.46 mmol) and the product from Example 56A (0.14 g, 0.49 mmol) were treated as described in Example 1F to yield 0.095 g (35%) of the title compound: m.p. 238-241°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 9.34 (d, 1H), 8.76 (d, 1H), 8.47 (d, 1H), 8.38 (d, 1H), 7.99 (d, 1H), 7.52 (dd, 1H), 7.11 (t, 1H), 6.5 (d, 1H), 6.41 (d, 1H), 4.66 (dd, 1H), 4.51 (m, 2H), 4.2 (m, 1H), 3.85 (m, 1H), 3.78 (s, 3H), 2.83 (m, 1H), 2.64 (m, 4H), 2.52 (m, 1H), 2.3 (m, 1H), 1.78 (m, 2H), 1.72 (m, 2H); MS (DCI/NH₃) m/e 456(M+H)⁺; Analysis calc'd for C₃₀H₂₉N₅SO₄·3HCl·2H₂O: C, 51.40; H, 5.18; N, 9.99; found: C, 51.24; H, 5.23; N, 9.82.

Example 59

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 3E (0.13 g, 0.44 mmol) and the product from Example 57A (0.13 g, 0.45 mmol) were treated as described in Example 1F to yield 0.045 g (17%) of the title compound: ¹H NMR (300 MHz, CDCl₃(free base)) δ 9.09 (s, 1H), 8.12 (d, 1H), 7 (81, J=d

H₂, 1H), 7.52 (dd, 1H), 7.11 (t, 1H), 6.51 (d, 1H), 6.42 (d, 1H), 4.52 (dd, 1H), 4.17 (m, 2H), 4.08 (m, 1H), 3.85 (m, 1H), 3.8 (s, 3H), 3.2 (m, 4H), 3.1 (m, 1H), 2.8 (m, 1H), 2.62 (m, 1H), 2.05 (m, 2H), 1.95 (m, 2H); MS (DCI/NH₃) m/e 562(M+H)⁺.

Example 60

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Example 60A

Methyl 7-amino-2-(3-pyridyl)thieno[2,3-b]pyrazine-6-carboxylate

A solution of the methyl 7-amino-2-chloro-thieno[2,3-b]pyrazine-6-carboxylate prepared as described in Example 10C (0.468 g), diethyl(3-pyridyl)borane (0.293 g), Pd(dppf)Cl₂ (0.157 g), and K₂CO₃ (0.800 g) in degassed DMF (10 mL) was heated to 95°C for 1.5 h, cooled, quenched in sat'd NH₄Cl, the solid precipitate collected, washed with water and dried. Purification by silica gel column chromatography provided 0.44 g (80%) of the title compound. ¹H NMR (DMSO-d₆) δ 3.87 (3H, s), 7.25 (2H, br s), 7.6 (1H, dd), 8.75 (2H, m), 9.49 (1H, s), 9.58 (1H, m).

Example 60B

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl)-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

The product from Example 3E (0.24 g, 0.87 mmol) and the product from Example 60A (0.25 g, 0.87 mmol) were treated as described in Example 1F to yield 0.14 g (29%) of the title compound: m.p. 235-240°; ¹H NMR (300 MHz, CDCl₃) δ 1.9 (4H, br m), 2.4 (4H, br m), 3.05 (1H, br m), 3.10 (3H, br m), 3.65 (1H, m), 3.74 (3H, s), 4.03 (1H, t), 4.19 (2H, t), 4.40 (1H, dd), 6.38 (1H, d), 6.46 (1H, d), 7.07 (1H, t), 7.45 (1H, dd), 8.40 (1H, dt), 8.80 (1H, dd), 9.05 (1H, s), 9.36 (1H, d); MS (CI(NH₃)) m/e 557; Analysis calc'd for C₂₉H₂₈N₆O₆S·1.75 HCl·2.75 H₂O: C, 51.99; H, 5.30; N, 12.54; Cl, 9.26; found: C, 51.78; H, 5.12; N, 12.20; Cl, 9.14.

Example 61

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

The product from Example 1E (0.18 g, 0.65 mmol) and the product from Example 60A (0.165 g, 0.58 mmol) were treated as described in Example 1F to yield 0.18 g (56%) of the title compound: m.p. 190-205°; ¹H NMR (300 MHz, CDCl₃) δ 1.84 (4H, br m), 2.7-3.05 (6H, br m), 3.5 (4H, br m), 3.72 (3H, s), 3.87 (1H, br d), 4.10 (2H, br m), 4.22 (1H, br m), 6.20 (1H, br s), 6.34 (1H, br d), 6.93 (1H, br t), 7.55 (1H, dd), 8.41 (1H, dt), 8.80 (1H, dd), 9.12 (1H, s), 9.34 (1H, d); MS (CI(NH₃)) m/e 557; Analysis calc'd for C₂₉H₂₈N₆O₄S·1.7 HCl·2.5H₂O: C, 52.48; H, 5.27; N, 12.66; Cl, 9.08; found: C, 52.21; H, 5.11; N, 12.42; Cl, 8.80.

Example 62

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-furyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Example 62A

Methyl 7-amino-2-(3-furyl)thieno[2,3-b]pyrazine-6-carboxylate

A solution of the methyl 7-amino-2-chloro-thieno[2,3-b]pyrazine-6-carboxylate prepared as described in Example 10C (0.300 g, 1.23 mmol), β-furanboronic acid (0.207 g, 1.85 mmol) were dissolved in 12 mL of anhydrous DMF. To this solution was added triethylamine (0.26 mL, 1.85 mMol, 1.5 equiv.), DPPP (153 mg, 0.37 mMol, 0.3 equiv.) and Pd(OAc)₂ (83 mg, 0.37 mMol, 0.3 equiv.), followed by heating to 90°C for 2h. The solvent was evaporated and the resulting residue was chromatographed (SiO₂, 3:1 Hexanes / Ethyl Acetate) yielding the product as a light yellow solid (93 mg): ¹H NMR (300 MHz, CDCl₃) δ 7.02 (m, 1H), 7.57 (t, J = 3.0 Hz, 1H), 8.15 (m, 1H), 8.83 (s, 1H).

Example 62B

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-furyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

5 The product from Example 1E (0.097 g, 0.35 mmol), the product from Example 62A (0.073 g, 0.27 mmol), Et₃N (0.1 mL, 0.68 mmol), and phosgene (0.7 mL 1.93 M solution in toluene, 1.4 mmol) were treated as described in Example 1F to yield 0.040 g (26%) of the title compound: m.p. 183-186°; ¹H NMR (300 MHz, DMSO-d₆) δ 1.61-1.80 (m, 5H), 2.70-2.81 (m, 1H), 1.81-2.96 (m, 2H), 3.12-3.33 (m, 2H), 3.37-3.53 (m, 1H), 3.77-3.93 (m, 1H), 10
3.80 (s, 3H), 3.93-4.02 (m, 2H), 4.02-4.15 (m, 2H), 6.51 (d, J=8 Hz, 1H), 6.61 (d, J=8 Hz, 1H), 7.14 (t, J=8 Hz, 1H), 7.29 (d, J=2 Hz, 1H), 7.92 (d, J=2 Hz, 1H), 8.66 (s, 1H), 9.28 (s, 1H), 10.35 and 10.55 (bs and bs, 1H), 12.75 (bs, 1H); MS (CI(NH₃)) m/e (M+H)⁺ at 546; Analysis calc'd for C₂₈H₂₇N₅O₅S•(HCl)₂: C, 54.37; H, 4.73; N, 11.32; found: C,
15 54.48; H, 5.03; N, 11.13.

Example 63

3-[2-((±)-cis-7-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 63A

(±)-cis-7-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

20 From 7-methoxy-coumarin and N-methoxymethyl-N-trimethylsilylmethyl-benzylamine in an analogous manner as described in Examples 1A-C: ¹H NMR (300 MHz, CDCl₃) δ 1.92 (br s, 1H), 2.60 (m, 1H), 2.81 (m, 2H), 3.17 (q, 1H), 3.29 (dd, 1H), 3.40 (dd, 1H), 3.77 (s, 3H), 3.78 (t, 1H), 4.10 (dd, 1H), 6.43 (d, 1H), 6.52 (dd, 1H), 7.03 (d, 1H).

Example 63B

30 3-[2-((±)-cis-7-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 63A (0.41 g, 2.00 mmol), N-(2-Chloroethyl)-N'-[3-[(2-methoxycarbonyl)benzothienyl]]-urea (0.654 g, 2.00 mmol), prepared by the procedure
35 described in *Eur. J. Med. Chem.*, 28: 499-504 (1993), and ethyldiisopropylamine (0.44 mL, 2.5 mmol) were dissolved in DMSO (3 mL) and the reaction was heated to 100° C for 3h. The

reaction was cooled to room temperature and 10 mL water added. The product was collected by filtration, recrystallized from 50% aqueous DMF, and the resulting product treated with excess anhydrous HCl in ethanol. After addition of anhydrous ether, the title compound was collected to yield 0.337 g: m.p. 204-7°; ¹H NMR (300 MHz, DMSO-d₆) δ 2.75-2.9 (m, 1H), 2.9-3.2 (m, 2H), 3.4-3.7 (m, 3H), 3.71 (s, 3H), 3.85-4.4 (m, 6H), 6.44 (dd, J=1, 6.57, m Hz, 1H), 7.10 (d, 1H), 7.56 (m, 1H), 7.64 (m, 1H), 8.12 (b, 1H), 8.41 (d, 1H), 12.68 (br s, 1H); MS (DCI/NH₃) m/e 450 (M+H)⁺; Analysis calc'd for C₂₄H₂₄ClN₃O₄S: C, 59.32; H, 4.98; N, 8.65; found: C, 59.06; H, 5.06; N, 8.45.

Example 64

3-[3-((±)-cis-7-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)propyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 63A (0.41 g, 2.00 mmol), N-(3-Chloropropyl)-N'-[3-[(2-methoxycarbonyl)benzothienyl]]-urea (0.750 g, 2.20 mmol), prepared by the procedure described in *Eur. J. Med. Chem.*, 28: 499-504 (1993), were treated as described in Example 63 to yield 0.296 g of the title compound: m.p. 220-2°; ¹H NMR (300 MHz, DMSO-d₆) δ 1.95-2.15 (m, 2H), 2.7-3.0 (m, 3H), 3.1-3.7 (m, 4H), 3.70 (s, 3H), 3.86 (m, 1H), 3.91-4.17 (m, 4H), 6.42 (d, 1H), 6.55 (dd, J=1, 7.56, t Hz, 1H), 7.64 (t, 1H), 8.11 (d, 1H), 8.41 (d, 1H), 12.59 (br s, 1H); MS (DCI/NH₃) m/e 464 (M+H)⁺; Analysis calc'd for C₂₄H₂₆ClN₃O₄S·1/2H₂O: C, 58.99; H, 5.34; N, 8.25; found: C, 59.10; H, 5.25; N, 8.09.

Example 65

3-[2-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 65A

(±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

From 5-methoxy-coumarin and N-methoxymethyl-N-trimethylsilylmethyl-benzylamine in an analogous manner as described in Examples 1A-C. ¹H NMR (300 MHz, CDCl₃) δ 2.55 (m, 1H), 2.67 (dd, 1H), 2.80 (dd, 1H), 3.21 (q, 1H), 3.32 (dd, 1H), 3.62 (dd, 1H), 3.70 (m, 1H), 3.81 (s, 3H), 4.10 (dd, 1H), 6.46 (d, 1H), 6.55 (d, 1H), 7.17 (t, 1H).

Example 65B

3-[2-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 65A (515 mg, 2.5 mmol), N-(2-Chloroethyl)-N'-[3-[(2-methoxycarbonyl)benzothienyl]]-urea (915 mg, 2.8 mmol), prepared by the procedure described in *Eur. J. Med. Chem.*, 28: 499-504 (1993), and ethyldiisopropylamine (1.0 mL) were treated as described in Example 63B to yield 0.200 g (18%) of the title compound, m.p.: 224-228°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 2.40-2.53 (m, 2H), 2.56-2.68 (m, 1H),
10 2.81-3.01 (m, 2H), 3.30 (dd, J=7, 9 Hz, 1H), 3.43 (q, J=8 Hz, 1H), 3.58 (t, J=9 Hz, 1H), 3.72 (s, 3H), 3.77 (dd, J=9, 11 Hz, 1H), 4.02 (dd, J=5, 11 Hz, 1H), 4.35 (t, J=7 Hz, 2H), 6.39 (d, J=8 Hz, 1H), 6.49 (d, J=8 Hz, 1H), 7.04 (t, J=8 Hz, 1H), 7.40 (t, J=8 Hz, 1H), 7.54 (t, J=8 Hz, 1H), 7.88 (d, J=8 Hz, 1H), 8.24 (d, J=8 Hz, 1H); MS (CI(NH₃)) m/e (M+H)⁺ at 450; Analysis calc'd for C₂₄H₂₃N₃O₄S•HCl•(H₂O)_{0.5}: C, 58.24; H, 5.09; N,
15 8.49; found: C, 57.90; H, 4.76; N, 8.24.

Example 66

3-[3-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)propyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

20 The product from Example 65A (500 mg, 2.4 mmol), N-(3-Chloropropyl)-N'-[3-[(2-methoxycarbonyl)benzothienyl]]-urea (1.7 g, 5.0 mmol), prepared by the procedure described in *Eur. J. Med. Chem.*, 28: 499-504 (1993), and ethyldiisopropylamine (1.0 mL) were treated as described in Example 63B to yield 300 mg (27 %) of the title compound, m.p.: 197-199°;
25 ¹H NMR (300 MHz, CD₃OD) δ 2.08-2.20 (m, 2H), 2.87-3.01 (m, 1H), 3.14-3.45 (m, 3H), 3.69 (q, J=8 Hz, 1H), 3.77-3.87 (m, 1H), 3.85 (s, 3H), 3.92 (dd, J=7, 12 Hz, 1H), 4.02-4.20 (m, 5H), 6.51 (dd, J=1, 8 Hz, 1H), 6.58 (dd, J=1, 8 Hz, 1H), 7.11 (t, J=8 Hz, 1H), 7.54 (t, J=8 Hz, 1H), 7.60-7.67 (m, 1H), 7.99 (d, J=8 Hz, 1H), 8.18 (d, J=8 Hz, 1H); MS (CI(NH₃)) m/e (M+H)⁺ at 464; Analysis calc'd for C₂₅H₂₅N₃O₄S•HCl•CH₃OH: C, 58.69;
30 H, 5.68; N, 7.90; found: C, 58.43; H, 5.23; N, 7.93.

Example 67

3-[2-((±)-cis-6-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 67A(±)-cis-6-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

From 8-methoxy-coumarin and N-methoxymethyl-N-trimethylsilylmethyl-benzylamine in an analogous manner as described in Examples 1A-C.

Example 67B3-[2-((±)-cis-6-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 67A (600 mg, 2.9 mmol), N-(2-Chloroethyl)-N'-[3-[(2-methoxycarbonyl)benzothienyl]]-urea (1.2 g, 3.7 mmol), prepared by the procedure described in *Eur. J. Med. Chem.*, 28: 499-504 (1993), and ethyldiisopropylamine (1.5 mL) were treated as described in Example 63B to yield 320 mg (24 %) of the title compound, m.p.: 251-254°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 2.43-2.52 (m, 2H), 2.67-2.79 (m, 1H), 2.90 (t, J=7 Hz, 2H), 3.32-3.45 (m, 2H), 3.51 (t, J=8 Hz, 1H), 3.82 (dd, J=8, 11 Hz, 1H), 3.85 (s, 3H), 4.13 (dd, J=5, 9 Hz, 1H), 4.34 (t, J=7 Hz, 2H), 6.65-6.72 (m, 2H), 6.81 (t, J=8 Hz, 1H), 7.39 (t, J=8 Hz, 1H), 7.55 (t, J=8 Hz, 1H), 7.88 (d, J=8 Hz, 1H), 8.24 (d, J=8 Hz, 1H); MS (CI(NH₃)) m/e (M+H)⁺ at 450; Analysis calc'd for C₂₄H₂₃N₃O₄S·HCl: C, 59.32; H, 4.98; N, 8.65; found: C, 59.18; H, 5.06; N, 8.54.

Example 683-[3-((±)-cis-6-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)propyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 67A (500 mg, 2.4 mmol), N-(3-Chloropropyl)-N'-[3-[(2-methoxycarbonyl)benzothienyl]]-urea (1.7 g, 5.0 mmol), prepared by the procedure described in *Eur. J. Med. Chem.*, 28: 499-504 (1993), and ethyldiisopropylamine (1.5 mL) were treated as described in Example 63B to yield 610 mg (54 %) of the title compound, m.p.: 191-195°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.95-2.07 (m, 2H), 2.20-2.34 (m, 2H), 2.57-2.74 (m, 3H), 3.21 (dd, J=8, 9 Hz, 1H), 3.28-3.40 (m, 2H), 3.76 (dd, J=8, 11 Hz, 1H), 3.83 (s, 3H), 4.10 (dd, J=5, 11 Hz, 1H), 4.27 (t, J=7 Hz, 2H), 6.61-6.70 (m, 2H), 6.80 (t, J=8 Hz, 1H), 7.47 (dd, J=1, 8 Hz, 1H), 7.56 (dd, J=1, 8 Hz, 1H), 7.88 (d, J=8 Hz, 1H), 8.26 (d, J=8 Hz, 1H); MS (CI(NH₃)) m/e (M+H)⁺ at 464; Analysis calc'd for C₂₄H₂₅N₃O₄S·HCl·(H₂O)_{0.25}: C, 59.52; H, 5.29; N, 8.33; found: C, 59.17; H, 5.22; N, 8.24.

Example 69

3-[2-((±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 69A

(±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

From coumarin and N-methoxymethyl-N-trimethylsilylmethyl-benzylamine in an analogous manner as described in Examples 1A-C.

Example 69B

3-[2-((±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-[1]benzthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 69A (540 mg, 2.8 mmol), N-(2-Chloroethyl)-N'-[3-[(2-methoxycarbonyl)benzothienyl]]-urea (0.89 g, 3.6 mmol), prepared by the procedure described in *Eur. J. Med. Chem.*, 28: 499-504 (1993) and ethyldiisopropylamine (1.5 mL) were treated as described in Example 63B to yield 410 mg (35 %) of the title compound, m.p.: 256-257°; ¹H NMR (300 MHz, CD₃OD) δ 3.00-3.13 (m, 1H), 3.23-3.70 (m, 3H), 3.58 (t, J=6 Hz, 1H), 3.72-3.80 (m, 1H), 3.87-4.20 (m, 2H), 4.03 (dd, J=6, 12 Hz, 1H), 4.15 (dd, J=4, 12 Hz, 1H), 4.41 (t, J=6 Hz, 2H), 6.89 (dd, J=1, 8 Hz, 1H), 6.96-7.02 (m, 1H), 7.18 (dt, J=2, 8 Hz, 1H), 7.25 (dd, J=1, 8 Hz, 1H), 7.51-7.58 (m, 1H), 7.60-7.67 (m, 1H), 7.99 (d, J=8 Hz, 1H), 8.18 (d, J=8 Hz, 1H); MS (CI(NH₃)) m/e (M+H)⁺ at 420; Analysis calc'd for C₂₃H₂₁N₃O₃S·HCl: C, 60.59; H, 4.86; N, 9.22; found: C, 60.38; H, 4.83; N, 9.14.

Example 70

3-[4-((±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Example 70A

(±)-cis-2-(4-aminobutyl)-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

The product from Example 69A (1.0 g, 5.71 mmol) was treated as described in Examples 1D and 1E to yield 1.1 g (98%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.4-1.8 (m, 6H), 2.20 (dd, 1H), 2.27 (t, 1H), 2.45 (m, 2H), 2.68-2.80 (m, 3H), 3.19 (dd, 1H), 3.37 (m, 2H), 3.75 (dd, 1H), 4.07 (dd, 1H), 6.9 (m, 2H), 7.12 (m, 1H).

Example 70B

3-[4-((±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

5 The product from Example 70A (0.24g, 1mmol) and methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.30 g, 1.2 mmol) were treated as described in Example 1F to yield 0.20 g (44 %) of the title compound: m.p. 203-205°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.78 (d, 1H), 8.28 (d, 1H), 8.48 (bs, 1H), 7.52 (dd, 1H), 7.13 (m, 2H), 6.92 (m, 2H), 4.08 (m, 4H), 3.92 (m, 1H), 3.82 (m, 1H), 3.68 (q, 1H), 2.98 (m, 3H), 2.73 (m, 2H), 1.78 (m, 4H); MS (DCI/NH₃) m/e 449(M+H)⁺; Analysis calc'd for C₂₄H₂₄N₄O₃S·2HCl·H₂O: C, 53.43; H, 5.23; N, 10.39; found: C, 53.24; H, 4.83; N, 10.25.

Example 71

15 3-[4-((±)-trans-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 71A

(±)-trans-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

20 Ethyl 2-methoxymethyl-cinnamate and N-methoxymethyl-N-trimethylsilylmethyl-benzylamine were treated, in an analogous manner as described in Examples 3A-C.

Example 71B

(±)-trans-2-(4-aminobutyl)-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

25 The product from Example 71A (1.22 g, 6.97 mmol) was treated as described in Examples 1D and 1E to yield 0.58 g (34%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.45-1.8 (m, 6H), 2.29 (m, 1H), 2.60-2.83 (m, 6H), 2.95 (m, 2H), 3.39 (dd, 1H), 4.12 (dd, 1H), 4.50 (dd, 1H), 6.83 (m, 2H), 6.91 (m, 1H), 7.13 (m, 1H).

Example 71C

30 3-[4-((±)-trans-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

35 The product from Example 71B (0.24g, 1.0 mmol) and methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.35 g, 1.35 mmol) were treated as described in Example 1F to yield 0.18 g (38 %) of the title compound: m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ

8.78 (d, 1H), 8.3 (bs, 1H), 8.29 (d, 1H), 7.53 (dd, 1H), 7.18 (t, 1H), 6.88 (m, 3H), 4.55 (dd, 1H), 4.12 (m, 3H), 4.05 (m, 1H), 3.51 (m, 1H), 3.23 (m, 4H), 3.08 (m, 1H), 2.48 (m, 1H), 1.85 (m, 4H); MS (DCI/NH₃) *m/e* 452(M+H)⁺; Analysis calc'd for C₂₄H₂₄N₄O₃S·HCl·0.5H₂O: C, 58.35; H, 5.30; N, 11.34; found: C, 58.43; H, 4.97; N, 11.34.

Example 72

3-[4-((±)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Example 72A

(±)-*trans*-2-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

From ethyl 2-methoxy-6-methoxymethyl-cinnamate and N-methoxymethyl-N-trimethylsilylmethyl-benzylamine, in an analogous manner as described in Examples 3A-C: ¹H NMR (300 MHz, CDCl₃) δ 2.07 (br s, 1H), 2.24 (m, 1H), 2.70 (m, 2H), 2.84 (t, 1H), 3.21 (dd, 1H), 3.77 (s, 3H), 3.83 (dd, 1H), 4.07 (dd, 1H), 4.53 (dd, 1H), 6.40 (d, 1H), 6.51 (d, 1H), 7.06 (t, 1H).

Example 72B

(±)-*trans*-2-(4-aminobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

The product from Example 72A (1.2, 4.75 mmol) was treated as described in Examples 3D-E to yield 1.0 g (64%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.40-1.80 (m, 4H), 2.32 (m, 1H), 2.57 (t, 1H), 2.62-2.90 (m, 4H), 2.95 (t, 1H), 3.60 (m, 1H), 3.78 (s, 3H), 4.06 (dd, 1H), 4.45 (dd, 1H), 6.40 (d, 1H), 6.49 (d, 1H), 7.04 (t, 1H).

Example 72C

3-[4-((±)-*trans*-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 72B (0.28 g, 1.0 mmol) and methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.27 g, 1.15 mmol) were treated as described in Example 1F to yield 0.22 g (46 %) of the title compound: m.p. >250°; ¹H NMR (300 MHz, DMSO-d₆ (free base)) δ 1.42-1.54 (m, 2H), 1.60-1.72 (m, 2H), 2.04-2.18 (m, 1H), 2.25-2.89 (m, 4H), 3.10-3.48

(m, 3H), 3.68 (s, 3H), 3.95 (t, J=7 Hz, 2H), 4.02 (dd, J=10, 12 Hz, 1H), 4.39 (dd, J=4, 10 Hz, 1H), 6.39 (dd, J=1, 8 Hz, 1H), 6.44 (dd, J=1, 8 Hz, 1H), 7.01 (t, J=8 Hz, 1H), 7.64 (dd, J=5, 8 Hz, 1H), 8.63 (dd, J=1, 8 Hz, 1H), 8.83 (dd, J=1, 5 Hz, 1H); MS (DCI(NH₃)) *m/e* 479 (M+H)⁺; Analysis calc'd for C₂₅H₂₆N₄O₄S·2HCl·0.5H₂O: C, 53.57; H, 5.21; N, 10.00; found: C, 53.49; H, 5.35; N, 9.88.

Example 73

3-[4-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Example 73A

(±)-cis-2-(4-aminobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

From 5-methoxycoumarin and N-methoxymethyl-N-trimethylsilylmethyl-benzylamine, in an analogous manner as described in Examples 1A-C: ¹H NMR (300 MHz, CDCl₃) δ 2.55 (m, 1H), 2.67 (dd, 1H), 2.80 (dd, 1H), 3.21 (q, 1H), 3.32 (dd, 1H), 3.62 (dd, 1H), 3.70 (m, 1H), 3.81 (s, 3H), 4.10 (dd, 1H), 6.46 (d, 1H), 6.55 (d, 1H), 7.17 (t, 1H).

Example 73B

(±)-cis-2-(4-aminobutyl)-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

The product from Example 73A (0.2, 1.0 mmol) was treated as described in Examples 1D-E to yield 0.08 g (29%) of the title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.65-1.80 (m, 4H), 2.19 (m, 1H), 2.25 (dd, 1H), 2.42 (m, 1H), 2.52 (t, 2H), 3.14 (dd, 1H), 3.18-3.30 (m, 2H), 3.79 (dd, 1H), 3.80 (s, 3H), 4.04 (dd, 1H), 6.46 (d, 1H), 6.54 (d, 1H), 7.07 (t, 1H).

Example 73C

3-[4-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 73B (0.28 g, 1.0 mmol) and methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.27 g, 1.15 mmol) were treated as described in Example 1F to yield 0.20 g (42 %) of the title compound: m.p. 198-200°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.56-1.99 (m, 2H), 1.71-1.83 (m, 2H), 2.26 (t, J=9 Hz, 1H), 2.34 (dd, J=6, 10 Hz, 1H), 2.50-2.70 (m, 3H), 3.26 (dd, J=7, 10 Hz, 1H), 3.43 (q, J=8 Hz, 1H), 3.63 (t, J=8 Hz, 1H),

3.79 (s, 3H), 3.76-3.86 (m, 1H), 4.01 (dd, J=4, 11 Hz, 1H), 4.11 (t, J=7 Hz, 1H), 6.43 (d, J=8 Hz, 1H), 6.49 (d, J=8 Hz, 1H), 7.04 (t, J=8 Hz, 1H), 7.49 (dd, J=4, 8 Hz, 1H), 8.23 (dd, J=1, 8 Hz, 1H), 8.78 (dd, J=1, 4 Hz, 1H); MS (DCI/NH₃) *m/e* 479(M+H)⁺; Analysis calc'd for C₂₅H₂₆N₄O₄S·2HCl·0.5H₂O: C, 53.57; H, 5.21; N, 10.00; found: C, 53.41; H, 5.24; N, 9.88.

Example 74

3-[4-((±)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Ethyl 7-amino-thieno[2,3-b]pyrazine-6-carboxylate (0.25 g, 1.0 mmol) prepared by the method of Schneller and Clough, *J. Het. Chem.*, 12: 513 (1975) and the product from Example 72B (0.28 g, 1.0 mmol) were treated as described in Example 1F to yield 0.18 g (38%) of the title compound: m.p. 193-195°; ¹H NMR (300 MHz, DMSO-d₆(free base)) δ 8.98 (d, 1H), 8.89 (d, 1H), 7.11 (t, 1H), 6.52 (d, 1H), 6.45 (d, 1H), 4.5 (dd, 1H), 4.2 (m, 1H), 4.1 (m, 1H), 3.92 (m, 2H), 3.73 (s, 3H), 3.0 (m, 1H), 2.6 (m, 5H), 2.3 (m, 1H), 1.8 (m, 4H); MS (DCI/NH₃) *m/e* 4809(M+H)⁺; Analysis calc'd for C₂₄H₂₅N₅SO₄·2HCl·2H₂O: C, 48.98; H, 5.31; N, 11.90; found: C, 48.48; H, 5.80; N, 11.94.

Example 75

3-[4-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Example 75A

(±)-cis-2-(8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

From 6-methoxycoumarin and N-methoxymethyl-N-trimethylsilylmethyl-benzylamine, in an analogous manner as described in Examples 1A-C.

Example 75B

(±)-cis-2-(4-aminobutyl)-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

The product from Example 75A (1.0g, 4.9 mmol) was treated as described in Examples 1D-E to yield 0.72 g (54%) of the title compound.

Example 75C

3-[4-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

5 Methyl 3-amino-thieno[2,3-b]pyridine-2-carboxylate (0.25 g, 1.07 mmol) and the product from Example 75B (0.26 g, 1.0 mmol) were treated as described in Example 1F to yield 0.20 g (46%) of the title compound: m.p. 203-204°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.72 (dd, 1H), 8.6 (d, 1H), 8.38 (bs, 1H), 7.41 (dd, 1H), 6.82 (d, 1H), 6.71 (dd, 1H), 6.6 (d, 1H), 4.12 (m, 4H), 3.98 (m, 2H), 3.78 (m, 1H), 3.73 (s, 3H), 3.12 (m, 2H),
10 3.05 (m, 1H), 2.92 (m, 1H), 2.85 (m, 1H), 1.82 (m, 4H); MS (DCI/NH₃) *m/e* 479(M+H)⁺; Analysis calc'd for C₂₅H₂₆N₄O₄S·2HCl·0.5H₂O: C, 53.57; H, 5.22; N, 10.00; found: C, 53.81; H, 5.06; N, 9.91.

Example 76

15 3-[4-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Ethyl 7-amino-thieno[2,3-b]pyrazine-6-carboxylate (0.25 g, 1.05 mmol) prepared by the method of Schneller and Clough, *J. Het. Chem.*, 12: 513 (1975) and the product from
20 Example 75B (0.28 g, 1.0 mmol) were treated as described in Example 1F to yield 0.30 g (62%) of the title compound: m.p. 218-220°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.72 (m, 2H), 6.8 (d, 1H), 6.68 (dd, 1H), 6.61 (d, 1H), 4.12 (t, 2H), 4.0 (dd, 1H), 3.82 (m, 1H), 3.75 (s, 3H), 3.58 (m, 3H), 2.89 (m, 1H), 2.79 (m, 2H), 2.52 (m, 2H), 1.75 (m, 4H); MS (DCI/NH₃) *m/e* 480(M+H)⁺; Analysis calc'd for C₂₄H₂₅N₅O₄S·HCl·2H₂O: C, 52.22; H, 5.48; N, 12.69; found: C, 52.68; H, 5.22; N, 12.63.
25

Example 77

3-[3-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)propyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 77A

(±)-cis-2-(3-aminopropyl)-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrole

5 The product from Example 75A (1.26 g, 6.14 mmol) was treated with 0.61 mL (7.36 mmol) 3-bromopropionitrile, followed by LiAlH₄ and AlCl₃ in an analogous manner as described in Examples 1D-E to yield 0.85 g (52%) of title compound.

Example 77B

10 3-[3-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)propyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

15 Methyl 3-amino-thieno[2,3-b]pyridine-2-carboxylate (0.25 g, 1.07 mmol) and the product from Example 78A (0.26 g, 1.0 mmol) were treated as described in Example 1F to yield 0.23 g (50%) of the title compound: ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.64 (dd, 1H), 8.43 (dd, 1H), 8.45 (s, 1H), 7.32 (dd, 1H), 6.82 (d, 1H), 6.7 (dd, 1H), 6.61 (d, 1H), 4.2 (m, 1H), 4.13 (t, 2H), 3.98 (m, 3H), 3.73 (m, 1H), 3.72 (s, 3H), 3.22 (m, 2H), 3.0 (m, 1H), 2.95 (d, 1H), 2.85 (m, 1H), 2.48 (m, 2H); MS (DCI/NH₃) m/e 465(M+H)⁺; Analysis calc'd for C₂₄H₂₄N₄O₄S·HCl·H₂O: C, 55.54; H, 5.24; N, 10.79; found: C, 55.18; H, 4.98; N, 10.63.

Example 78

25 3-[2-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrol-2-yl)ethyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 78A

(±)-cis-2-(2-aminoethyl)-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranof[3,4-c]pyrrole

30 The product from Example 75A (1.0 g, 4.88 mmol) was treated with 0.34 mL (5.36 mmol) 2-chloroacetonitrile, followed by LiAlH₄ and AlCl₃ in an analogous manner as described in Examples 1D-E to yield 0.72 g (59%) of title compound: ¹H NMR (300 MHz, CDCl₃) δ 2.1 (br s, 2H), 2.25-2.45 (m, 2H), 2.52-2.65 (m, 2H), 2.72 (m, 1H), 2.83 (t, 2H), 3.17 (dd, 1H), 3.28-3.45 (m, 2H), 3.75 (dd, 1H), 3.77 (s, 3H), 4.01 (dd, 1H), 6.63 (d, 1H), 6.68 (dd, 1H), 6.81 (d, 1H).

Example 78B

3-[2-((±)-cis-8-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)ethyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 Methyl 3-amino-thieno[2,3-b]pyridine-2-carboxylate (0.25 g, 1.07 mmol) and the product from Example 78A (0.25 g, 1.0 mmol) were treated as described in Example 1F to yield 0.20 g (44%) of the title compound: ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.7 (dd, 1H), 8.48 (dd, 1H), 8.3 (bs, 1H), 7.32 (dd, 1H), 6.81 (d, 1H), 6.7 (dd, 1H), 6.65 (d, 1H), 4.5-4.7 (m, 3H), 4.0 (m, 3H), 3.76 (s, 3H), 3.4 (m, 2H), 3.1 (m, 2H), 2.9 (m, 2H); MS
10 (DCI/NH₃) *m/e* 451(M+H)⁺; Analysis calc'd for C₂₃H₂₂N₄O₄S·HCl·0.5H₂O: C, 55.70; H, 4.88; N, 11.30; found: C, 55.61; H, 4.66; N, 11.19.

Example 79

3-[4-((±)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione hydrochloride

15 Methyl 2-amino-4,5-dimethoxybenzoate (0.28 g, 1.18 mmol) and the product from Example 73A (0.28 g, 1.0 mmol) were treated as described in Example 1F to yield the intermediate urea, which was treated with 1.5 mL of 1.0M KOtBu in 20 mL THF to yield the title compound (0.19 g, 40%): m.p. 178-180° (dec.); ¹H NMR (300 MHz, CDCl₃(free base))
20 δ 7.44 (s, 1H), 7.06 (t, 1H), 6.48 (m, 2H), 6.42 (s, 1H), 4.06 (m, 3H), 4.0 (m, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.83 (m, 1H), 3.8 (s, 3H), 3.48 (m, 1H), 3.2 (m, 1H), 2.58 (m, 3H), 2.3 (m, 2H), 1.75 (m, 2H), 1.65 (m, 2H); MS (DCI/NH₃) *m/e* 482(M+H)⁺; Analysis calc'd for C₂₆H₃₁N₃O₆·HCl·2H₂O: C, 56.37; H, 6.55; N, 7.58; found: C, 56.61; H, 6.30; N, 7.47.

Example 80

3-[4-((±)-trans-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione hydrochloride

30 Methyl 2-amino-4,5-dimethoxybenzoate (0.27 g, 1.15 mmol) and the product from Example 71B (0.25 g, 1.0 mmol) were treated as described in Example 1F to yield the intermediate urea, which was treated with 1.5 mL of 1.0M KOtBu in 20 mL THF to yield the title compound (0.12 g, 26%): m.p. 182-184°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 7.41
35 (s, 1H), 7.18 (m, 1H), 6.88 (s, 1H), 6.86 (m, 2H), 6.71 (s, 1H), 4.55 (dd, 1H), 4.18 (t, 1H), 4.08 (t, 2H), 3.95 (s, 3H), 3.91 (s, 3H), 3.9 (m, 1H), 3.48 (m, 1H), 3.22 (m, 4H), 3.08 (m,

1H), 2.5 (m, 1H), 1.82 (m, 4H); MS (DCI/NH₃) *m/e* 452(M+H)⁺; Analysis calc'd for C₂₅H₂₉N₃O₅·HCl·H₂O: C, 59.34; H, 6.37; N, 8.32; found: C, 59.12; H, 6.21; N, 7.82.

Example 81

5 3-[4-((±)-cis-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione hydrochloride

Methyl 2-amino-4,5-dimethoxybenzoate (0.27 g, 1.15 mmol) and the product from Example 70A (0.25 g, 1.0 mmol) were treated as described in Example 1F to yield the
10 intermediate urea, which was treated with 1.5 mL of 1.0M KOtBu in 20 mL THF to yield the title compound (0.18 g, 39%): ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.3 (b s, 1H), 7.46 (s, 1H), 7.08 (m, 2H), 6.88 (m, 2H), 6.39 (s, 1H), 4.08 (m, 3H), 3.96 (s, 3H), 3.94 (s, 3H), 3.72 (m, 1H), 3.38 (m, 2H), 3.21 (m, 1H), 2.72 (m, 1H), 2.52 (m, 2H), 2.28 (m, 2H), 1.75 (m, 2H), 1.62 (m, 2H); MS (DCI/NH₃) *m/e* 452(M+H)⁺; Analysis calc'd for
15 C₂₅H₂₉N₃O₅·HCl·2H₂O: C, 57.19; H, 6.1; N, 8.00; found: C, 56.63; H, 6.08; N, 7.51.

Example 82

20 3-[4-((±)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione dihydrochloride

Methyl 2-amino-4,5-dimethoxybenzoate (0.28 g, 1.18 mmol) and the product from Example 72A (0.28 g, 1.0 mmol) were treated as described in Example 1F to yield the
intermediate urea, which was treated with 1.5 mL of 1.0M KOtBu in 20 mL THF to yield the
title compound (0.38 g, 79%): m.p. 189-191°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 7.44
25 (s, 1H), 7.05 (t, 1H), 6.49 (d, 1H), 6.41 (s, 1H), 6.39 (d, 1H), 4.44 (dd, 1H), 4.1 (m, 3H), 3.96 (s, 3H), 3.93 (s, 3H), 3.76 (s, 3H), 3.6 (m, 1H), 2.99 (t, 1H), 2.78 (m, 4H), 2.58 (t, 1H), 2.3 (m, 1H), 1.75 (m, 2H), 1.65 (m, 2H); MS (DCI/NH₃) *m/e* 482(M+H)⁺; Analysis calc'd for C₂₆H₃₁N₃O₆·2HCl·2H₂O: C, 52.89; H, 6.32; N, 7.12; found: C, 52.89; H, 5.99; N, 7.02.

Example 83

30 3-[3-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione hydrochloride

Example 83A(±)-trans-N-benzyl-3-carboethoxy-4-(2-methoxy-6-methoxymethyl)phenyl-piperidine-2,5-dione

5 Ethyl 2-methoxy-6-methoxymethyl-cinnamate (13.2 g, 59.7 mmol) was treated with ethyl N-benzylamidomalonate according to the method of Faruk and Martin, U. S. Patent No. 4,902,801, to yield the title compound (8.34 g, 38%). ¹H NMR (300 MHz, DMSO) δ 7.47-7.24 (m, 5H), 7.19 (dd, 1H), 6.71 (d, 1H), 6.68 (d, 1H), 5.19 (dd, 2H), 4.88 (s, 2H), 4.70 (d, 2H), 4.25 (dt, 1H), 3.90 (dq, 2H), 3.78 (s, 3H), 3.41 (dd, 1H), 3.40 (s, 3H), 2.63 (dd, 1H), 0.87 (t, 3H). MS (DCI/NH₃) m/e 442 (M+H)⁺.

Example 83B(±)-trans-N-benzyl-3-chloromethyl-4-(2-hydroxy-6-methoxy)phenyl-piperidine

15 To a solution of LiAlH₄ (2.45 g, 64.6 mmol) in THF (250 mL) was added dropwise at 0°C a solution of the product from Example 83A (9.50 g, 21.5 mmol) in THF (50 mL). The reaction was warmed to room temperature, and then refluxed for 3 hours. The reaction was cooled to 0°C and quenched by the consecutive addition of water (4 mL), 1M NaOH (4 mL), and water (10 mL), and stirred for 1 hour. The mixture was filtered through a pad of Celite and
20 rinsed with EtOAc (500 mL). The organic layer was dried over MgSO₄, and condensed in vacuo to yield 8.0 g of a clear oil. The oil was taken up in methanol (250 mL) and concentrated HCl (15 mL) and stirred at reflux for 6 hours. The mixture was cooled, condensed in vacuo, and the residue was partitioned between EtOAc and a saturated solution of NaHCO₃. The layers were separated and the aqueous layer extracted with 2x EtOAc. The combined organic
25 layers were dried over MgSO₄, and condensed in vacuo to yield 7.0 g of a clear oil. To a solution of this oil in CCl₄ (75 mL) and CH₃CN (75 mL) was added triphenylphosphine (11.3 g, 43.1 mmol), and the solution was refluxed for 1 hour. The mixture was cooled and condensed in vacuo, and the residue was chromatographed on SiO₂ using NH₃-saturated 35% EtOAc/hexanes to yield the title compound (5.30 g, 71%). ¹H NMR (300 MHz, DMSO) δ
30 9.32 (br s, 1H), 7.35-7.22 (m, 5H), 6.96 (dd, 1H), 6.44 (br d, 2H), 3.72 (s, 3H), 3.51 (dd, 2H), 3.26 (m, 1H), 3.16 (m, 2H), 2.98 (dt, 1H), 2.85 (m, 2H), 2.24 (m, 1H), 1.93 (m, 1H), 1.78 (m, 1H), 1.39 (m, 1H). MS (DCI/NH₃) m/e 346 (M+H)⁺.

Example 83C(±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyridine

To a solution of the product from Example 83B (5.30 g, 15.3 mmol) in THF (125 mL) was added a 1.0M solution of potassium t-butoxide (16 mL), and the reaction was refluxed for 2 hours. The reaction was cooled, poured into water, and extracted with 3x EtOAc. The extracts were dried over MgSO₄, and condensed in vacuo to yield 4.7 g of a clear oil. To a solution of the oil and 10% Pd on carbon (2 g) in MeOH (125 mL) was added ammonium formate (4.7 g, 75 mmol), and the reaction was refluxed for 2 h. The reaction mixture was cooled, filtered through a small pad of Celite, and rinsed with EtOAc (200 mL). The filtrate was dried over Na₂SO₄, and condensed in vacuo to yield the title compound (3.01 g, 90%). ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.36 (d, 1H), 4.03 (dd, 1H), 3.72 (s, 3H), 3.55 (dd, 1H), 3.01 (m, 1H), 2.94 (dd, 1H), 2.83 (ddd, 1H), 2.62 (dt, 1H), 2.51 (dt, 1H), 2.29 (t, 1H), 1.64 (ddt, 1H), 1.05 (ddd, 1H). MS (DCI/NH₃) m/e 220 (M+H)⁺.

Example 83D(±)-trans-3-(2-Cyanoethyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyridine

A mixture of the product from Example 83C (340 mg, 1.55 mmol), 3-bromopropionitrile (193 μL, 2.33 mmol), and ethyldiisopropylamine (675 μL, 3.88 mmol) in acetonitrile (4 mL) was refluxed for 18 hours. The reaction was cooled, and partitioned between EtOAc and 1M NaOH. The organic layer was dried over MgSO₄, the solvent was condensed in vacuo, and the crude product was chromatographed on SiO₂ using EtOAc to yield the title compound (0.335 g, 79%). ¹H NMR (300 MHz, DMSO) δ 7.03 (dd, 1H), 6.49 (d, 1H), 6.38 (d, 1H), 4.08 (dd, 1H), 3.73 (s, 3H), 3.62 (t, 1H), 3.04-2.86 (m, 3H), 2.65 (m, 4H), 2.41 (m, 1H), 2.16 (m, 1H), 1.81 (m, 2H), 1.18 (m, 1H). MS (DCI/NH₃) m/e 273 (M+H)⁺.

Example 83E(±)-trans-3-(3-Aminopropyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyridine

The product from Example 83D (355 mg, 1.30 mmol) was treated with 7.5 equivalents of LiAlH₄ and 2.5 equivalents of AlCl₃ by the procedure described in Example 1E to yield the

title compound (0.347 g, 96%). ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.37 (d, 1H), 4.08 (dd, 1H), 3.73 (s, 3H), 3.62 (t, 1H), 2.96 (m, 2H), 2.89 (m, 1H), 2.57 (m, 2H), 2.39 (m, 1H), 2.33 (m, 2H), 2.01 (dt, 1H), 1.77 (m, 1H), 1.66 (t, 1H), 1.51 (m, 2H), 1.17 (m, 1H). MS (DCI/NH₃) m/e 277 (M+H)⁺.

5

Example 83F

3-[3-((±)-*trans*-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione hydrochloride

10

Methyl 2-amino-4,5-dimethoxybenzoate (258 mg, 1.09 mmol) and the product from Example 83E (250 mg, 0.905 mmol) were treated as described in Example 1F to yield the title compound (347 mg, 71%): m.p. 230°C. ¹H NMR (300 MHz, DMSO) δ 11.35 (s, 1H), 10.61 (br s, 1H), 7.31 (s, 1H), 7.08 (t, 1H), 6.74 (s, 1H), 6.54 (d, 1H), 6.42 (d, 1H), 4.13 (dd, 1H), 3.98 (m, 2H), 3.84 (s, 3H), 3.81 (s, 3H), 3.75 (s, 3H), 3.63 (m, 1H), 3.58 (m, 2H), 3.10 (m, 4H), 2.84 (m, 1H), 2.76 (m, 1H), 2.24 (m, 1H), 2.19 (m, 2H), 1.57 (m, 1H). MS (DCI/NH₃) m/e 482 (M+H)⁺. Anal calcd for C₂₆H₃₁N₃O₆·1.6HCl: C, 57.85; H, 6.09; N, 7.78. Found: C, 57.73; H, 5.99; N, 7.57.

15

Example 84

20

3-[3-((±)-*trans*-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

25

Methyl 3-amino-thieno[2,3-b]pyridine-2-carboxylate (254 mg, 1.09 mmol) and the product from Example 83E (250 mg, 0.904 mmol) were treated as described in Example 1F to yield the title compound (281 mg, 59%). m.p. >300°C. ¹H NMR (300 MHz, DMSO) δ 12.80 (s, 1H), 10.44 (br s, 1H), 8.83 (d, 1H), 8.78 (d, 1H), 7.67 (dd, 1H), 7.09 (t, 1H), 6.53 (d, 1H), 6.42 (d, 1H), 4.14 (dd, 1H), 4.03 (m, 2H), 3.76 (s, 3H), 3.64 (m, 1H), 3.59 (m, 2H), 3.24-3.02 (m, 4H), 2.85 (m, 1H), 2.76 (m, 1H), 2.22 (m, 1H), 2.13 (m, 2H), 1.53 (m, 1H). MS (DCI/NH₃) m/e 479 (M+H)⁺. Anal calcd for C₂₅H₂₆N₄O₄S·1.35HCl: C, 56.89; H, 5.22; N, 10.62. Found: C, 57.03; H, 5.06; N, 10.45.

30

Example 85

3-[4-((±)-*trans*-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

35

Example 85A

(±)-trans-3-(3-Cyanopropyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyridine

5 The product from Example 83C (380 mg, 1.73 mmol) was treated with 1.5 equivalents of 4-bromobutyronitrile and 2.5 equivalents of ethyldiisopropylamine by the procedure described in Example 83D to yield the title compound (0.38 g, 71%). ¹H NMR (300 MHz, DMSO) δ 7.03 (dd, 1H), 6.49 (d, 1H), 6.38 (d, 1H), 4.09 (dd, 1H), 3.73 (s, 3H), 3.62 (t, 1H), 2.93 (m, 3H), 2.39 (m, 2H), 2.08 (m, 1H), 1.74 (m, 3H), 1.30 (m, 1H). MS
10 (DCI/NH₃) m/e 287 (M+H)⁺.

Example 85B

(±)-trans-3-(4-Aminobutyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyridine

15 The product from Example 85A (380 mg, 1.33 mmol) was treated with 7.5 equivalents of LiAlH₄ and 2.5 equivalents of AlCl₃ by the procedure described in Example 83E to yield the title compound (0.358 g, 93%). ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.37 (d, 1H), 4.08 (dd, 1H), 3.73 (s, 3H), 3.62 (t, 1H), 2.97 (m, 2H), 2.89 (m, 1H), 2.53
20 (m, 2H), 2.38 (m, 1H), 2.29 (m, 2H), 2.01 (dt, 1H), 1.78 (m, 1H), 1.67 (t, 1H), 1.46 (m, 2H), 1.34 (m, 2H), 1.18 (m, 1H). MS (DCI/NH₃) m/e 291 (M+H)⁺.

Example 85C

3-[4-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

25 Methyl 3-amino-thieno[2,3-b]pyridine-2-carboxylate (0.194 g, 1.09 mmol) and the product from Example 85B (0.200 g, 0.69 mmol) were treated as described in Example 1F to yield the title compound (0.245 g, 59%): m.p. 251-4°C; ¹H NMR (300 MHz, DMSO) δ 12.72
30 (s, 1H), 10.76 (br s, 1H), 8.77 (d, 1H), 8.74 (d, 1H), 7.61 (dd, 1H), 7.04 (t, 1H), 6.50 (d, 1H), 6.38 (d, 1H), 4.12 (dd, 1H), 3.92 (t, 2H), 3.71 (s, 3H), 3.62 (t, 1H), 3.52 (m, 2H), 3.06 (m, 4H), 2.78 (m, 2H), 2.25 (m, 1H), 1.76 (m, 2H), 1.64 (m, 2H), 1.54 (m, 1H). MS (DCI/NH₃) m/e 493 (M+H)⁺. Anal calcd for C₂₆H₂₈N₄O₄S·2HCl: C, 51.88; H, 5.19; N, 9.31. Found: C, 52.24; H, 5.52; N, 9.32.

Example 86

3-[4-((+)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyrido-3-yl)butyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione hydrochloride

5 Methyl 2-amino-4,5-dimethoxybenzoate (0.196 g, 0.83 mmol) and the product from Example 85B (0.200 g, 0.69 mmol) were treated as described in Example 1F to yield the title compound (0.140 g, 37%): m.p. 220°C. ¹H NMR (300 MHz, DMSO) δ 11.27 (s, 1H), 10.54 (br s, 1H), 7.25 (s, 1H), 7.04 (t, 1H), 6.68 (s, 1H), 6.50 (d, 1H), 6.39 (d, 1H), 4.12 (dd, 1H), 3.87 (t, 2H), 3.79 (s, 3H), 3.76 (s, 3H), 3.71 (s, 3H), 3.62 (t, 1H), 3.62 (m, 2H),
10 3.06 (m, 4H), 2.76 (m, 2H), 2.21 (m, 1H), 1.71 (m, 2H), 1.59 (m, 2H), 1.51 (m, 1H). MS (DCI/NH₃) m/e 496 (M+H)⁺. Anal calcd for C₂₇H₃₃N₃O₆·1.4HCl: C, 59.37; H, 6.35; N, 7.69. Found: C, 59.36; H, 6.56; N, 7.57.

Example 87

15 3-[4-((+)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyrido-3-yl)butyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Methyl 3-amino-benzo[b]thiophene-2-carboxylate (0.143 g, 0.58 mmol) and the product from Example 85B (0.14 g, 0.48 mmol) were treated as described in Example 1F to yield the
20 title compound (0.121 g, 48%): m.p. >305°C. ¹H NMR (300 MHz, DMSO) δ 12.56 (s, 1H), 10.44 (br s, 1H), 8.37 (d, 1H), 8.07 (d, 1H), 7.60 (t, 1H), 7.52 (t, 1H), 7.04 (t, 1H), 6.50 (d, 1H), 6.38 (d, 1H), 4.12 (dd, 1H), 3.93 (t, 2H), 3.71 (s, 3H), 3.62 (t, 1H), 3.53 (m, 2H), 3.06 (m, 4H), 2.77 (m, 2H), 2.20 (m, 1H), 1.76 (m, 2H), 1.65 (m, 2H), 1.52 (m, 1H). MS (DCI/NH₃) m/e 492 (M+H)⁺. Anal calcd for C₂₇H₂₉N₃O₄S·HCl: C, 61.41; H, 5.73; N, 7.96. Found: C, 61.16; H, 5.48; N, 7.79.

Example 88

3-[4-((+)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

30 Methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.135 g, 0.58 mmol) and the product from Example 85B (0.14 g, 0.48 mmol) were treated as described in Example 1F to yield the title compound (0.15 g, 54%): m.p. >325°C. ¹H NMR (300 MHz, DMSO) δ 12.68 (s, 1H), 10.65 (br s, 1H), 8.85 (d, 1H), 8.66 (d, 1H), 7.68 (dd, 1H), 7.09 (t, 1H), 6.54 (d, 1H), 6.42 (d, 1H), 4.17 (dd, 1H), 3.97 (t, 2H), 3.76 (s, 3H), 3.67 (t, 1H), 3.58 (m, 2H),
35 3.11 (m, 4H), 2.81 (m, 2H), 2.28 (m, 1H), 1.79 (m, 2H), 1.69 (m, 2H), 1.58 (m, 1H). MS

(DCI/NH₃) m/e 493 (M+H)⁺. Anal calcd for C₂₆H₂₈N₄O₄S·2HCl·0.5H₂O: C, 54.36; H, 5.44; N, 9.75. Found: C, 54.25; H, 5.59; N, 9.68.

Example 89

5 3-[3-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyrido-3-yl)propyl]-[1]benzthien[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Methyl 3-amino-benzo[b]thiophene-2-carboxylate (0.177 g, 0.72 mmol) and the product from Example 83E (0.165 g, 0.60 mmol) were treated as described in Example 1F to yield the
10 title compound (0.187 g, 61%): m.p. >300°C. ¹H NMR (300 MHz, DMSO) δ 12.65 (s, 1H), 10.41 (br s, 1H), 8.43 (d, 1H), 8.13 (d, 1H), 7.66 (t, 1H), 7.57 (t, 1H), 7.08 (t, 1H), 6.54 (d, 1H), 6.42 (d, 1H), 4.14 (dd, 1H), 4.02 (m, 2H), 3.76 (s, 3H), 3.63 (m, 1H), 3.59 (m, 2H), 3.22-3.03 (m, 4H), 2.86 (m, 1H), 2.77 (m, 1H), 2.22 (m, 1H), 2.13 (m, 2H), 1.54 (m, 1H). MS (DCI/NH₃) m/e 478 (M+H)⁺. Anal calcd for C₂₆H₂₇N₃O₄S·1.0HCl: C, 60.75;
15 H, 5.49; N, 8.17. Found: C, 60.48; H, 5.50; N, 8.02.

Example 90

20 3-[2-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyrido-3-yl)ethyl]-[1]benzthien[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Example 90A

(±)-trans-3-(Cyanomethyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyridine

25 To a solution of the product from Example 83C (0.80 g, 3.65 mmol) and K₂CO₃ (1.21 g, 8.8 mmol) in acetone (20 mL) and water (2 mL) was added chloroacetonitrile (278 μL, 4.4 mmol), and the solution stirred at reflux for 18 hours. The reaction was cooled and poured into brine, the solution was extracted with 3x EtOAc, and the combined extracts were dried over MgSO₄. The solvent was condensed in vacuo, and the crude product was chromatographed on
30 SiO₂ using 30% EtOAc/hexanes to yield the title compound (0.55 g, 58%). ¹H NMR (300 MHz, DMSO) δ 7.04 (dd, 1H), 6.50 (d, 1H), 6.38 (d, 1H), 4.08 (dd, 1H), 3.74 (s, 3H), 3.68 (t, 1H), 2.91 (m, 2H), 2.39 (ddt, 2H), 2.03 (m, 1H), 1.83 (m, 1H), 1.24 (m, 1H). MS (DCI/NH₃) m/e 259 (M+H)⁺.

Example 90B

(±)-trans-3-(2-Aminoethyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyridine

To a solution of LiAlH₄ (285 mg, 7.50 mmol) in Et₂O (25 mL) was added dropwise a solution of AlCl₃ (333 mg, 2.50 mmol) in Et₂O (10 mL), and the reaction was stirred for 10 min. A solution of the product from Example 90A (259 mg, 1.00 mmol) in THF (10 mL) was added via syringe, and the reaction stirred for 1 hour. The reaction was cooled to 0°C and quenched by the consecutive addition of water (2 mL), 1M NaOH (4 mL), and water (4 mL), and stirred for 1 hour. The mixture was filtered through a pad of Celite and rinsed with EtOAc (100 mL) and CHCl₃ (100 mL). The organic layer was rinsed with brine, dried over Na₂SO₄, and condensed in vacuo to yield the title compound (0.225 g, 86%). ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.49 (d, 1H), 6.38 (d, 1H), 4.08 (dd, 1H), 3.73 (s, 3H), 3.61 (t, 1H), 2.93 (m, 2H), 2.89 (m, 1H), 2.53 (m, 2H), 2.39 (m, 1H), 2.33 (m, 2H), 2.07 (dt, 1H), 1.79 (m, 1H), 1.62 (m, 2H), 1.19 (m, 1H). MS (DCI/NH₃) m/e 263 (M+H)⁺.

Example 90C

3-[2-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)ethyl]-[1]benzthienof[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

Methyl 3-amino-benzo[b]thiophene-2-carboxylate (0.158 g, 0.64 mmol) and the product from Example 90B (0.140 g, 0.53 mmol) were treated as described in Example 1F to yield the title compound (0.143 g, 54%): m.p. >305°C. ¹H NMR (300 MHz, DMSO) δ 12.74 (s, 1H), 10.34 (s, 1H), 8.42 (d, 1H), 8.12 (d, 1H), 7.67 (dd, 1H), 7.58 (dd, 1H), 7.09 (dd, 1H), 6.55 (d, 1H), 6.43 (d, 1H), 4.34 (m, 2H), 4.15 (dd, 1H), 3.85 (m, 2H), 3.76 (s, 3H), 3.71 (t, 1H), 3.42 (m, 2H), 3.15 (m, 2H), 2.98 (m, 1H), 2.82 (m, 1H), 2.20 (m, 1H), 1.54 (m, 1H). MS (DCI/NH₃) m/e 464 (M+H)⁺. Anal calcd for C₂₅H₂₅N₃O₄S·HCl: C, 60.05; H, 5.24; N, 8.40. Found: C, 59.68; H, 5.21; N, 8.25.

Example 91

3-[2-((±)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)ethyl]-6,7-dimethoxy-quinazoline-2,4(1H,3H)-dione hydrochloride

Methyl 2-amino-4,5-dimethoxybenzoate (0.152 g, 0.64 mmol) and the product from Example 90B (0.140 g, 0.53 mmol) were treated as described in Example 1F to yield the title compound (0.060 g, 22%): m.p. 291-2°C. ¹H NMR (300 MHz, DMSO) δ 11.44 (s, 1H),

10.09 (s, 1H), 7.30 (s, 1H), 7.09 (dd, 1H), 6.72 (s, 1H), 6.55 (d, 1H), 6.42 (d, 1H), 4.30 (m, 2H), 4.14 (dd, 1H), 3.85 (m, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H), 3.71 (t, 1H), 3.42 (m, 2H), 3.15 (m, 2H), 2.95 (m, 1H), 2.81 (m, 1H), 2.16 (m, 1H), 1.50 (m, 1H). MS (DCI/NH₃) m/e 468 (M+H)⁺. Anal. calcd for C₂₄H₂₉N₃O₆·1.25HCl: C, 58.52; H, 5.94; N, 8.19. Found: C, 58.79; H, 6.00; N, 8.01.

Example 92

3-[3-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyrido-3-yl)propyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Example 92A

(4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyridine-4-menthyl carbamate and (4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyridine-4-menthyl carbamate

To a solution of the product from Example 83C (3.16 g, 14.41 mmol) and ethyldiisopropylamine (5.02 mL, 28.8 mmol) in CH₂Cl₂ (200 mL) was added at 0°C (+)-menthyl chloroformate (3.71 mL, 17.3 mmol). The reaction was warmed to 23°C and stirred for 3 hours. The reaction was then poured into 1M NaOH, the layers separated, and the aqueous layer extracted with 3x Et₂O. The combined organic layers were dried over MgSO₄, the solvent was condensed in vacuo, and the crude product was chromatographed on SiO₂ using 10% EtOAc/hexanes to yield a mixture of diastereomers (5.30 g, 92%). The 1:1 mixture of two diastereomers was separated on a preparatory chiral HPLC column. ¹H NMR (300 MHz, DMSO) δ 7.04 (dd, 1H), 6.50 (d, 1H), 6.39 (d, 1H), 4.46 (m, 1H), 4.10 (m, 3H), 3.74 (s, 3H), 3.61 (t, 1H), 2.94 (m, 2H), 2.63 (m, 2H), 1.89 (m, 2H), 1.83 (m, 1H), 1.62 (m, 3H), 1.41 (m, 1H), 1.36 (m, 1H), 1.00 (m, 4H), 0.87 (m, 6H), 0.72 (m, 3H). MS (DCI/NH₃) m/e 402 (M+H)⁺.

Example 92B

(4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranof[3,4-c]pyridine

To a solution of (4aS, 10bR), slower moving diastereomer from Example 92A (2.38 g, 5.93 mmol) in THF (125 mL) was added at 0°C a solution of 1.6M n-BuLi (15.0 mL, 24.0 mmol) dropwise, and the reaction was stirred for 15 min. The reaction was quenched with 1M NaOH, poured into brine, and extracted with 3x EtOAc and 2x CH₂Cl₂. The combined extracts

were dried over Na₂SO₄, the solvent was condensed in vacuo, and the crude product was chromatographed on SiO₂ using NH₃-saturated 5% MeOH/CH₂Cl₂ to yield the title compound (1.07 g, 82%); ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.36 (d, 1H), 4.03 (dd, 1H), 3.72 (s, 3H), 3.55 (dd, 1H), 3.01 (m, 1H), 2.94 (dd, 1H), 2.83 (ddd, 1H), 2.62 (dt, 1H), 2.51 (dt, 1H), 2.29 (t, 1H), 1.64 (ddt, 1H), 1.05 (ddd, 1H). MS (DCI/NH₃) m/e 220 (M+H)⁺

Example 92C

(4aS,10bR)-trans-3-(3-Aminopropyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranol[3,4-c]pyridine

The product from Example 92B was treated as described in Examples 83 D and 83E to yield the title compound; ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.37 (d, 1H), 4.08 (dd, 1H), 3.73 (s, 3H), 3.62 (t, 1H), 2.96 (m, 2H), 2.89 (m, 1H), 2.57 (m, 2H), 2.39 (m, 1H), 2.33 (m, 2H), 2.01 (dt, 1H), 1.77 (m, 1H), 1.66 (t, 1H), 1.51 (m, 2H), 1.17 (m, 1H). MS (DCI/NH₃) m/e 277 (M+H)⁺.

Example 92D

3-[3-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranol[3,4-c]pyrido-3-yl)propyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (107 mg, 0.456 mmol) and the product from Example 92C (105 mg, 0.380 mmol) were treated as described in Example 1F to yield the title compound (135 mg, 64%): m.p. 235°C; ¹H NMR (300 MHz, DMSO) δ 12.72 (s, 1H), 10.66 (br s, 1H), 8.86 (d, 1H), 8.68 (d, 1H), 7.68 (dd, 1H), 7.09 (t, 1H), 6.53 (d, 1H), 6.41 (d, 1H), 4.14 (dd, 1H), 4.00 (m, 2H), 3.76 (s, 3H), 3.63 (m, 1H), 3.59 (m, 2H), 3.21-3.03 (m, 4H), 2.86 (m, 1H), 2.76 (m, 1H), 2.28 (m, 1H), 2.12 (m, 2H), 1.56 (m, 1H). MS (DCI/NH₃) m/e 479 (M+H)⁺. Anal calcd for C₂₅H₂₆N₄O₄S·2.0HCl·0.5H₂O: C, 53.57; H, 5.22; N, 10.00. Found: C, 53.35; H, 5.05; N, 9.92. [α]_D^{25.0°C} = -79.4°.

Example 93

3-[3-((4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyranol[3,4-c]pyrido-3-yl)propyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Example 93A

(4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyridine

To a solution of (4aR, 10bS), faster moving diastereomer from Example 92A (2.27 g, 5.74 mmol) in THF (125 mL) was added at 0°C a solution of 1.6M n-BuLi (15.0 mL, 24.0 mmol) dropwise, and the reaction was stirred for 15 min. The reaction was quenched with 1M NaOH, poured into brine, and extracted with 3x EtOAc and 2x CH₂Cl₂. The combined extracts were dried over Na₂SO₄, the solvent was condensed in vacuo, and the crude product was chromatographed on SiO₂ using NH₃-saturated 5% MeOH/CH₂Cl₂ to yield the title compound (0.96 g, 80%); ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.36 (d, 1H), 4.03 (dd, 1H), 3.72 (s, 3H), 3.55 (dd, 1H), 3.01 (m, 1H), 2.94 (dd, 1H), 2.83 (ddd, 1H), 2.62 (dt, 1H), 2.51 (dt, 1H), 2.29 (t, 1H), 1.64 (ddt, 1H), 1.05 (ddd, 1H). MS (DCI/NH₃) m/e 220 (M+H)⁺

Example 93B

(4aR,10bS)-trans-3-(3-Aminopropyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyridine

The product from Example 93A was treated as described in Examples 83D and 83E to yield the title compound; ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.37 (d, 1H), 4.08 (dd, 1H), 3.73 (s, 3H), 3.62 (t, 1H), 2.96 (m, 2H), 2.89 (m, 1H), 2.57 (m, 2H), 2.39 (m, 1H), 2.33 (m, 2H), 2.01 (dt, 1H), 1.77 (m, 1H), 1.66 (t, 1H), 1.51 (m, 2H), 1.17 (m, 1H). MS (DCI/NH₃) m/e 277 (M+H)⁺.

Example 93C

3-[3-((4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl)-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.116 g, 0.495 mmol) and the product from Example 93B (0.114 g, 0.413 mmol) were treated as described in Example 1F to yield the title compound (0.091 g, 39%): m.p. 235°C. ¹H NMR (300 MHz, DMSO) δ 12.72 (s, 1H), 10.66 (br s, 1H), 8.86 (d, 1H), 8.68 (d, 1H), 7.68 (dd, 1H), 7.09 (t, 1H), 6.53 (d, 1H), 6.41 (d, 1H), 4.14 (dd, 1H), 4.00 (m, 2H), 3.76 (s, 3H), 3.63 (m, 1H), 3.59 (m, 2H), 3.21-3.03 (m, 4H), 2.86 (m, 1H), 2.76 (m, 1H), 2.28 (m, 1H), 2.12 (m, 2H), 1.56 (m, 1H).

MS (DCI/NH₃) m/e 479 (M+H)⁺. Anal calcd for C₂₅H₂₆N₄O₄S·2.0HCl·H₂O: C, 52.73; H, 5.31; N, 9.84. Found: C, 52.59; H, 5.04; N, 9.75. [α]_D^{25.0°C} = +77.7°.

Example 94

5 3-[4-((4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Example 94A

10 (4aR,10bS)-trans-3-(4-Aminobutyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyridine

The product from Example 93A was treated as described in Examples 85A and 85B to yield the title compound; ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.37 (d, 1H), 4.08 (dd, 1H), 3.73 (s, 3H), 3.62 (t, 1H), 2.97 (m, 2H), 2.89 (m, 1H), 2.53 (m, 2H), 2.38 (m, 1H), 2.29 (m, 2H), 2.01 (dt, 1H), 1.78 (m, 1H), 1.67 (t, 1H), 1.46 (m, 2H), 1.34 (m, 2H), 1.18 (m, 1H). MS (DCI/NH₃) m/e 291 (M+H)⁺.

Example 94B

20 3-[4-((4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.087 g, 0.372 mmol) and the product from Example 94A (0.090 g, 0.310 mmol) were treated as described in Example 1F to yield the title compound (0.080 g, 43%): ¹H NMR (300 MHz, DMSO) δ 12.68 (s, 1H), 10.65 (br s, 1H), 8.85 (d, 1H), 8.66 (d, 1H), 7.68 (dd, 1H), 7.09 (t, 1H), 6.54 (d, 1H), 6.42 (d, 1H), 4.17 (dd, 1H), 3.97 (t, 2H), 3.76 (s, 3H), 3.67 (t, 1H), 3.58 (m, 2H), 3.11 (m, 4H), 2.81 (m, 2H), 2.28 (m, 1H), 1.79 (m, 2H), 1.69 (m, 2H), 1.58 (m, 1H). MS (DCI/NH₃) m/e 493 (M+H)⁺. Anal calcd for C₂₆H₂₈N₄O₄S·2.0HCl·2.0H₂O: C, 51.92; H, 5.70; N, 9.31. Found: C, 52.27; H, 5.56; N, 9.24. [α]_D^{25.0°C} = +83.2°.

Example 95

35 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

Example 95A

(4aS,10bR)-trans-3-(4-Aminobutyl)-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyridine

The product from Example 92B was treated as described in Examples 85A and 85B to yield the title compound; ¹H NMR (300 MHz, DMSO) δ 7.02 (dd, 1H), 6.48 (d, 1H), 6.37 (d, 1H), 4.08 (dd, 1H), 3.73 (s, 3H), 3.62 (t, 1H), 2.97 (m, 2H), 2.89 (m, 1H), 2.53 (m, 2H), 2.38 (m, 1H), 2.29 (m, 2H), 2.01 (dt, 1H), 1.78 (m, 1H), 1.67 (t, 1H), 1.46 (m, 2H), 1.34 (m, 2H), 1.18 (m, 1H). MS (DCI/NH₃) m/e 291 (M+H)⁺.

Example 95B

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

Methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate (0.097 g, 0.413 mmol) and the product from Example 95A (0.100 g, 0.344 mmol) were treated as described in Example 1F to yield the title compound (0.114 g, 55%): ¹H NMR (300 MHz, DMSO) δ 12.68 (s, 1H), 10.65 (br s, 1H), 8.85 (d, 1H), 8.66 (d, 1H), 7.68 (dd, 1H), 7.09 (t, 1H), 6.54 (d, 1H), 6.42 (d, 1H), 4.17 (dd, 1H), 3.97 (t, 2H), 3.76 (s, 3H), 3.67 (t, 1H), 3.58 (m, 2H), 3.11 (m, 4H), 2.81 (m, 2H), 2.28 (m, 1H), 1.79 (m, 2H), 1.69 (m, 2H), 1.58 (m, 1H). MS (DCI/NH₃) m/e 493 (M+H)⁺. Anal calcd for C₂₆H₂₈N₄O₄S·2.0HCl·2.0H₂O: C, 51.92; H, 5.70; N, 9.31. Found: C, 51.48; H, 5.62; N, 9.05. [α]_D^{25.0°C} = -82.4°.

Example 96

3-[4-((4aR,10bS)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyran[3,4-c]pyrido-3-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

The product from Example 10C (0.106 g, 0.372 mmol) and the product from Example 94A (0.090 g, 0.310 mmol) were treated as described in Example 1F to yield the title compound (0.020 g, 11%): m.p. 253-4°C. ¹H NMR (300 MHz, DMSO) δ 12.92 (s, 1H), 10.45 (br s, 1H), 9.02 (s, 1H), 7.09 (t, 1H), 6.54 (d, 1H), 6.42 (d, 1H), 4.17 (dd, 1H), 3.97 (t, 2H), 3.76 (s, 3H), 3.67 (t, 1H), 3.57 (m, 2H), 3.11 (m, 4H), 2.81 (m, 2H), 2.25 (m, 1H), 1.78 (m, 2H), 1.69 (m, 2H), 1.56 (m, 1H). MS (DCI/NH₃) m/e 528 (M+H)⁺. Anal calcd for

C₂₅H₂₆N₅O₄SCl·2.0HCl·0.5H₂O: C, 49.23; H, 4.79; N, 11.48. Found: C, 48.95; H, 4.77; N, 11.22. $[\alpha]_D^{25.0^\circ\text{C}} = +57.6^\circ$.

Example 97

5 3-[4-((4aS,10bR)-*trans*-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
dihydrochloride

10 The product from Example 10C (0.189 g, 0.667 mmol) and the product from Example 95A (0.176 g, 0.606 mmol) were treated as described in Example 1F to yield the title compound (0.192 g, 55%): m.p. 254-5°C. ¹H NMR (300 MHz, DMSO) δ 12.92 (s, 1H), 10.45 (br s, 1H), 9.02 (s, 1H), 7.09 (t, 1H), 6.54 (d, 1H), 6.42 (d, 1H), 4.17 (dd, 1H), 3.97 (t, 2H), 3.76 (s, 3H), 3.67 (t, 1H), 3.57 (m, 2H), 3.11 (m, 4H), 2.81 (m, 2H), 2.25 (m, 1H), 1.78 (m, 2H), 1.69 (m, 2H), 1.56 (m, 1H). MS (DCI/NH₃) m/e 528 (M+H)⁺. Anal calcd for
15 C₂₅H₂₆N₄O₄S·2.0HCl·3.0H₂O: C, 45.84; H, 5.23; N, 10.69. Found: C, 45.47; H, 5.03; N, 10.51. $[\alpha]_D^{25.0^\circ\text{C}} = -58.4^\circ$.

Example 98

20 3-[4-((4aS,10bR)-*trans*-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
hydrochloride

25 The product from Example 7A (0.24 g, 1.00 mmol) and the product from Example 95A (0.276 g, 1.00 mmol) were treated as described in Example 1F to yield the title compound (0.30 g, 57%): m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.04 (d, 1H), 7.03 (t, 1H), 6.98 (d, 1H), 6.46 (d, 1H), 6.41 (d, 1H), 4.12 (t, 2H), 4.08 (dd, 1H), 4.04 (s, 3H), 3.79 (s, 3H), 3.67 (m, 1H), 3.08 (m, 1H), 2.98 (m, 2H), 2.42 (m, 3H), 2.13 (m, 1H), 2.02 (m, 1H), 1.76 (m, 3H), 1.62 (m, 2H), 1.38 (m, 1H); MS (DCI/NH₃) m/e 523 (M+H)⁺; Analysis calc'd for C₂₇H₃₀N₄O₅S·HCl·0.5H₂O: C, 57.09; H, 5.68; N, 9.86; found: C, 57.01; H, 5.43; N,
30 9.64.

Example 99

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

5 The product from Example 31A (0.167 g, 0.70 mmol) and the product from Example 95A (0.195 g, 0.70 mmol) were treated as described in Example 1F to yield the title compound (0.29 g, 78%): m.p. 220-224°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 8.39 (s, 1H), 7.04 (t, 1H), 6.46 (d, 1H), 6.41 (d, 1H), 4.11 (m, 3H), 4.08 (s, 3H), 3.79 (s, 3H), 3.67 (t, 1H), 10 3.08 (m, 1H), 2.98 (m, 2H), 2.42 (m, 3H), 2.15 (m, 1H), 2.0 (m, 1H), 1.78 (m, 3H), 1.6 (m, 2H), 1.4 (m, 1H); MS (DCI/NH₃) m/e 524(M+H)⁺; Analysis calc'd for C₂₆H₂₉N₅O₅S·HCl·2H₂O: C, 52.39; H, 5.75; N, 11.75; found: C, 52.59; H, 5.70; N, 11.65.

Example 100

15 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

20 The product from Example 9B (0.16 g, 0.56 mmol) and the product from Example 95A (0.154 g, 0.56 mmol) were treated as described in Example 1F to yield the title compound (0.17 g, 53%): m.p. >250°; ¹H NMR (300 MHz, CDCl₃(free base)) δ 9.16 (s, 1H), 8.08 (m, 2H), 7.59 (m, 3H), 7.02 (t, 1H), 6.42 (d, 1H), 6.38 (d, 1H), 4.18 (m, 2H), 3.93 (dd, 1H), 3.77 (s, 3H), 3.6 (t, 1H), 3.18 (m, 1H), 3.07 (m, 1H), 2.93 (m, 1H), 2.5 (m, 2H), 2.41 (m, 1H), 25 2.16 (m, 1H), 1.97 (m, 1H), 1.8 (m, 3H), 1.76 (m, 2H), 1.18 (m, 1H); MS (DCI/NH₃) m/e 570(M+H)⁺; Analysis calc'd for C₃₁H₃₁N₅SO₄·HCl·1.5H₂O: C, 58.81; H, 5.57; N, 11.06; found: C, 58.69; H, 5.52; N, 11.03.

Example 101

30 3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione dihydrochloride

35 The product from Example 95B (0.145 g, 0.50 mmol) and the product from Example 52A (0.15 g, 0.53 mmol) were treated as described in Example 1F to yield 0.230 g (80%) of the title compound: m.p. > 255°; ¹H NMR (300 MHz, CDCl₃ (free base)) δ 1.35 (dd, J=3, 12

Hz, 1H), 1.58-1.72 (m, 2H), 1.72-1.87 (m, 3H), 1.91-2.05 (m, 1H), 2.12 (dd, J=3, 12 Hz, 1H), 2.36-2.50 (m, 3H), 2.89-3.02 (m, 2H), 3.04-3.13 (m, 1H), 3.63 (dd, J=10, 11 Hz, 1H), 3.77 (s, 3H), 4.03 (dd, J=3, 10 Hz, 1H), 4.18 (t, J=7 Hz, 2H), 6.39 (dd, J=1, 8 Hz, 1H), 6.45 (dd, J=1, 8 Hz, 1H), 7.03 (t, J=8 Hz, 1H), 7.45-7.56 (m, 3H), 7.93 (d, J=9 Hz, 1H), 8.05-8.11 (m, 2H), 8.27 (d, J=9 Hz, 1H); MS (CI(NH₃)) *m/e* (M+H)⁺ at 569; Analysis calc'd for C₃₂H₃₂N₄O₄S•(HCl)₂•(H₂O)_{0.5}: C, 59.07; H, 5.42; N, 8.61; found: C, 59.04; H, 5.53; N, 8.35.

Example 102

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-clpyrido-3-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 95B (0.290 g, 1.0 mmol) and methyl 3-amino-6-chloro-thieno[2,3-b]pyridine-2-carboxylate (0.242 g, 1.00 mmol) were treated as described in Example 1F to yield 0.375 g (66%) of the title compound.: m.p. 236° (d); ¹H NMR (300 MHz, DMSO-d₆) δ 1.4-1.6 (m, 2H), 1.6-1.85 (n, 4H), 2.04-2.24 (m, 2H), 2.7-3.6 (m, 6H), 3.66 (t, 2H), 3.77 (s, 3H), 3.95 (t, 2H), 4.15 (m, 1H), 6.41 (d, 1H), 6.52 (d, 1H), 7.07 (t, 1H), 7.78 (d, 1H), 8.77 (d, 1H); MS (DCI/NH₃) *m/e* 527 (529 (M+H)⁺); Analysis calc'd for C₂₆H₂₈Cl₂N₄O₄S·1.25H₂O: C, 53.29; H, 5.25; N, 9.56; Cl, 12.10; found: C, 53.26; H, 5.28; N, 9.27; Cl, 11.82.

Example 103

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-clpyrido-3-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride

The product from Example 95B (0.290 g, 1.0 mmol) and methyl 3-amino-6-methoxy-thieno[2,3-b]pyridine-2-carboxylate (0.238 g, 1.00 mmol) were treated as described in Example 1F to yield 0.315 g (56%) of the title compound.: m.p. 224° (d); ¹H NMR (300 MHz, DMSO-d₆) δ 1.4-1.6 (m, 2H), 1.6-1.85 (m, 4H), 2.04-2.15 (m, 2H), 2.7-3.6 (m, 6H), 3.67 (t, 2H), 3.77 (s, 3H), 3.96 (m, 2H), 3.98 (s, 3H), 4.15 (m, 1H), 6.41 (d, 1H), 6.54 (d, 1H), 7.07 (d, 1H), 7.08 (t, 1H), 8.58 (d, 1H); MS (DCI/NH₃) *m/e* 523 (M+H)⁺; Analysis calc'd for C₂₇H₃₁ClN₄O₅S·1.4H₂O: C, 54.65; H, 5.78; N, 9.44; Cl, 7.47; found: C, 54.52; H, 5.91; N, 9.31; Cl, 7.55.

Example 104

3-[4-(*cis*-7-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

5

Example 104A

3-[4-(*cis*-7-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

10 A solution of 7-hydroxy-5-methoxycoumarin (300 mg, 1.6 mmol), prepared as described in *Monatsh. Chem.*, 1333, (1988), in dry DMF (10 mL) was treated with a 60 % dispersion of sodium hydride (70 mg, 1.7 mmol), stirred for 1 hour, treated with benzyl bromide (0.37 mL, 3.1 mmol) and stirred for 1 hour. The mixture was diluted with diethyl ether (100 mL), washed with water, washed with brine, dried (MgSO₄), filtered and
15 concentrated. Purification of the residue on silica gel using dichloromethane and then 25:1 dichloromethane:ethyl acetate provided 420 mg (95 %) of the intermediate benzylated derivative.

A solution of 7-benzyloxy-5-methoxycoumarin (0.42 g, 1.5 mmol) in dichloromethane (5 mL) at 0°C was treated with trifluoroacetic acid (0.15 mL of a 1 M solution in dichloromethane), treated dropwise with a solution of N-methoxymethyl-N-trimethylsilylmethylbenzylamine, (750 mg, 3.0 mmol) in dichloromethane (5 mL) and stirred
20 for 1 hour at ambient temperature. The mixture was diluted with dichloromethane, washed with sodium bicarbonate solution, dried (MgSO₄), filtered and concentrated. The residue was dissolved in THF (5 mL), added dropwise to a stirred suspension of lithium aluminum hydride (115 mg, 3.0 mmol) in THF (10 mL), stirred for 1 hour and treated with sodium sulfate decahydrate (5 g) in portions. The mixture was diluted with ethyl acetate, filtered and
25 concentrated. Purification on silica gel using 2:1 ethyl acetate:hexane provided 620 mg (96 %) of the intermediate diol.

A solution of the diol (0.60 g, 1.4 mmol) in a mixture of acetonitrile (16 mL) and carbon tetrachloride (4 mL) was treated with triphenylphosphine (0.73 g, 2.8 mmol), heated to reflux
30 for 10 minutes, cooled to ambient temperature and concentrated. Purification on silica gel using 2:1 diethyl ether:hexane saturated with ammonia provided 530 mg (92 %) of the intermediate chloro-phenol. The chloro-phenol (530 mg, 1.3 mmol) was dissolved in THF (30 mL), treated with potassium tert-butoxide (3 mL of a 1 M in THF solution), stirred for 1 hour, concentrated, treated with dichloromethane (100 mL), washed with water (25 mL), dried (MgSO₄), filtered
35 and concentrated to yield 0.40 g (76 %) of the cyclized product. A suspension of the this product (0.40 g, 0.96 mmol) and 10 % palladium on carbon (0.070 g) in methanol (20 mL)

was stirred under a hydrogen atmosphere for 16 hours. The atmosphere was exchanged with nitrogen, the palladium on carbon was removed by filtration and the mixture was concentrated. Purification of the residue on silica gel using 8:1:1 ethyl acetate:water:formic acid provided an impure product which was repurified on silica gel using 40 % ethanol in dichloromethane saturated with ammonia providing 0.060 g (28 %) of the title compound: ¹H NMR (300 MHz, DMSO-d₆) δ 2.25-2.39 (m, 1H), 2.34 (dd, 1H), 2.48-2.55 (m, 1H), 2.89 (q, 1H), 3.10 (dd, 1H), 3.33-3.42 (m, 1H), 3.49 (t, 1H), 3.70 (s, 3H), 3.98 (dd, 1H), 5.86 (d, J=1 Hz, 2H), 5.99 (d, J=1 Hz, 2H), 9.23 (bs, 1H); MS (DCI/NH₃) m/e 222 (M+NH₄)⁺.

Example 104B

3-[4-(-cis-7-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

A solution of the product from Example 104A (60 mg, 0.27 mmol) in DMF (1.5 mL) was treated with 4-bromobutyronitrile (0.030 mL, 0.30 mmol) and sodium bicarbonate (25 mg, 0.30 mmol), heated for 3 hours at 70°C and concentrated. Purification using silica gel with 2 % ethanol in dichloromethane saturated with ammonia provided 70 mg (90 %) of the intermediate nitrile.

A suspension of lithium aluminum hydride (70 mg, 1.8 mmol) in a mixture of diethyl ether (3 mL) and THF (3 mL) was treated with aluminum chloride (81 mg, 0.61 mmol) in diethyl ether (3 mL), stirred for 1 hour, treated with the nitrile (70 mg, 0.24 mmol), stirred for 2 hours, treated with water (0.080 mL), treated with 4 M sodium hydroxide (0.080 mL), treated with water (0.24 mL), stirred for 15 minutes and concentrated. Purification of the residue using silica gel with 12:5:3 ethyl acetate:formic acid:water provided the formic acid salt of the primary amine product.

A solution of the product from Example 9B (82 mg, 0.29 mmol) in THF (5 mL) was treated with sodium bicarbonate (100 mg, 1.2 mmol), treated with phosgene (3.75 mL of a 1.93 M solution in toluene), stirred for 1 hour, concentrated, dried at 60°C under high vacuum for 1 hour and cooled to ambient temperature. The residue was treated with a suspension of the primary amine intermediate in DMF (4.5 mL), stirred for 1 hour, heated to 150°C under nitrogen for 30 minutes and concentrated. Purification of the residue using silica gel with 10 % and then 20 % ethanol in dichloromethane saturated with ammonia provided 60 mg (43 %) of the title compound: ¹H NMR (300 MHz, DMSO-d₆) δ 1.42-1.54 (m, 2H), 1.58-1.71 (m, 2H), 2.14-2.25 (m, 2H), 2.38-2.51 (m, 2H), 2.99 (t, 1H), 3.10 (q, 1H), 3.17-3.26 (m, 1H), 3.39-3.49 (m, 1H), 3.62 (t, 1H), 3.69 (s, 3H), 3.90-4.00 (m, 3H), 5.84 (d, J=1 Hz, 2H),

5.98 (d, J=1 Hz, 2H), 7.53-7.65 (m, 3H), 8.40-8.47 (m, 2H), 9.24 (bs, 1H), 9.51 (s, 1H), 12.60 (bs, 1H); MS (ESI) m/e 572 (M+H)⁺; 570 (M-H)⁻.

Example 105

3-[4-((3aR,9bR)-cis-6-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

Example 105A

(3aR,9bR)-cis 6-Bromo-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

The HCl salt of the product from Example 1C (1 g, 4.14 mmol) was dissolved in formic acid, cooled to 0° and Br₂ (0.68 g, 4.25 mmol) was added. The reaction was stirred at 0°C for 1 hr then solvent was evaporated and the product was partitioned in 1N NaOH/CH₂Cl₂. The organic extracts were dried and concentrated. The resulting product was purified by column chromatography on silica gel, eluting with 5% EtOH / CH₂Cl₂ sat. with NH₄OH to yield 0.45 g (38%) of the title compound. ¹H NMR (300 MHz, CDCl₃) δ 2.58 (m, 1H), 2.64 (m, 1H), 2.84 (dd, 1H), 3.24 (q, 1H), 3.32 (dd, 1H), 3.62 (dd, 1H), 3.80 (m, 1H), 3.81 (s, 3H), 6.38 (d, 1H), 7.32 (d, 1H); MS (DCI(NH₃)) m/e 284 (M+H)⁺

Example 105B

(3aR,9bR)-cis 6-Hydroxy -9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrole

The product from Example 105A (0.45 g, 1.6 mmol) was dissolved in CH₂Cl₂ and di-*t*-butyl-dicarbonate (0.69 g, 3.2 mmol) was added. After the reaction mixture was stirred at rt for 1 hr it was evaporated and the residue was purified by column chromatography on silica gel, eluting with 1:1 hexane : EtOAc to yield *t*-BOC-protected product (0.42 g). To the solution of *t*-BOC-protected product (0.18 g, 0.46 mmol) in THF and cooled to -78°C was added 0.22 ml of 2.5M *n*-BuLi solution in hexane. The reaction mixture was stirred at -78°C for 1 hr and triisopropyl borate (0.11 g, 0.59 mmol) was added. The reaction mixture was warmed to rt and stirred for 2 hr. Then acetic acid (0.55 mmol) was added to the reaction mixture followed by the addition of H₂O₂ (0.78 mmol). The reaction mixture was stirred at rt for 16 hr, then quenched into NH₄Cl solution and extracted with CH₂Cl₂. The organic layer was dried over MgSO₄ and concentrated to yield *t*-BOC protected title compound (0.8 g). To the solution of *t*-BOC-protected title compound (0.12 g, 0.37 mmol) in CH₂Cl₂ was added CF₃COOH and the reaction

mixture was stirred overnight. Solvent was evaporated and residue was purified by column chromatography eluting with 2% EtOH/CH₂Cl₂ to yield 0.08 g of the title compound. ¹H NMR (300 MHz, CDCl₃) δ 2.67 (m, 1H), 2.82 (dd, 1H), 2.97 (dd, 1H), 3.39 (m, 2H), 3.62 (dd, 1H), 3.78 (m, 1H), 3.77 (s, 3H), 3.81 (m, 1H), 4.18 (dd, 1H), 6.37 (d, 1H), 6.74 (d, 1H);

Example 105C

(3aR,9bR)-cis-2-(3-cyanopropyl)-6-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

To the product of Example 105B (0.075 g, 0.34 mmol) in DMF (2 ml) was added NaHCO₃ (0.032 g, 0.38 mmol) and 4-bromobutyronitrile (0.056 g, 0.38 mmol). The reaction mixture was heated at 90°C for 3 hr and evaporated. The residue was purified by column chromatography on silica gel, eluting with 2% EtOH/CH₂Cl₂/ sat. with ammonia to yield 0.086 g (88 %) of the title compound. ¹H NMR (300 MHz, CDCl₃) δ 1.82 (m, 2H), 2.26 (m, 2H), 2.43 (t, 2H), 2.6 (m, 3H), 3.39 (m, 2H), 3.75 (s, 3H), 3.87 (m, 1H), 4.12 (dd, 1H), 5.15 (d, 1H), 6.73 (d, 1H)

Example 105D

(3aR,9bR)-cis-2-(4-aminobutyl)-6-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrole

The product of Example 105C (0.084 g, 0.3 mmol) in THF was added to the solution of LiAlH₄ (0.085 g, 2.3 mmol) in THF and AlCl₃ (0.1 g, 0.75 mmol) in ether. The reaction mixture was stirred at rt for 3hr to yield after Fieser workup 0.075 g (88%) of the title compound. ¹H NMR (300 MHz, CDCl₃) δ 1.48-1.7 (m, 4H), 2.38 (m, 1H), 2.43 (m, 3H), 2.73 (m, 2H), 3.06 (m, 1H), 3.39 (m, 2H), 3.47 (m, 1H), 3.77 (s, 3H), 3.84-3.95 (m, 2H), 4.05 (m, 1H), 6.38 (d, 1H), 6.73 (d, 1H).

Example 105E

3-[4-((3aR,9bR)-cis-6-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

The product from the Example 105D (0.084 g, 0.3 mmol) and the product from the Example 9B (0.087 g, 0.3 mmol) were treated as described in the Example 1F to 0.03g (17%) of the title compound. ¹H NMR (500 MHz, CDCl₃) δ 1.72 (m, 2H), 1.81 (m, 1H), 2.45 (m, 1H), 2.57

(m, 1H), 2.73 (m, 3H), 3.32 (m, 1H), 3.5 (m, 1H) 3.7 (s, 3H), 3.86 (m, 1H), 4.06 (m, 1H), 4.15 (m, 2H), 6.28 (d, 1H), 6.67 (d, 1H), 7.55 (m, 3H), 8.08 (m, 2H), 9.12 (s, 1H); MS(ESI)m/e 572(M+H)⁺s

5

Example 106

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-8-(2-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

To the solution of the product from Example 16 (0.075 g, 0.136 mmol) in DMF (2ml) was added Pd(dppf)Cl₂ (0.03 g, 0.034 mmol), 2-(benzyloxy)benzeneboronic acid (0.033 g, 0.145 mmol) and triethylamine (0.05ml). The reaction mixture was heated at 90°C for 3 hours. Then it was diluted with water and the precipitate formed was filtered off. The filtrate was extracted with EtOAc, dried over MgSO₄ and evaporated. The residue was chromatographed on silica gel, eluting with 5% ethanol/CH₂Cl₂ saturated with ammonia to yield 0.05 g (55%) of oil. To the solution of this product (0.08 g, 0.12 mmol) in CH₃OH (2ml) was added ammonium formate (0.07 g) and Pd/C (0.07 g). The reaction mixture was refluxed for 2 hours, then it was filtered and the evaporated residue was chromatographed on silicagel eluting with 10% EtOH/CH₂Cl₂/sat. with NH₄OH to yield 0.022g (32%) of title compound: ¹H NMR (300 MHz, CDCl₃) δ 1.8 (m, 4H), 2.5 (m, 1H), 2.58 (m, 1H), 2.8 (m, 3H), 3.58 (m, 2H), 3.78 (s, 3H), 3.82 (m, 2H), 3.88 (dd, 1H), 4.28 (m, 2H), 6.45 (m, 2H), 7.06 (m, 3H), 7.42 (t, 1H), 7.92 (dd, 1H), 9.33 (s, 1H); MS(ESI)m/e 572 (M+H)⁺

15

20

Example 107

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyranol[3,4-c]pyrrol-2-yl)butyl]-8-(3-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

The product of Example 16 (0.07 g, 0.105 mmol) and 3-(benzyloxy)benzeneboronic acid were treated as described in example 106 to yield 0.03g (43%) of benzyl-protected product. To the solution of this product (0.015 g, 0.02 mmol) in CH₃COOH a few drops of H₂SO₄ were added and the solution was refluxed for 0.5 h. The reaction mixture was cooled, neutralized and extracted with CH₂Cl₂/CH₃OH to yield 0.003g (26%) of the title compound ¹H NMR (500 MHz, CDCl₃) δ 1.81 (m, 2H), 1.98 (m, 2H), 2.25 (m, 1H), 2.62 (m, 1H), 2.85 (m, 1H), 3.03 (m, 2H), 3.25 (m, 2H), 3.8 (s, 3H), 3.82 (m, 2H), 4.0 (m, 2H), 4.42 (m, 1H), 6.52 (m, 3H), 7.12 (m, 3H), 7.42 (t, 1H), 7.85 (s, 1H), 9.11 (s, 1H); MS(ESI)m/e 572 (M+H)⁺

30

35

Example 108


3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyran[3,4-c]pyrrol-2-yl)butyl]-8-(4-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

5 The product of Example 16 (0.07 g, 0.105 mmol) and 4-(methoxymethoxy) phenyl boronic acid (0.02 g, 0.11 mmol) prepared by the procedure described in *Tetr. Lett.*, 31, 27, (1990) were treated as described in Example 106 to yield 0.029g(45%) of MOM-protected product. To the solution of this product (0.11g, 0.17 mmol) in CH₃OH/THF was added 2N HCl (0.2ml) and the reaction mixture was refluxed for 1 hour. The reaction was evaporated and
10 partitioned in NaHCO₃ sol. and CH₂Cl₂/CH₃OH to yield 0.005 g (51%) of the title compound. ¹H NMR (500 MHz, CDCl₃) δ 1.81 (m, 2H), 1.98 (m, 2H), 2.25 (m, 1H), 2.65 (m, 1H), 2.88 (m, 1H), 3.08 (m, 2H), 3.22(m, 2H), 3.65 (m, 1H), 3.73 (m, 1H), 3.82 (s, 3H), 3.9 (m, 1H), 4.25 (m, 1H), 4.42 (m, 1H), 6.52 (m, 2H), 7.38 (m, 2H), 7.49(m, 1H), 7.9 (t, 1H), 8.09 (d, 1H), 9.12 (s, 1H); MS(ESI)m/e 572 (M+H)⁺.

15 The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the
20 appended claims.


WE CLAIM:


1. A compound of formula I:



I

or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, and R₃ is selected from the group consisting of,






wherein G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl,

Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent,

V and V' are independently selected from the group of nitrogen and methine and U is a ring that is fused to its adjacent ring and is selected from the group consisting of (a) an unsubstituted or substituted five member ring having five carbon atoms; (b) an unsubstituted or substituted five membered ring having four carbon atoms and one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; (c) an unsubstituted or substituted five membered ring having three carbon atoms and two heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; (d) a substituted or unsubstituted six membered ring having six carbon atoms; (e) a substituted or unsubstituted six membered ring having 5 carbon atoms and one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; (f) a substituted or unsubstituted 6 membered ring having 4 carbon atoms and two heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; and (g) a substituted or unsubstituted 6 membered ring having three carbon atoms and three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. The five membered rings constituting U may contain 0, 1, or 2 double bonds. The six membered rings constituting U may contain 0, 1, 2, or 3 double bonds. The rings (a)- (g) of the group constituting U may be mono or di-substituted with substituents independently selected from the group consisting of alkyl, alkoxy, cyano, nitro, carboxy, alkoxy carbonyl of two to eight carbon atoms, halogen, cycloalkyl, aryl, and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

2. A compound of claim 1 wherein said five and six membered ring comprising U contains at least 1 double bond.

3. A compound according to Claim 1 of formula II:




II

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl,

Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent,

P', Q, S', and T are independently selected from the group consisting of nitrogen and methine, with the proviso that no more than two of P', Q, S', and T can be nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


4. A compound according to Claim 1 of the formula III:



III

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, P' and T are nitrogen, Q and S' are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


5. A compound according to Claim 1 of formula IV:



IV

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, P' is nitrogen, Q, S', and T are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


6. A compound according to Claim 1 of formula V:



V

- 5 wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, Q is nitrogen, P', S', and T are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

7. A compound according to Claim 1 of formula VI:




VI

- 5 wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, Q is nitrogen, P', S', and T are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

- 10 hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, S' is nitrogen, P', Q, and T are methine, and R₄ and R₅ are independently selected from
 15 hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.


8. A compound according to Claim 1 of formula VII:



VII

- 5 wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting
 10 hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, T is nitrogen, P', Q, and S' are methine, and R₄ and R₅ are independently selected
 15 from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

9. A compound according to Claim 1 of formula VIII:



VIII

- 5 wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, A is methylene, n is 1 or 2, W is alkylene of from 2 to 10 carbon atoms, G and G' are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulfonyl, and aminoalkyl, Y and Y' are
 10 independently selected from the group consisting of oxygen, nitrogen, and sulfur, with the proviso that when Y is oxygen or sulfur, G is absent and when Y' is oxygen or sulfur, G' is absent, P', Q, S', and T are methine, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically
 15 acceptable salt, ester, or prodrug thereof.

10. A compound according to Claim 1 of formula I selected from the group consisting of:

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

- 10 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
15 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
20 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
25 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
30 3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-isopropoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
35 3-[3-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,


3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-furyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, and

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

or a pharmaceutically acceptable salt, ester, or prodrug thereof.

11. A compound according to Claim 1 of formula IX:



IX

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 1, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, P', Q, S', are methine, T is nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

12. A compound of formula IX according to claim 11 wherein said compound is selected from the group of:

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,


3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-isopropoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,
and

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

or a pharmaceutically acceptable salt, ester, or prodrug thereof.

13. A compound according to Claim 1 of formula X:



X

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 2, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, P', Q and S', are methine, T is nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

14. A compound of formula X according to claim 13 selected from the group consisting of:


3-[3-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)propyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]- benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, and

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]- benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt, ester, or prodrug thereof.

15. A compound according to Claim 1 of formula XI:



XI


wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 2, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, Q and S' are methine, P' and T are nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

16. A compound of formula XI according to claim 15 wherein said compound is selected from the group consisting of:

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]-benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, and

3-[4-((4aS,10bR)-trans-10-Methoxy-1,3,4,4a,5,10b-hexahydro-2H-[1]- benzopyrano[3,4-c]pyrido-3-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt, ester, or prodrug thereof.

17. A compound according to Claim 1 of formula XII:



XII

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 1, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, Q and S', are methine, P' and T are nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

18. A compound of formula XII according to claim 17 wherein said compound is selected from the group consisting of:

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-chloro-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-methoxy-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrido[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

30

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-pyridyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

35

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-furyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-thienyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

40

3-[4-(-cis-7-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-6-Hydroxy-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

45

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(2-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

50


3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(3-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, and

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-(4-hydroxyphenyl)-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

55

or a pharmaceutically acceptable salt, ester, or prodrug thereof.

19. A compound according to Claim 1 of formula XIII:



XIII

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, A is methylene, n is 1, W is an alkylene of 2 to 10 carbon atoms, G is hydrogen, G' is absent, Y is nitrogen, Y' is sulfur, Q, S', and T are methine, P' is nitrogen, and R₄ and R₅ are independently selected from hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, cycloalkyl, aryl and heterocyclic; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

20. A compound of the formula XIII according to claim 19 wherein said compound is selected from the group consisting of:

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,


3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-methoxy-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, and

3-[4-((3aS,9bR)-trans-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-7-chloro-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione,

or a pharmaceutically acceptable salt, ester, or prodrug thereof.

21. A compound according to Claim 1 of formula XIV:

165




XIV

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, and alkoxy, Y is nitrogen, G is hydrogen, Y' is sulphur, P' and T are nitrogen, and Q is methine, and S' is carbon; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

22. A compound of formula XIV according to claim 21 wherein said compound is 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

23. A compound of formula XIV according to claim 22 wherein said compound is 3-[4-((3aR,9bR)-cis-9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride.

24. A compound according to formula XV:




XV

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxyacetyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, and n is 1 or 0; or a pharmaceutically acceptable salt thereof.

166


20 25. A compound according to formula XVI:



XVI

25 wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, and n is 1 or 0; or a pharmaceutically acceptable salt thereof.

30 26. A compound according to formula XVII:




XVII

35 wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, m is from 2 to 10, and n is 1 or 0; or a pharmaceutically acceptable salt thereof.

40

27. A compound of claim 24 having formula XVIII:




XVIII

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, and n is 1 or 0; or a pharmaceutically acceptable salt thereof.

28. A compound of claim 27 wherein the absolute stereochemistry is 3aR and 9bR.

29. A compound of claim 25 having formula XIX:




XIX

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, and n is 1 or 0; or a pharmaceutically acceptable salt thereof.

30. A compound of claim 29 wherein the absolute stereochemistry is 3aR and 9bR.

31. A compound of claim 26 having formula XX:




XX

wherein R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxy carbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino, and aminoalkyl, m is from 2 to 10, and n is 1 or 0; or a pharmaceutically acceptable salt thereof.

32. A compound of claim 31 wherein the absolute stereochemistry is 3aR and 9bR.

33. A compound according to formula XXI:




XXI

wherein U, Y', G' are as defined in formulae I-XIV and R is alkyl; or a pharmaceutically acceptable salt thereof.

169


34. A compound according to formula XXII:



XXII

wherein U, Y', G' are as defined in formulae I-XIV and R alkyl; or a pharmaceutically acceptable salt thereof.


35. A compound according to formula XXIII:



XXIII


wherein U, Y', G', and m are as defined in formulae I-XIV and R is alkyl; or a pharmaceutically acceptable salt thereof.

36. A compound according to formula XXIV:




170

37. A compound according to Formula XXV:




38. A compound according to Formula XXVI:




wherein X is halogen and R is selected from alkyl and arylalkyl.

39. A compound according to formula XXVII:




110

40. A compound according to formula XXVIII:




115

41. A compound according to formula XXIX:



42. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable carrier.
43. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 22 in combination with a pharmaceutically acceptable carrier
44. A method of antagonizing α -1 adrenoreceptors in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 1.
45. A method of antagonizing α -1 adrenoreceptors in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 22.
46. A method of treating benign prostatic hyperplasia (BPH) in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 1.
47. A method of treating benign prostatic hyperplasia (BPH) in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 22.
48. A method of treating bladder outlet obstruction (BOO) in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 1.

49. A method of treating bladder outlet obstruction (BOO) in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 22.
50. A method of treating neurogenic bladder in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 1.
51. A method of treating neurogenic bladder in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 22.
52. A method of treating uterine smooth muscle contraction in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 1.
53. A method of treating uterine smooth muscle contraction in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 22.
54. A process for preparing a compound of Formula I




120

or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R_1 , R_2 , A, n, W, Y, G, Y', G', P, Q, S, T, R_4 , and R_5 are as previously defined; comprising the steps of:

173


a) reacting a compound of the formula




125

wherein Ra is aminoalkyl,

b) with a compound of the formula



or



130

wherein R is alkyl.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/22279

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D491/04 A61K31/415 //(C07D491/04,311:00,209:00),
(C07D491/04,311:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 095 666 A (ABBOTT LABORATORIES) 7 December 1983 see the whole document ---	1-43
A	EP 0 556 119 A (ADIR ET COMPAGNIE) 18 August 1993 see the whole document ---	1-43
A	HARRY G. PARS: JOURNAL OF MEDICINAL CHEMISTRY, vol. 19, no. 4, - April 1976 pages 445-453, XP002060293 see the whole document ---	1-43
A	US 3 888 946 A (HARRY G. PARS) 10 June 1975 see the whole document ---	1-43
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 April 1998

Date of mailing of the international search report

29.04.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/22279

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 4 117 140 A (RICHARD E. BROWN) 26 September 1978 see the whole document -----</p>	1-43

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 22279

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 44-53 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/22279

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 95666 A	07-12-83	AU 560459 B AU 1445283 A CA 1215376 A JP 1760125 C JP 4043064 B JP 58225064 A US 4618683 A	09-04-87 08-12-83 16-12-86 20-05-93 15-07-92 27-12-83 21-10-86
EP 556119 A	18-08-93	FR 2687146 A AT 153016 T AU 655868 B AU 3301093 A CA 2089349 A DE 69310567 D DE 69310567 T JP 2008864 C JP 6009552 A JP 7039385 B NZ 245884 A US 5387591 A US 5407946 A ZA 9300996 A	13-08-93 15-05-97 12-01-95 19-08-93 13-08-93 19-06-97 18-12-97 11-01-96 18-01-94 01-05-95 25-11-94 07-02-95 18-04-95 20-09-93
US 3888946 A	10-06-75	US 3994922 A	30-11-76
US 4117140 A	26-09-78	AU 8030475 A BE 838361 A CH 616680 A DE 2515226 A DK 51576 A, B, FR 2299866 A JP 51105099 A JP 51095098 A LU 74318 A NL 7601350 A SE 7601361 A US 4276296 A ZA 7507572 A ZA 7600216 A	21-10-76 06-08-76 15-04-80 19-08-76 11-08-76 03-09-76 17-09-76 20-08-76 13-08-76 12-08-76 11-08-76 30-06-81 24-11-76 29-12-76